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Pathogenic bacteria are becoming increasingly resistant to antibiotics.  In response to this 
alarming trend, the scientific community must determine therapeutic targets. Essential nutrients, 
such as iron, are necessary for pathogens to survive and become virulent within a host system. 
One mechanism used by pathogenic bacteria to acquire iron from its surrounding environment is 
to produce low-molecular weight compounds which have a high affinity towards ferric iron. 
These compounds are called siderophores, and studies have shown their production to be 
essential for growth and virulence of some pathogens in iron-limited environments, such as the 
human host. Siderophores are often biosynthesized by nonribosomal peptide synthetases 
(NRPSs), which rarely have human homologs, making them attractive targets for novel 
therapeutics.   
NRPSs are enzymes utilized by bacteria, fungi, and plants to generate bioactive peptides. 
These bioactive peptides are not only used as secondary metabolites (toxins, pigments, 
siderophores) but have also found their way into the clinic as antibiotics, anticancer drugs, and 
immunosuppressants. To elicit their unique bioactivity, these peptides are tailored, making the 
compound chemically unique. Natural product chemists, metabolic engineers, and researchers in 
biochemistry and biotechnology work to exploit NRPS biosynthesis to generate new compounds 
for clinical use.  
This dissertation describes mechanistic and structural analyses of the adenylation and 
tailoring domains of the NRPS biosystem responsible for the production of pyochelin, a 
siderophore produced by antibiotic resistant Pseudomonas aeruginosa. A large portion of this 
work aims to better understand adenylation and “stuffed” tailoring didomains which lack 
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structural characterization and have limited mechanistic understanding yet are ubiquitous in 
NRPS bioassembly. Pyochelin biosynthesis employs an adenylation-epimerase stuffed didomain 
in PchE and an adenylation-methyltransferase stuffed didomain in PchF. Substrate and product 
analogs were synthesized and steady-state adenylation, epimerase, and methyltransferase assays, 
along with onium chalcogen effects of the methyltransferase reaction, were used to characterize 
the adenylation-tailoring stuffed domains in pyochelin bioassembly. Similarly, substrate analogs 
were generated and used in steady-state kinetic and crystallography experiments with the stand-
alone tailoring, NADPH-dependent reductase, PchG, and homolog, Irp3, of yersiniabactin 
biosynthesis. Finally, a steady-state adenylation assay was developed for the stand-alone 
salicylate adenylation enzyme, PchD, and potential warhead inhibitors were synthesized and co-
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Nonribosomal peptides for iron acquisition: pyochelin biosynthesis as a case study 
 
*This chapter was published in Ronnebaum, T.A., and Lamb, A.L. (2018) Nonribosomal 
peptides for iron acquisition: pyochelin biosynthesis as a case study, Curr. Opin. Struct. Biol. 53, 
1-11. 
 
Iron uptake: Siderophores 
Iron is an essential nutrient that is needed by microbes to perform critical biological 
processes necessary for survival.1 Due to the paucity of free iron in aerobic environments, 
microbes have developed intricate systems to acquire iron from their surroundings.1 One such 
system is the biosynthesis of small molecules known as siderophores that have a high affinity for 
ferric iron.2 When iron availability is low, microbes synthesize and secrete siderophores, and 
selectively reimport the iron-loaded form from the surrounding environment. Siderophore 
biosynthesis in bacteria is accomplished by nonribosomal peptide synthetase (NRPS) enzymes, 
polyketide synthase (PKS) enzymes, and/or by NRPS independent siderophore (NIS) synthetase 
enzymes.3-5 Typically these enzymes do not have human homologues and knockdown 
experiments of siderophore biosynthesis have shown partial or complete suppression of 
pathogenicity for many different bacteria, making these enzymes attractive drug targets.6 This 
introduction will provide an overview of the structural biology of NRPS enzymes and then focus 
on the structural and catalytic aspects of the enzymes involved in the biosynthesis of pyochelin, a 
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siderophore from Pseudomonas aeruginosa, highlighting the involved accessory and tailoring 
activities that generate the unique chemical structure of pyochelin. 
 
Nonribosomal peptide synthetases (NRPS): chemical logic of peptide chain formation 
NRPS enzymes are large multidomain and multifunctional enzymes that display a 
chemical logic in which each module is responsible for the addition of a single amino acid to a 
growing peptide chain, including non-proteinogenic amino acids and hydroxy acids. An NRPS 
module consists of a condensation (C) domain, an adenylation (A) domain, and a peptidyl carrier 
protein (P) domain, except for the first initiation module, which lacks a condensation domain. 
The P-domain acts as a tethering system for the growing peptide chain and must be post-
translationally modified with coenzyme A on a conserved serine residue thereby generating a 
4’phosphopantetheinyl (Ppant) swinging arm. A-domains have been named the “gate keepers” of 
the NRPS assembly line as they selectively activate and incorporate the appropriate amino acids 
into the growing peptide chain.7  The A-domains activate an amino acid by catalyzing the 
formation of an aminoacyl-AMP, using ATP and releasing inorganic phosphate (Figure 1-1A).  
The Ppant thiol of the P-domain performs a nucleophilic attack on the carboxyl group of the 
aminoacyl-AMP, eliminating AMP and generating an aminoacyl-thioester bond, thereby priming 
the module. Once primed, the thioester tether on the P-domain transfers its amino acid cargo to 
subsequent domains, similar to a mechanical crane.  
Peptide bond formation, or elongation, is catalyzed between the amino acids of two 
primed modules within the C-domain of the downstream module. The upstream thioester bond is 
broken as the peptide bond is formed, thereby transferring the elongating peptide to the 
downstream module. This process is repeated with each subsequent module until the full chain is 
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Figure 1-1: NRPS assembly line and crystal structures highlighting intra- and inter- 
domain contacts and movements. A) NRPS natural product biosynthesis takes place in three 
phases: initiation, condensation, and termination. Adenylation and subsequent thiolation of the 
amino acid onto the Ppant tether prime a module. A condensation reaction is performed between 
amino acids tethered to primed modules to generate a peptide bond, thereby elongating the 
peptide chain. Termination and release of the mature peptide occurs by hydrolysis within a 
terminal thioesterase domain after transfer of the product to a conserved serine.  Throughout this 
review: yellow = adenylation (A); blue = peptidyl carrier domain (P); green = condensation (C); 
red = thioesterase (T). B)  The first crystal structure of a complete NRPS module, SrfA-C (PDB: 
2VSQ). Note that the Acore-domains (light yellow) are aligned in parts B thru F of this figure to 
highlight domain movements.  The substrate leucine (cyan spheres) is in the Acore-domain. The 
Asub-domains are in dark yellow.  C) The full module of AB3403 (PDB: 4ZXI) with the Ppant 
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tether (purple carbon and red oxygen spheres) in the closed C-domain ready to accept an 
upstream peptide. The substrates AMP and Gly (cyan spheres) are in the Acore-domain active site. 
D) A full-module crystal structure of EntF with its MLP, YbdZ (black), bound to the Acore (PDB: 
5JA1).  The mechanistic-based inhibitor, Ser-AVS, is covalently attached to the Ppant tether 
(spheres) which is trapped in the Acore-domain. E) Domain movements of the Asub- and P-domain 
are highlighted by the multi-domain structures of LgrA. These snap-shots show the movement of 
the Asub-domain in “open” and “closed” (PDB: 5ES5) conformations during adenylation, and the 
movement of the Asub- and P-domains during thioester formation (Val-NH-Ppant analog shown 
in spheres) (PDB: 5ES8) and for tailoring by the formyltransferase domain (pink) (PDB: 5ES9). 
F) The cross-module structure of DhbF containing an A- and P-domain from module 1 and C-
domain from module 2.  The cartoon emphasizes the cross-module construct.  The MLP from 
Geobacillus sp. is bound to the Acore-domain and shown in black.  The mechanistic-based 




made. Chain elongation is terminated by a thioesterase (T) domain in the terminal module.8  The 
peptide is transferred from the thioester of the P-domain to a conserved serine residue of the T-
domain, generating an amino ester, and allowing for hydrolysis and release of the mature 
peptide.8 
 
Nonribosomal peptide synthetases (NRPS): structural biology of an assembly line 
The C-, A-, and P-domains have been well-studied, with both structural and kinetic 
characterizations.9-13 The first structure elucidating the organization of a full NRPS module was 
the termination module (C-A-P-T) of surfactin biosynthesis, SrfA-C, from Bacillus subtilis 
(Figure 1-1B).14 Crystals of the full module were obtained after mutating the serine of the P-
domain that is post-translationally modified with Ppant to alanine. The A-domain contains two 
subdomains, a larger N-terminal A core (Acore) domain and a smaller C-terminal A sub (Asub) 
domain. The structure revealed a large interface between the C-domain and Acore-domain 
creating a platform for the Asub- and P-domains. In this structure, the P-domain was oriented so 
that the tether would be directed towards the acceptor site of the C-domain.  
Structures harboring the Ppant tether were documented with holo-AB3403 (C-A-P-T), a 
NRPS termination module from an uncharacterized biosynthetic pathway from Acinetobacter 
baumanni (AB3403, Figure 1-1C) and EntF from E. coli for the production of enterobactin 
(Figure 1-1D).15  In AB3403, the C-domain adopted a closed conformation and the P-domain 
was found to be rotated ~30˚ in comparison to the apo-SrfA-C structure thereby promoting 
insertion of the Ppant into the C-domain.15 In EntF, the Ppant tether was directed into the 
adenylation domain, causing a shift in domain orientation of both the Asub- and P-domains.  
Therefore, during the two different catalytic steps (adenylation and thiolation), the Asub-domain 
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assumes different orientations relative to the Acore-domain to promote the appropriate chemistries 
(Figure 1-1 C,D).16 This has been named “domain alternation”.17  Importantly, when the Ppant 
tether is directed into the condensation domain for peptide bond formation, the Asub-domain is in 
an adenylate-forming conformation, supporting hypotheses that while the peptide bond is being 
formed in the condensation domain for one biosynthetic product molecule, the Acore-domain 
adenylates an amino acid for the next catalytic cycle, suggesting NRPS enzymes work in true 
assembly line fashion.15 
Domain alternation of Asub- and P-domains were captured in multiple structures of LgrA, 
an NRPS of gramicidin synthase, representing the different steps of the catalytic cycle.16 LgrA is 
an initiation module containing a formyltransferase tailoring domain, an A-, and a P-domain.16 
Structures of Asub in the open and closed adenylation conformations were determined (Figure 1-
1E) in which the P-domains were disordered. An isosteric analog mimicked the natural Ppant 
tether, replacing the hydrolyzable thioester with an amide (Val-NH-Ppant).  With this analog, 
structures in the thiolation and formyltransferase conformations were determined in which the P-
domain is ordered.16, 18 In the thiolation state, the Asub-domain was oriented so that the P-domain 
inserts the Ppant mimic into the adenylation domain extending evidence that Asub-domain 
positioning is altered by the P-domain conformation. The differing thiolation and 
formyltransferase conformations of LgrA demonstrate the remarkable variability in module 
architecture.16 
A cross-module structure consisting of an A- and P-domain from the first module of 
DhbF and a C-domain from the second module was determined (Figure 1-1F).19  DhbF is a 
dimodular NRPS involved in the biosynthesis of the Bacillus siderophore, bacillibactin.19 Unlike 
the observed interactions between A-domains and upstream C-domains, the downstream C-
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domain had no interaction with the upstream A-domain. In this structure, the C-domain only 
interacts with the “back” face of the P-domain as the Ppant tether was trapped in the thiolation 
state of the upstream adenylation domain by a mechanistic inhibitor.19 These data in addition to 
cryo-EM structures and modeling suggest a lack of conserved intermodular surface 
interactions.19 Additional higher-order structures examining intermodular interfaces may reveal 
specific structural interactions necessary for chain elongation. 
MbtH-like proteins (MLPs) are auxiliary proteins sometimes found in NRPS gene 
clusters that have been hypothesized to have chaperone properties or to augment the catalytic 
activity of adenylation domains.20, 21 Crystal structures have been determined of MLPs alone and 
bound to Acore-domains.22-24 The DhbF structure described above was determined with an MLP 
bound to the Acore-domain (Figure 1-1F), and the MLP was shown to be essential for substrate 
binding and adenylation activity.19  The full-length EntF NRPS module was co-crystallized with 
MLPs that enhance its adenylation activity: the MLP encoded within its operon, YbdZ (Figure 
1-1D), and an MLP from P. aeruginosa, PA2412.24, 25 These structures exhibit no significant 
change in secondary structure of the A-domain upon MLP binding suggesting MLP binding may 
alter protein dynamics, though the mechanism by which MLPs enhance solubility or catalytic 
activity of A-domains remain elusive.19, 24  
 
Pyochelin from Pseudomonas aeruginosa 
The chemical logic and structural biology of NRPS modules is key for understanding 
how the peptide bonds are made by these nanomachines.  However, the bioactive peptides 
produced by these enzymes are far more diverse than the 20 amino acids found in proteins.  The 
diversity is incorporated by accessory enzymes that produce unusual amino and hydroxy acid 
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substrates for adenylation enzymes or by tailoring enzymes that alter amino acids already 
incorporated into the growing chain.  Here, we use the biosynthesis of pyochelin, a small 
salicylate-capped, siderophore produced by P. aeruginosa, as an example to describe some of the 
accessory enzymes and tailoring domains involved in the biosynthesis of nonribosomal peptides.  
Pyochelin is derived from three precursor molecules: one molecule of salicylate, a 
hydroxy acid, and two molecules of cysteine. Therefore, biosynthesis requires three NRPS 
modules: an initiation module that lacks a C-domain, an elongation module, and a termination 
module with a T-domain (Figure 1-2A).  Biosynthesis of pyochelin is initiated by two accessory 
enzymes.26-28   Chorismate is converted to isochorismate by the isochorismate synthase (ICS), 
PchA,29 and the isochorismate is subsequently converted to salicylate by the isochorismate 
pyruvate lyase (IPL), PchB (Figure 1-2B).30 The salicylate is activated by the stand-alone A-
domain, PchD, and transferred to the N-terminal P-domain of the NRPS, PchE (the initiation 
module).31 The elongation module of PchE integrates an L-cysteine into the growing peptide 
chain, cyclizes the L-cysteine to a thiazoline ring, and alters the stereochemistry with an 
epimerase tailoring domain.32 The termination module of PchF adds and cyclizes a second L-
cysteine to generate a second thiazoline.  The tailoring protein PchG reduces the thiazoline to 
thiazolidine.27  The stuffed methyltransferase domain of PchF performs an S-adenosylmethionine 
(AdoMet) dependent N-methylation of the thiazolidine.33 The mature pyochelin is released by 
the T-domain of PchF.  
 
Accessory enzymes in pyochelin biosynthesis: PchA and PchB  
PchA, isochorismate synthase.  PchA catalyzes the first step in pyochelin biosynthesis, 




Figure 1-2: Pyochelin biosynthesis. A) Three NRPS enzymes consisting of eleven different 
domains, two accessory enzymes, and one stand-alone tailoring enzyme are used to generate 
pyochelin, a siderophore from P. aeruginosa.  Domain abbreviations are as in Figure 1-1, with 
the exception that domain types are numbered in the assembly line (A1 = first adenylation 
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domain), and these additions: ICS = isochorismate synthase, IPL = isochorismate-pyruvate lyase, 
R = reductase.  B) Biosynthesis is initiated by PchA and PchB, which generate the hydroxy acid, 
salicylate, for the N-terminal cap.  PchA converts chorismate to isochorismate and PchB 
converts isochorismate to salicylate and pyruvate. Salicylate is activated by PchD and delivered 
to the Ppant tether of the first P-domain in PchE. Adenylation and thiolation of L-cysteine occur 
in the second module. Condensation with the upstream salicylate and cyclization and 
epimerization of L-cysteine to D-thiazoline occurs in the elongation module of PchE. The 
termination module in PchF, primed with an L-cysteine, condenses and cyclizes the cysteine 
with the upstream peptide chain to form a hydroxyphenyl-bis-thiazoline intermediate. PchG, the 
stand-alone tailoring domain, reduces the second thiazoline to a thiazolidine in an NADPH-
dependent manner. Subsequent AdoMet-dependent methylation of the thiazolidine nitrogen is 
catalyzed by the stuffed tailoring methyltransferase domain of PchF. Mature pyochelin is 
hydrolyzed and released by the T-domain. 
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siderophore, and tryptophan (MST) family of enzymes that are Mg2+-dependent chorismate 
utilizing enzymes.34-36 Although the structure of PchA remains unsolved, the structure is 
hypothesized to be homologous to the isochorismate synthases, EntC 37, 38 and MenF 35 (both E. 
coli enzymes) and the salicylate synthases Irp9 39 and MbtI 34, 40, 41 (Figure 1-3B). Interestingly, 
Irp9 and MbtI are the initiating enzymes to generate salicylate-capped siderophores for Yersinia 
spp. and Mycobacterium tuberculosis. These enzymes generate salicylate, first performing the 
isomerase activity of PchA and then the lyase activity, described below for PchB, in a single 
active site. The active site amino acids for all four isochorismate and salicylate synthase enzymes 
are highly conserved,42 catalyzing the isomerase activity using a general acid – general base 
mechanism.43  The active site is found at the interface of two structural domains capped shut by 
the binding of a catalytically required magnesium ion, preventing substrates entering or products 
leaving the active site. Magnesium ions at high concentrations are found to be inhibitory for 
isochorismate synthase enzymes, but promote lyase activity in the salicylate synthase enzymes.39  
Interestingly, ferrous ions bind to the catalytic metal binding site with nanomolar affinity for 
both isochorismate and salicylate synthase enzymes inhibiting catalytic turnover and suggesting 
a potentially physiologically relevant negative feedback mechanism for siderophore 
production.39 
 
PchB, isochorismate-pyruvate lyase.  PchB is the second enzyme in the pyochelin biosynthetic 
pathway, cleaving isochorismate to salicylate and pyruvate, a lyase activity (Figure 1-3C).30 
PchB has no structural homology to the salicylate synthase enzymes that perform the lyase 
activity (described above), and is instead a structural homologue of E. coli chorismate mutase   
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Figure 1-3: Accessory enzymes in pyochelin biosynthesis. A) PchA is an isochorismate 
synthase (ICS) converting chorismate to isochorismate. B) PchA structural homolog MenF in the 
“open” (PDB: 3BZM) and “closed” (PDB: 3BZN) structures, showing the magnesium ion 
(green) that creates a button closing the active site. C) PchB is an isochorismate pyruvate-lyase 
(IPL) converting isochorismate to salicylate and pyruvate. D) Crystal structure of dimeric PchB 
(PDB: 3REM).  Monomers are shown in blue and gray, with the products (green sticks) in the 
active sites.  
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(EcCM) of the AroQ class (Figure 1-3D).  Interestingly, PchB has adventitious chorismate 
mutase activity, albeit with much lower catalytic efficiency.  The chorismate mutase reaction is a 
pericyclic Claisen rearrangement converting chorismate to prephenate.44, 45  The mechanism of 
the lyase reaction is an asynchronous and sigmatropic pericylic reaction, with a quantitative 
hydrogen transfer from the ring to the pyruvylenol tail, substantiated by NMR experiments 46 and 
further supported computationally.47  While this mechanism has also been proposed for the 
lyase-active salicylate synthases,48 a second hypothesis for the salicylate synthases is that the 
reaction is performed by acid-base chemistry.49 PchB is as an intertwined dimer, in which each 
monomer consists of three helices.44, 50, 51 The active site loop is between helix 1 and helix 2 and 
is fully ordered when products are bound, whereas in the apo-structure the loop is disordered 
suggesting an open state for substrate entry or product egress, with closure during catalysis.50 
Lys42 is part of the mobile site loop and is hydrogen bonded to the pyruvate product.44 Mutating 
Lys42 to an Ala lowers lyase activity 100-fold although active site architecture is maintained 
suggesting that the chemical nature of Lys42 is key for efficient catalysis.44 
 
Stuffed tailoring domains in pyochelin biosynthesis: PchE and PchF  
 Most commonly, tailoring domains are incorporated into an NRPS module as an 
independent domain following the P-domain. However, in some cases tailoring domains are 
inserted within the A-domain, considered “interrupted” adenylation domains.52 The tailoring 
domains of both PchE and PchF are stuffed into interrupted adenylation domains between the 
core sequence motifs, A8 and A9, of the Asub-domain (Figure 1-4A).33, 52 The adenylation-






Figure 1-4: Tailoring enzymes. A) The A-domain of AB3403 (PDB: 4ZXI) highlighting the 
core adenylation sequences A8 and A9 (purple), between which tailoring domains are stuffed. 
Also highlighted is a sequence-based prediction of where the PchE epimerase-domain (blue) and 
PchF M-domain (green) are stuffed into the Asub-domain. B) PchE first condenses the upstream 
salicylate to the L-cysteine within its condensation domain. From here, two hypotheses arise. 
The first (top) suggests that the peptide tether moves to the epimerase domain to epimerize the L-
cysteine to D-cysteine, and then moves back to the condensation/cyclization domain to cyclize 
the D-cysteine to D-thiazoline. The second hypothesis (bottom) suggests that after condensation 
to the upstream salicylate, L-cysteine cyclizes to L-thiazoline while in the condensation domain 
and then moves to the epimerization domain to generate D-thiazoline, resulting in less domain 
movement. C) The “stuffed” methyltransferase domain of PchF performs a AdoMet-dependent 
methyl transfer to the nitrogen of the thiazolidine ring. D) MtfA (PDB: 3G2O), a stand-alone 
AdoMet-dependent nitrogen methyltransferase of vancomycin biosynthesis from Amycolatopsis 
orientalis, with AdoMet (cyan sticks) bound. E) Pyochelin-like natural products made by 
NRPSs: Pyochelin – Pseudomonas aeruginosa. Enantio-pyochelin – Pseudomonas fluorescens. 
Yersiniabactin – Yersinia pestis. Watasemycin – Streptomyces venezuelae. F) PchG, the stand-
alone tailoring enzyme, is a NADPH-dependent reductase converting the second thiazoline of the 
PchF intermediate to a thiazolidine. G) Irp3 (PDB: 5KVS), the PchG homologue for the 
production of yersiniabactin, is dimeric. The M-N loop closes the active site of an opposing 
monomer, with NADP+ (green sticks) and substrate analog bound (cyan sticks).  
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Epimerase domain of PchE.  PchE incorporates the first L-cysteine into the growing chain, 
which is cyclized and epimerized to a D-thiazoline in the final pyochelin product. The  
condensation domain is specialized, also being called a cyclization domain, because it cyclizes 
the cysteine to make the thiazoline ring. Cyclization domains are common in NRPS assembly 
lines generating natural products with thiazoline or oxazoline derivatives.9, 55 The substrate for 
the epimerase domain is not a free cysteine amino acid, but is instead the product of the 
condensation reaction of L-cysteine with the upstream salicylic acid.32 Experiments designed to 
determine if the conjugated L-cysteine was cyclized before or after epimerization were 
inconclusive, although the authors lean toward epimerase activity preceding cyclization (Figure 
1-4B, upper path).32 However, this would require an additional domain movement. If the 
cysteine is epimerized before cyclization, the peptide bond would be formed in the condensation 
domain, epimerized in the stuffed tailoring domain, and then move back to the condensation 
domain for cyclization.  The peptide would only have to visit the condensation domain once if 
both condensation and cyclization occur concurrently or sequentially, before epimerization 
(Figure 1-4B, lower path). 
Currently there is no determined structure for any stuffed-epimerase domains, but 
structures of the independent epimerase domain from TycA (A-P-E)56 of tyrocidine biosynthesis 
and an apo- and holo-P-epimerase didomain structure from GrsA (A-P-E)57 of gramicidin S 
biosynthesis have been determined, both from Bacillus brevis. The canonical epimerase domains 
of TycA and GrsA have similar active site motifs and share secondary structure homology to C-
domains.58 However, the epimerase domain of PchE (PchE-E) does not share any sequence 




Methyltransferase domain of PchF.  PchF adds the second L-cysteine to the growing peptide 
chain. After condensation to the upstream peptide and cyclization, the thiazoline is reduced to 
thiazolidine by NADPH-dependent PchG, described below. The stuffed methytransferase 
domain (M-domain) of PchF catalyzes an S-adenosyl methionine (AdoMet)-dependent methyl 
transfer to the nitrogen of the thiazolidine ring (Figure 1-4C).31, 33 The M-domain is a Class I 
methyltransferase possessing the consensus (GxG) AdoMet-binding motif.59 MtfA, a AdoMet-
dependent N-methyltransferase accessory protein of vancomycin biosynthesis from 
Amycolatopsis orientalis, shares a 32% sequence identity with the M-domain of PchF. MtfA 
transfers the AdoMet methyl group to the backbone nitrogen of leucine in the vancomycin-type 
antibiotics.60 Grouped into five different classes, methyltransferases exhibit diverse tertiary 
structure and different binding modes of the cofactor and substrate.  AdoMet, the 
methyltransferase product S-adenyosylhomocysteine (AdoHCys), and the inhibitor sinefungin 
were separately crystallized with MtfA (Figure 1-4D).60 AdoMet and AdoHCys bound in the 
consensus AdoMet-binding motif of the Rossmann fold, corresponding to binding modes seen in 
other Class I AdoMet-dependent methyltransferases.60  
 
Stuffed epimerase as a defunct methyltransferase.  Interestingly, the epimerase domain of PchE 
and the methyltransferase domain of PchF share ~21% sequence identity and ~55% sequence 
similarity, suggesting the epimerase domain of PchE is more similar to a dysfunctional AdoMet-
dependent M-domain than a canonical epimerase domain.  This can be rationalized 
mechanistically, since the first step of the methyltransferase activity is removal of a proton to 
generate an enol that is randomly reprotonated in the absence of AdoMet, racemizing the 
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position.  Only the appropriate epimer is a substrate for subsequent steps. Indeed, the PchE-
epimerase possesses a Gly to Arg mutation in the conserved AdoMet-binding motif (RxG), 
suggesting interruption of AdoMet binding.32, 52 This hypothesis can be applied more broadly to 
other pyochelin-like natural products. The biosynthesis of enantio-pyochelin (Figure 1-4E), the 
enantiomer of pyochelin generated by Pseudomonas fluorescens under iron-limiting conditions, 
lacks the stuffed epimerase domain.61 A stuffed epimerase of the multi-module NRPS called high 
molecular weight protein 2 (HMWP2) in yersiniabactin biosynthesis may also be a defunct 
methyltransferase, sharing the same substrate as PchE and possessing a Gly to Arg mutation in 
the AdoMet-binding motif (GxRxG).62 Watasemycin, an NRPS natural product from 
Streptomyces venezuelae, possesses a stuffed methyltransferase domain with neither 
methyltransferase nor epimerase activity, though it has the same domain architecture and 
substrates as PchE.63 Further structure-function studies of the aforementioned enzymes will be 
necessary to elucidate the differences between the methyltransferase, epimerase, and non-
functional stuffed domains of pyochelin-like natural products.  Stuffed domains have also been 
with other, unrelated catalytic activities, such as the oxidase activity of epothilone biosynthesis64 
and the monooxygenase activity of myxothiozole65 and thuggacin66 biosynthesis.    
 
Stand-alone tailoring domain: PchG   
The terminal cyclized cysteine must be reduced to a thiazolidine while tethered to the Ppant tail 
on PchF, prior to final methylation and release of the mature pyochelin by the thioesterase 
domain (Figure 1-4F).27  PchG, a stand-alone tailoring enzyme, is proposed to perform the 
reduction by proton donation from a general acid and subsequent hydride transfer from NADPH. 
Structures of a functionally homologous enzyme of yersiniabactin biosynthesis,67 Irp3, have been 
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determined: an apo-form, NADP+-bound form, and with NADP+- and substrate analog-bound 
(Figure 1-4G).68, 69 Irp3 is structurally similar to sugar oxidoreductases and to biliverdin 
reductase and possesses an N-terminal Rossmann fold domain for binding NADPH cofactor and 
a C-terminal a/b domain for substrate binding and dimerization.69  Upon binding of a substrate 
analogue, a long loop creates a lid over the active site of the opposing monomer leaving a tunnel 
that is the proposed entrance of the Ppant tether.68 As the authors point out, the binding of the 
substrate analog observed in this study may not be physiologically relevant, because the substrate 
analog binds in a position that would promote incorrect stereochemistry if hydride transfer were 
to take place.68 
 
Conclusion 
Siderophores are small, iron-chelating molecules generated by NRPS systems. NRPS 
structures have provided insight into how these nanomachines form peptide bonds outside of the 
ribosome. Recently, several full-module structures have elucidated the different domain 
interactions and domain alternations that occur during peptide assembly. Additional full-module 
and cross-module structures are necessary to understand domain interactions between modules. 
While NRPS enzymes generate peptide assembly, accessory and tailoring enzymes provide the 
chemical diversity that make each natural product unique. Using pyochelin biosynthesis as a 
model system, we have provided examples of the differing accessory and tailoring activities 
required to generate even a small natural product.  In pyochelin biosynthesis, accessory proteins 
are required to make the salicylate that caps the N-terminal end.  Tailoring domains in the 
generation of pyochelin fall into two categories.  Epimerase and methyltransferase domains are 
stuffed within the Asub-domain. This understudied class of tailoring domains may provide a 
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unique assembly line logic.  Pyochelin biosynthesis also requires a stand-alone tailoring 
reductase. While NRPS enzymes have been the subject of considerable investigation and the 
field is considered mature, there are still many unanswered questions regarding peptide bond 
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Stuffed Methyltransferase Catalyzes Penultimate Step of Pyochelin Biosynthesis 
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Bacteria, fungi, and plants generate siderophores, small molecules with high affinity for 
ferric iron, to scavenge the surrounding environment during times of iron starvation. Indeed, 
many siderophores have been identified as virulence factors in pathogenic bacteria due to the 
metal-limiting environment of the host species. Siderophores are classified by the chemical 
nature of the oxygen involved in ferric iron coordination.1 Pyochelin is a phenolate siderophore 
from Pseudomonas aeruginosa, a commensal and opportunistic gram-negative pathogen, 
notorious for causing infections in immunocompromised patients, burn-wound victims, and lung 
infections of cystic fibrosis patients.2-5  
The precursors of pyochelin are chorismate and two cysteine molecules (Figure 2-1A).6-8  
Chorismate, from the shikimate pathway, is converted to salicylate in two steps, and is the 
initiating hydroxy acid.  The cysteine molecules are added in succession by nonribosomal 
peptide synthetases (NRPSs), forming peptide bonds.6  Encoded within the pch operon are 
tailoring domains, which perform the epimerization, reduction and methyltransferase activities 
required to make the final bioactive compound.6, 9-11  Pyochelin is a tricyclic acid: the 2’-




Figure 2-1: Synthesis of pyochelin.  A) Biosynthetic pathway for pyochelin production. PchA, 
an isochorismate synthase, and PchB, an isochorismate pyruvate lyase, convert chorismate to 
salicylate. PchD-G consists of 12 different domains constituting three NRPS modules with 3 
tailoring domains. Together, they assemble pyochelin from salicylate and two L-cysteines, with 
co-substrates AdoMet, ATP, and NADPH. AdoMet = S-adenosylmethionine, AdoHcys = S-
adenosylhomocysteine. B) PchF is a full-NRPS module consisting of 5 different domains: a 
condensation domain (C; grey), adenylation domain (A; blue), stuffed methyltransferase tailoring 
domain (M; red), peptidyl carrier protein domain (P; yellow), and thioesterase domain (T; green). 
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PchF-FL refers to the “full-length” protein, whereas PchF-AMP only includes the stuffed 
adenylation methyltransferase-didomain and the peptidyl carrier domain. G667I-PchF-AMP has 
a mutation to the proposed AdoMet binding domain of the variant PchF-AMP. C) The proposed 
order of chemistries performed by PchF.  PchF incorporates L-cysteine to the growing peptide 
chain. The C-domain of PchF continues chain elongation by generating a peptide bond between 
L-cysteine and the upstream hydroxyphenyl-D-thiazoline moiety of PchE (an intermediate 
attached to the Ppant of the P-domain of PchE). The C-domain then cyclizes the cysteine to form 
a hydroxyphenyl-(D)-thiazoline-(L)-thiazoline intermediate.  PchG (green) reduces the terminal 
thiazoline of the hydroxyphenyl-bis-heterocycle to thiazolidine using NADPH. The stuffed 
methyltransferase domain of PchF then catalyzes the AdoMet-dependent methyl transfer 
(highlighted in red) onto the nitrogen of the newly reduced thiazolidine ring before transferring 
the complete heterocyclic siderophore to the T-domain releasing the fully mature pyochelin by 
hydrolysis in the T-domain. The alternate synthetic schemes where methyl transfer occurs at a 
different position in the sequence of biosynthesis are shown in Figure 2-2. D) During 
reconstitution assays, premature hydrolysis releases peptidyl intermediates during biosynthesis. 
Intermediates previously recovered by Walsh and colleagues are noted with an asterisk. 
Intermediate analogs used as potential substrates in this study are surrounded by a square. 
Nomenclature of intermediates is as follows: HP, hydroxyphenyl; Tox, thiazole; T, thiazoline; 
Tred, thiazolidine; CO2- carboxyl; Et, ethyl; Me/M, methyl.  
 29 
cyclized and epimerized cysteine, followed by a methylated 4’-thiazolidine (Tred-M) heterocycle 
from the second cyclized cysteine. 
NRPSs are multi-domain, multi-catalytic proteins arranged in modules to activate and 
add one substituent each to the growing chain, with each module containing a condensation 
domain, an adenylation domain and a carrier domain.  The NRPS assembly line uses a 
4’phosphopantetheinyl (Ppant) thiotemplate tethering system reminiscent of polyketide and fatty 
acid biosynthesis.  This means that the peptide bond forming and tailoring chemistries are 
performed while the intermediates are covalently attached to a carrier domain. The NRPS 
tailoring domains are affiliated with particular modules in several geometries.  The most 
common and best characterized geometry has the tailoring domain included at the end of a 
module following the carrier domain, as an independent domain that works in cis with the 
peptide bond forming domains of the module.  Pyochelin biosynthesis lacks this most common 
type of tailoring domain.  Some tailoring domains are stand-alone: independently expressed 
proteins acting in trans, such as the reductase of pyochelin biosynthesis (PchG).11  Finally, there 
are tailoring domains that are incorporated within the adenylation domain.12  Adenylation 
domains activate the substrate and attach it to the thiotemplate tethering system.  The “stuffed” 
tailoring domains replace a loop within an adenylation domain, making a true di-domain (Figure 
2-1B).13  Pyochelin biosynthesis uses two stuffed tailoring domains.  The first is an adenylation-
epimerase didomain in the protein named PchE, and the second is an adenylation-
methyltransferase didomain in PchF.10, 12-14    
Examples of stuffed tailoring domains, also known as “interrupted adenylation 
domians”,12 participating in natural product biosynthesis include oxygenases (i.e. epothilone,15 
myxothiazol,16 thuggacins)17, ketoreductases (i.e. cereulide)18, methyltransferases (i.e. 
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thiocoraline,1, 19 cyclosporine,20 echinomycin,21 enniatins,22 micacocidin,23 microcystin,24 
pyochelin,9, 10 yersiniabactin9), and epimerases (i.e. pyochelin,9, 10 yersiniabactin9). Importantly, 
some of the natural products synthesized using stuffed tailoring domains have been isolated and 
experimentally show anticancer (i.e. epothilone, thiocoraline, echinomycin), antifungal (i.e. 
myxothiazol), antibacterial (i.e. myxothiazol, thuggacin, micacocidin), or immunosuppressive 
(i.e. cyclosporine) activity. However, the mechanistic and structural characterization of stuffed 
tailoring domains has only just begun.  
Recently, mechanistic and structural studies of the stuffed methyltransferase domains 
from the biosynthesis of the microbial depsipeptides thiocoraline and kutzneride have been 
reported.19, 25-27 A main goal of these studies was to determine when in the biosynthetic pathway 
methylation occurs, with four possibilities: methylation of 1) the free amino acid, 2) the 
aminoacyl-AMP intermediate (after the amino acid is activated by ATP in the adenylation 
domain), 3) after thiolation (after the amino acid is attached to the Ppant tether of the peptidyl 
carrier protein domain), or 4) after condensation to the upstream peptide. Evidence suggests that 
the stuffed methyltransferase does not use the free amino acid as a substrate, but rather the 
substrate is either the aminoacyl-AMP intermediate or the amino acid attached to the carrier 
domain (after thiolation).19, 25-27  The possibility remains that methyl transfer occurs after 
elongation with the upstream peptide; however, thiocoraline and kutzneride are complex natural 
products, making intermediate analog synthesis to test the hypothesis of late stage methylation 
difficult.  Contradictory to the proposed model, isolates observed during reconstitution assays of 
epothilone biosynthesis and mechanistic studies of EpoB suggest tailoring occurs after 
condensation to the upstream peptide chain.14, 15  Epothilone biosynthesis employs a hybrid 
NRPS/PKS assembly line in which EpoB, a protein encoding a single NRPS module, has a 
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stuffed oxidase domain.  The EpoB substrate is simply a 2-methylthiazoline attached to the Ppant 
of the carrier domain.  
Here, using the termination module of pyochelin biosynthesis found in the protein PchF, 
we test the opposing hypotheses for the order of chemistry.  An order of catalytic events has been 
proposed in the literature (Figure 2-1C).   The PchF adenylation domain activates the cysteine 
substrate and attaches the cysteine to the thiotemplate of the carrier domain.6  The condensation 
domain of PchF links the nascent chain donated from the PchE carrier domain (HPT) to the 
cysteine on the carrier domain of PchF (HPT-Cys), and subsequently cyclizes this cysteine 
generating a thiazoline ring (HPTT).  While still tethered to the carrier domain of PchF, PchG 
reduces the second thiazoline ring generating a thiazolidine (HPTTred).  The N-methyltransferase 
stuffed domain in PchF modifies the ring to generate an N-methylated thiazolidine (HPTTred-M), 
the final proposed synthetic step before release of the mature pyochelin (HPTTred-MCO2−) by the 
thioesterase.  Two intermediates have been hydrolyzed from the thiotemplate tether, isolated and 
characterized during pyochelin reconstitution assays: HPT-Cys and HPTTred-CO2− (Figure 2-
1D).6, 11  The chemical release and isolation process also produced a more stable, off-pathway, 
product hypothesized to be the result of air oxidation: HPToxT- CO2−.6, 11  Since none of these 
isolated compounds contain the N-methyl on the thiazolidine, the order of the steps proposed for 
PchF is: adenylation, thiolation, condensation, cyclization, reduction, methylation and 
hydrolysis.  However, there are some contradictory data that suggest that methylation may 
proceed before reduction: labeled methyl groups, from either 14C-S-adenosylmethionine 
(AdoMet) or 3H-AdoMet were incorporated into the product in the absence of the reductase or 
NADPH.10 Altogether, the order of catalysis, and in particular when methyl transfer occurs 
remains elusive, leaving four reasonable pathways: 1) before condensation, 2) before cyclization, 
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3) before reduction, or 4) before hydrolysis (Figure 2-2).  Herein, we synthesized a series of 
substrate analogues and developed kinetic analyses for the adenylation and methyltransferase 
activities of PchF and PchF variants to establish the order of catalytic steps performed by PchF in 
pyochelin biosynthesis. Additionally, onium chalcogen effects were used to define the 
mechanism of PchF’s methyltransferase reaction.  
 
 
Materials and Methods 
 
Preparation of full-length PchF (pchf-fl) Overexpression Plasmid. The pchF overexpression 
construct was a gift from the laboratory of Christopher Walsh.6 The construct received was the 
kanamycin resistant, pET28b plasmid (Novagen).  
 
Preparation of Overexpression Plasmid containing PchF adenylation, methyltransferase, and 
peptidyl carrier protein domains (pchf-amp). The variant plasmid was produced by site directed 
mutagenesis using Herculase polymerase supplemented with 0-10% DMSO and the genomic 
DNA from Pseudomonas aeruginosa PAO1, which was purified using the DNeasy® Blood & 
Tissue Kit (Qiagen) as per the manufacturer’s instructions. The forward primer (5’-ATT AGA 
CAT ATG GTC GAG GCG CCG CCG CAG G-3’) including an NdeI site (underlined) and 
reverse primer (5’-TA ATA CTC GAG TCA GGT TCC GGC GCG CTG CGC AG-3’) 
including an XhoI site (underlined) were used to amplify the gene of interest. The amplified 
sequence was ligated into the kanamycin resistant pET28b plasmid (Novagen) digested with the 
same restriction enzymes. Upon sequencing, it was determined that there were an extra 2 
nucleotides inserted before the stop codon. Therefore, using QuikChange XL (Agilent), a 
forward primer (5’-GCA GCG CGC CGG AAT GAC TCG AGC AC-3’) and reverse primer (5’- 
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Figure 2-2: Possible biosynthetic strategies for PchF.  AdoMet dependent methylation is 
proposed to take place as the last tailoring step before hydrolysis and the release of the mature 
peptide; however previous evidence is contradictory. Four potential biosynthetic pathways are 
shown for methyl transfer: before condensation, before cyclization, before reduction, or directly 




GTC CTC GAG TCA TTC CGG CGC GCT GC-3’) were designed to remove the 2-nucleotide 
insertion before the stop codon (underlined). The isolated plasmid sequence encodes the entire 
adenylation domain, methyltransferase domain, and peptidyl carrier protein domain, residues 502 
to 1483 of PchF-FL. 
 
g667i-pchf-amp Overexpression plasmid. The variant plasmid was produced by using the 
kanamycin resistant pchF-AMP plasmid and the QuikChange XL (Agilent) as per the 
manufacturer’s instructions. The forward primer (5’-
GCGGCGGCGGTGATGGCGCCAAGCTC-3’) and reverse primer (5’-
GAGCTTGGCGCCATCACCGCCGCCGC-3’) were used to mutate the desired nucleotides 
(underlined). The isolated plasmid was sequenced showing that only the desired mutations were 
present. 
 
pa2412 Overexpression Plasmid. The pa2412 overexpression plasmid was a gift from the 
laboratory of Andrew Gulick.28 PA2412 is an MbtH-like protein (MLP) that increases P. 
aeruginosa NRPS protein expression including PchF (data not shown).29-32 The pa2412 gene is 
in a modified pET15b plasmid, conferring ampicillin resistance, containing a 5XHis affinity tag 
and a TEV protease recognition site in place of the thrombin site.28 
 
Methanococcus jannaschii (Mj) S-Adenosyl Methionine (AdoMet) Synthetase Overexpression 
Plasmid was a gift from Doug Markham from the Fox Chase Cancer Institute.33 
 
 35 
PchF-FL protein overexpression and purification. BL21 (DE3) E. coli containing the pchf-fl and 
pa2412 expression plasmids were grown in LB broth containing 50 µg/mL kanamycin and 200 
µg/mL ampicillin at 37 °C with shaking (250 rpm). Protein expression was induced when the 
OD600 reached ~0.6 by the addition of isopropyl β-D-thiogalactopyranoside (IPTG) to a final 
concentration of 200 µM. The temperature was reduced to 22 °C following induction. The cells 
were harvested by centrifugation (4 230 x g, 10 min, 4 °C) after ~21 hours.  The cell pellet was 
resuspended in 25 mM Tris-HCl pH 8, 500 mM NaCl, 50 mM imidazole (buffer A).  Cells were 
disrupted by French press (35 000 psi), and cellular debris was removed by centrifugation (23 
430 x g, 45 min, 4 °C).  The supernatant was applied to a chelating Sepharose fast-flow column 
(Amersham Biosciences) charged with nickel chloride and pre-equilibrated in buffer A.  Two 
column volumes of buffer A were followed by a 15-column volume linear gradient of 0-500 mM 
imidazole in buffer A. PchF-FL and PA2412 proteins eluted together in 1 peak at ~150 mM 
imidazole. Fractions containing the proteins of interest were pooled and concentrated using an 
Amicon stirred cell with YM30. The concentrated fractions were applied to a Superdex 200 size-
exclusion column (Amersham Biosciences) equilibrated with 50 mM Tris pH 8, 150 mM sodium 
citrate, 10% (v/v) glycerol (buffer B).  PchF-FL eluted separately from PA2412 and the PchF-FL 
fractions were concentrated as above to 1.4 mg/mL as determined by the general Beer-Lambert 
law and the predicted A280 of ε = 276 620 M-1 cm -1 (ProtParam).34 A total of 14.7 mg was 
obtained from the 2 L of cell growth. The protein was flash cooled and stored at -80 °C. 
 
PchF-AMP and G667I-PchF-AMP protein overexpression and purification. BL21 (DE3) E. coli 
containing the pchf-amp or g667i-pchf-amp and pa2412 expression plasmids were grown in LB 
broth containing 50 µg/mL kanamycin and 200 µg/mL ampicillin at 37 °C with shaking (225 
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rpm). When the OD600 reached ~0.6, protein expression was induced by the addition of IPTG to 
a final concentration of 200 µM and the temperature was reduced to 15°C. The cells were 
harvested by centrifugation (4 230 x g, 10 min, 4 °C) after ~26 hours.  The cell pellet was 
resuspended in 25 mM Tris-HCl pH 8, 500 mM NaCl, 5 mM imidazole, 10% glycerol (buffer C).  
Cells were disrupted by use of a French pressure cell (35 000 psi), and cellular debris was 
removed by centrifugation (11 950 x g, 60 min, 4 °C).  The supernatant was applied to a 
chelating Sepharose fast-flow column (Amersham Biosciences) charged with nickel chloride and 
pre-equilibrated in buffer C.  After injection, the column was washed with four column volumes 
of buffer C, followed by four column volumes of 50 mM imidazole in buffer C. A linear gradient 
from 50-500 mM imidazole in buffer C over 6 column volumes allowed elution of PchF-AMP or 
G667I-PchF-AMP and PA2412 proteins in a single peak around 200 mM imidazole. The pooled 
fractions were dialyzed using SnakeSkinâ Dialysis Tubing (10 kDa cutoff) against 50 mM Tris 
pH 8, 1 mM DTT, 10% (v/v) glycerol (buffer D).  The dialysate was changed for fresh buffer 
twice: at 1 and 2 hours before exchanging overnight. The protein solution was loaded onto a 
Source 30Q (GE Healthcare Life Sciences) anion exchange column pre-equilibrated in buffer D. 
After injection, two column volumes of buffer D were followed by a 0-500 mM NaCl linear 
gradient over 15 column volumes in buffer D. PchF-AMP or G667I-PchF-AMP eluted at ~150 
mM NaCl. The collected fractions were concentrated and applied to a Superdex 200 size-
exclusion column (Amersham Biosciences) equilibrated with 50 mM Tris pH 8, 100 mM NaCit, 
1 mM DTT, 10% (v/v) glycerol (buffer C).  The fractions containing PchF-AMP or G667I-PchF-
AMP were pooled and concentrated using a 30 kDa cutoff Amicon ultracentrifugal spin filter. 
The final concentration of PchF-AMP was 7.8 mg/mL as determined by the general Beer-
Lambert law and the predicted A280 of ε = 149 310 M-1 cm -1 (ProtParam).34 A total of 13.3 mg of 
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PchF-AMP was obtained from the 3 L cell growth. The protein was flash cooled and stored at -
80 °C. G667I-PchF-AMP was concentrated to 1.4 mg/mL, also determine by Beer-Lambert’s 
law and the predicted A280 of ε = 149 310 M-1 cm -1 (ProtParam).34 A total of 0.621 mg was 
obtained from the 3 L cell growth. The protein was flash cooled and stored at -80˚C.  
 
Methanococcus jannaschii (Mj) AdoMet Synthetase overexpression and purification. BL21 
(DE3) E. coli containing the pMJ1208-1 expression plasmid were grown in LB broth containing 
100 µg/mL ampicillin at 37 °C with shaking (225 rpm). When the OD600 reached ~0.6, protein 
expression was induced by the addition of IPTG to a final concentration of 500 µM. Cultures 
were incubated for an additional 5 hours. The cells were harvested by centrifugation (10 820 x g, 
10 min, 4 °C). The cell paste (50 g) was resuspended in 50mM HEPES pH 7.5, 10 mM  β-
mercapto-ethanol, 300 mM NaCl, 5 mM imidazole, supplemented with 1 mg/mL lysozyme, 0.1 
mg/mL DNAse I, 1 mM PMSF, and 0.1% Triton X (Buffer E).  Cells were lysed by sonication (6 
cycles of 45 seconds with 7 minutes between cycles, 4˚C) and subsequently heat denatured (50 
min, 75˚C). Cell debris and denaturants were removed by centrifugation (50 000 x g, 60 min, 
4˚C). The supernatant was loaded onto a Ni-NTA agarose column equilibrated with Buffer E. 
The column was washed with five column volumes of Buffer E and eluted with Buffer E 
supplemented with 500 mM imidazole. Fractions containing protein were concentrated using a 
10 kDa cutoff Amicon ultracentrifugal spin filter. The protein was loaded onto a G-25 column 
equilibrated in 50 mM Tris-HCl pH 8, 50 mM KCl, 0.1% BME, 10% (v/v) glycerol (Buffer F). 
Protein containing fractions determined by Bradford assay and were collected and concentrated 
using a 30-kDa cutoff Amicon ultracentrifugal spin filter. The concentrated protein was 
determined by the general Beer-Lambert law and the predicted A280 of ε = 24 870 M-1 cm -1 
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(ProtParam) before being flash cooled and stored at -80 ˚C.34 A total of 211 mg of Mj AdoMet 
synthetase was obtained from the 10 L of cell growth. 
 
Preparation of Substrate Analogues (Scheme 2-1).  
General experimental procedures. Chemical reagents purchased from commercial suppliers were 
not further purified prior to use. Flash column chromatography was performed using silica gel 
(4-63 mm) purchased from Sorbent Technologies. Other chemical separations were performed 
using a Teledyne Isco CombiFlash Rf.  A Biotage microwave reactor was used when 
microwaving was necessary. 1H and 13C NMR were recorded using a 500 MHz Bruker AVIII 
spectrometer equipped with a cryogenically-cooled carbon observe probe. Tetramethylsilane was 
used as an internal standard and chemical shifts (δ) are reported in ppm and coupling constants 
(J) are reported in Hz. High-resolution mass spectometry (HRMS) was performed using an 
electrospray ion source in either positive or negative mode on an LCT Premier (Micromass Ltd., 
Manchester UK). Melting points were measured with a Thomas Capillary Melting Point 
Apparatus and are uncorrected. Chiral analysis was carried out using HPLC, 1 ml/min 




A microwave vial was charged with 2-bromothiazole-4-carbaldehyde (2.08 mmol), 2-
hydroxyphenyl boronic acid (2.71 mmol), and Pd(PPh3)4 (0.104 mmol). The vial was sealed and 
flushed with argon for 5 minutes. Dimethoxyethane (16 mL) and a 2 M potassium carbonate 





Scheme 2-1:  Substrate analog synthesis of HPToxT-CO2−, HPToxT-CO2Et, HPToxTred-CO2−, 
HPToxTred-CO2Et, and HPT-Cys-Me. Substrate analogs were generated to assess the 
methyltransferase capabilities of PchF. Reagents and conditions: a) Pd(PPh3)4, K2CO3/DME, 
H2O, 150 °C, 49%;42 b) MeOH, K2HPO4(aq) (pH 6.5), 60 °C, 70%;42 c) SOCl2/EtOH, 40 °C, 
49%;42 d) Pd(PPh3)4, K2CO3/DME, H2O, 100˚C, 70%; e) EtOH/KCO2CH3 (aq), RT, 95%; f) 
SOCl2/EtOH, 40˚C, 55%; g) DIEA, COMU/DMF, 0˚C 1hr, RT 3hr, 12%; h) generated in the 
presence of 5mM TCEP in vitro.  
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temperature for an additional 5 minutes and heated to 100˚C for 45 minutes using a microwave 
reactor. The reaction was cooled to room temperature and filtered through a pad of celite and 
sepharose. The reaction was concentrated under reduced pressure and purified using flash 
chromatography (0:1-1:6 EtOAc/Hexane gradient) to yield a yellow solid (300 mg, 70%). The 
purified product was in agreement with literature values for melting point, 1H NMR, and 13C 
NMR.35  
 
(2RS-4R)-2-(2-(2-hydroxyphenyl)thiazol-4-yl)thiazolidine-4-carboxylic acid (HPToxTred -CO2−) 
2-(2-Hydroxyphenyl)thiazole-4-carbaldehyde (1.46 mmol) and potassium acetate (9.71 mmol) 
were dissolved in a solution of EtOH/H2O (10:3, 104 mL) in a round bottom flask. L-Cysteine-
HCl (5.40 mmol) was added and the reaction was stirred at room temperature for 1 hour. The 
reaction was washed with hexanes (50 mL), diluted with H2O and acidified with citric acid to 
~pH 2. The aqueous layer was extracted with CH2Cl2 (3 x 75 mL). The organic layers were 
combined and dried over Na2SO4. The solvent was removed in vacuo to afford a yellow/white 
solid (430 mg, 95%). The product was purified as a mixture of epimers and was in agreement 
with literature values for 1H NMR and 13C NMR.36  HRMS: [M + H]+ 309.0289 (calcd), 




Thionyl chloride (1.75 mmol) was added dropwise to anhydrous ethanol (3.25 mL) with 
vigorous stirring in a -10˚C ice water bath. The mixture was warmed to room temperature. 
HPToxTred-CO2− (0.649 mmols) was added and the reaction was heated to 40 ˚C and stirred for 16 
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hours. The mixture was cooled to room temperature and the solvent was removed in vacuo. The 
residue was reconstituted in saturated Na2CO3 (30 mL) and extracted with CH2Cl2 (4 x 50 mL). 
The organic layers were combined, and the mixture was concentrated under reduced pressure and 
purified using the CombiFlash (0:1-1:2 EtOAc/Hexane gradient) to yield a clear oil (119 mg, 
55%). The product was purified as a diastereomer (38:62) as determined by chiral 
chromatography (Figure 2-3). 1H NMR (500 MHz, DMSO-d6) δ 11.50 (d, J = 764.2 Hz, 2H), 
8.37 (s, 1H), 8.05 (dd, J = 7.9, 1.7 Hz, 1H), 8.02 (dd, J = 7.9, 1.7 Hz, 1H), 7.69 (s, 1H), 7.57 (s, 
1H), 7.34 – 7.21 (m, 2H), 7.00 (ddd, J = 8.3, 5.4, 1.2 Hz, 2H), 6.91 (dddd, J = 8.1, 7.2, 5.7, 1.1 
Hz, 2H), 5.84 (d, J = 9.9 Hz, 1H), 5.72 (d, J = 12.1 Hz, 1H), 4.41 (ddd, J = 8.7, 6.9, 5.1 Hz, 1H), 
4.25 – 4.10 (m, 4H), 4.03 – (ddd, J = 12.1, 8.8, 7.0 Hz, 1H), 3.94 (t, J = 9.4 Hz, 1H), 3.59 (t, J = 
12.2 Hz, 1H), 3.42 – 3.30 (m, 1H), 3.15 – 3.03 (m, 1H), 1.21 (td, J = 7.1, 4.7 Hz, 6H) 13C NMR 
126 MHz, DMSO-d6) δ 171.30, 170.84, 164.90, 163.92, 163.59, 155.35, 154.87, 152.37, 131.22 
– 131.01 (m), 127.43, 127.34, 119.27, 118.95, 118.82, 116.64, 116.51, 115.14, 67.06, 65.23, 
64.96, 61.08, 60.80, 38.03, 37.94, 14.08, 14.04. HRMS: [M + H]+ 337.0675 (calcd), 337.0708 
(found). 
 
(S)-2-(2-hydroxyphenyl)-4,5-dihydrothiazole-4-carboxylic acid (HPT-CO2−)  
Synthesis was performed as previously described in Bergeron et al and Zamri et al except 
starting materials differed by using D-cysteine instead of L-cysteine.37, 38 Product analysis agreed 
with previously reported 1H NMR and 13C NMR. HRMS: [M + H]+ 224.0303 (calcd), 224.0378 
(found). Chiral analysis was performed using HPLC and a CHIRALCELâ OD-H column. 
Elution was performed using a hexane:isopropanol (90:10) mixture supplemented with 0.1% 




Figure 2-3: Separation of HPToxTred-CO2Et diastereomers on CHIRALCEL OD-H column. 
Separation conditions: 1 mL/min, Hexane:Isopropanol (90:10), absorbance monitored at 320 nm. 





D-HPT-CO2−, L-cystine dimethyl ester dichloride (Sigma), and 1-cyano-2-ethoxy-2-
oxoethylidenaminooxy)dimethylamino-morpholino-carbenium hexafluorophosphate (Sigma) 
were purged under argon in a 25 mL round bottom flask before being dissolved in DMF (10 mL) 
at 0˚C. Diisopropylethylamine was then added dropwise  and the reaction was stirred vigorously 
for 1 hour at 4˚C and 3 hours at room temperature. Ethyl acetate (50 mL) was then added to the 
reaction. The organic fraction was washed with 1M HCl (2 x 50 mL), water (2 x 50 mL), and 
brine (2 x 50 mL) before being concentrated under reduced pressure. The residue was purified 
using the CombiFlash (DCM from 0-5 minutes before a gradient to 5% MeOH from 5-8 minutes 
and holding the 5% MeOH in DCM for 5 more minutes) eluting a peak at 10 minutes. An 
additional purification step was performed using a Waters Acquity UPLC with a photodiode 
array UV detector and an LCT premiere TOF mass spectrometer. The UPCL/HRMS used a 
gradient elution increasing 20% CH3CN in water over 5 minutes. Injections of a 1 mL DMSO 
stock were made onto a Waters (T3 C18) 19 x 150 mm, 5 µm column with a flow rate of 20 
mL/min to yield a white solid (35 mg, 12%). 1H NMR (500 MHz, DMSO-d6) δ 12.09 (s, 1H), 
8.86 (d, J = 8.0 Hz, 1H), 7.45 (ddd, J = 15.5, 7.8, 1.7 Hz, 2H), 7.02 – 6.92 (m, 2H), 5.38 (t, J = 
9.0 Hz, 1H), 4.68 (td, J = 8.7, 4.8 Hz, 1H), 3.66 (s, 3H), 3.55 (dd, J = 11.1, 8.4 Hz, 1H), 3.23 (dd, 
J = 13.9, 4.9 Hz, 1H), 3.07 (dd, J = 13.9, 9.1 Hz, 1H).  13C NMR 126 MHz, DMSO-d6) δ 173.03, 
171.05, 169.83, 158.61, 134.75, 131.09, 119.79, 117.35, 116.24, 77.99, 54.07, 52.32, 33.93. 




Preparation of Co-substrate Analogues.  
Se-Adenosyl selenomethionine (SeAdoMet).  
SeAdoMet was biosynthesized and purified by a modification of known methods.39 10 mM L-
methionine was added to a reaction mixture containing 100 mM Tris pH 8, 50 mM KCl, 40 mM 
MgCl2, 15 mM ATP, 8% 2-mercaptoethanol, 1.3 U inorganic pyrophosphatase (Sigma), 130 µM 
Mj AdoMet Synthetase in a final volume of 10 mL. The reaction was gently rocked for 4 hours, 
quenched with 1 mL 1 M H2SO4, and neutralized with 1 mL 2.5 M Ammonium Acetate. The 
mixture was centrifuged (3 082 x g for 10 minutes at 4˚C), flash cooled, and stored as 800 µL 
aliquots at -80˚C for further purification. 400 µL was injected onto a Waters Semi-Prep C18 
column (10 x 250 mm, 5µM) previously equilibrated in 95% 83 mM triethyl ammonium amine 
pH 5 (solvent A) and 5% methanol running at 5 mL/min. SeAdoMet was isolated at 3.7 minutes. 
A linear gradient of 0-50% acetonitrile and 5-50% methanol from 8-18 minutes was used to flush 
the column. A gradient back to 95% solvent A and 5% methanol was performed at 19 minutes to 
re-equilibrate the column for subsequent runs. Immediately after collection, SeAdoMet was flash 
cooled and lyophilized overnight. The lyophilized sample was resuspended in 250 µL of 100 
mM H2SO4 and the concentration was determined spectrophotometrically (AdoMet, ε260 = 15 
400 M-1cm-1)40 to be 35.3 mM.  
 
Te-Adenosyl telluromethionine (TeAdoMet).  





Steady-state Adenylation Assay  
Reactions contained 50 mM Tris pH 7.5, 1 mM MgCl2, 200 µM 2-amino-6-mercapto-7-
methylpurine ribonucleoside (MesGR), 0.002 U purine nucleoside phosphorylase (PNP, Sigma), 
0.001 U inorganic pyrophosphatase (IPP, Sigma), 2 mM ATP, 150 mM hydroxylamine, 0.600 
µM enzyme, and varying concentrations of L-cysteine. Stock concentrations (200 mM – 12.5 
µM) of L-cysteine were prepared by serial dilution in 25 mM Tris pH 8 buffer supplemented 
with 5 mM dithiothreitol. ATP, L-cysteine, and hydroxylamine were made fresh for each 
triplicate reaction. A parent mixture containing all reaction components except L-cysteine were 
incubated for 15 minutes at room temperature. The reaction (final volume, 100µL) was initiated 
by the addition of the parent mixture to substrate in a 96-well flat bottom plate (Corning Cat. 
#9017) and production of 2-amino-6-mercapto-7-methylpurine (MesG) was monitored at A360 on 
a Cary 50 UV-VIS Spectrophotometer with a plate reader attachment. Steady-state turnover was 
converted from AU/min to µM/min using the general Beer-Lambert law using 0.29 cm as the 
path-length and 11,000 cm-1M-1 as the molar extinction coefficient of MesG.41 The calculated 
rate was divided in half because each pyrophosphate released from the adenylation activity 
undergoes catalytic hydrolysis by inorganic pyrophosphatase creating two inorganic phosphates, 
both used individually by purine nucleoside phosphorylase to convert MesGR to MesG.  
Negative controls (without enzyme, without L-cysteine, and without ATP) were carried out with 
each triplicate reaction. The largest rate from the multiple negative control reactions was 
subtracted as background from all of the calculated rates. Triplicate trials were performed twice, 
on separate days for each enzyme. The initial rates were fit to the Michaelis-Menten equation 
using the nonlinear regression function of KaleidaGraph (Synergy Software). Kinetic parameters 
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were calculated for each of the six individual trials per enzyme. The reported values represent the 
average and standard deviation of these six sets of kinetic parameters. 
 
Methyltransferase Activity Assay  
Steady-state kinetics reactions varying HPToxTred-CO2Et substrate analog. Methyltransferase 
activity was observed with HPToxTred-CO2Et, but not observed with HPToxTred-CO2−, HPToxT-
CO2Et,42 or HPT-Cys-Me at 50 µM during a 1-hour incubation. Product formation of HPToxTred-
M-CO2Et was monitored at A320 by HPLC and confirmed by selected ion recording mass 
spectrometry. Each assay mixture (100 µL) contained 100 mM Tris-HCl pH 8.0, 45 nM enzyme, 
1 mM AdoMet, varying amounts of HPToxTred-CO2Et (1 µM – 30 µM) in DMSO (final DMSO 
concentration £ 2%), and 1 mM tryptophan (an internal standard). A parent mixture of all 
reaction components, excluding HPToxTred-CO2Et, was incubated at room temperature for 5 
minutes before initiating the reaction with HPToxTred-CO2Et. A time-course assay was performed 
for both low (1 µM) and high (30 µM) HPToxTred-CO2Et to determine that 15 minutes was within 
the linear steady-state turnover for PchF-FL and PchF-AMP.  Therefore, an endpoint assay was 
employed after a 15-minute incubation at room temperature. Reactions were quenched with 5 µL 
of 1 M H2SO4, vortexed, and neutralized with 10 µL of 1M sodium citrate pH 5.5.   
 
Steady-state kinetics varying Onium Chalcogen co-substrates. Each assay mixture (100 µL) 
contained 100 mM Tris-HCl pH 8.0, 45 nM enzyme, 50 µM HPToxTred-CO2Et, varying amounts 
of AdoMet, SeAdoMet or TeAdoMet (0-2 mM), and 1 mM tryptophan (an internal standard). A 
parent mixture of all reaction components, excluding AdoMet, SeAdoMet, or TeAdoMet, was 
incubated at room temperature for 5 minutes before initiating the reaction with AdoMet, 
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SeAdoMet or TeAdoMet. Reactions were quenched with 5 µL of 1 M H2SO4, vortexed, and 
neutralized with 10 µL of 1 M sodium citrate pH 5.5. Linear steady-state turnover was assessed 
for low (5 µM) and high (1 mM) concentrations of AdoMet and SeAdoMet. The reaction was 
quenched at 10 minutes, within the linear steady-state for both AdoMet and SeAdoMet. 
TeAdoMet reactions, also within steady-state, were incubated for 4 hours and contained twice 
the concentration of enzyme. AdoMet was varied in reactions from 0 – 2000 µM, SeAdoMet was 
varied from 0 – 650 µM, whereas TeAdoMet was varied from 0 – 800 µM.   
 
Methyltransferase steady-state kinetic analysis. Quenched and neutralized methyltransferase 
reaction samples were centrifuged (10 600 x g, 10 mins, 4 ˚C) to remove denatured enzyme, and 
100 µL of supernatant was injected onto an IRIS Technologies LLC IProSIL C18 column (4.6 X 
250 mm, 5 µM) previously equilibrated in 92% solvent B (0.016% formic acid, 0.02% 
triethylamine) and 8% acetonitrile. A linear gradient of 8-80% acetonitrile from 0-15 mins, an 
80-100% linear gradient from 15-20 minutes, and a 100-8% gradient from 20-21 minutes at 1 
mL/min gave good separation of HPToxTred-CO2Et (19.9 min) and methylated HPToxTred-CO2Et 
(21.6 min). A standard curve for product formation was determined by monitoring assay 
completion of 0-10 µM HPToxTred-CO2Et reactions with PchF-AMP performed in triplicate (9 
000 ± 100 mV/µM, Figure 2-4).  Due to substrate concentrations being less than 100 times 
enzyme concentration, Equation 1 was used to calculate steady-state parameters.43 The reported 
kinetic parameters were calculated by finding the average and standard deviation of each 









Equation 1.  
 48 
 
Figure 2-4: HPToxTred-M-CO2Et standard curve.  HPToxTred-M-CO2Et standard curve was 
produced by running methyltransferase assays to completion at concentrations varying from 0-25 
µM HPToxTred-CO2Et. Reactions were performed in triplicate. The slope, 9480 mAU/µM, was 





Cloning, sequencing, and purification of PchF-FL, PchF-AMP, and G667I-PchF-AMP.  
Three variants of PchF were generated heterologously in an E. coli expression system.  The first 
is the full-length protein as produced by P. aeruginosa, called PchF-FL herein (Figure 2-1B).  
The second consists of the adenylation-methyltransferase-didomain with the peptidyl-carrier-
protein domain, and is thus abbreviated PchF-AMP.  This construct removes the N-terminal 
condensation domain and the C-terminal thioesterase domain to eliminate confounding activities.  
Previously, Patel and colleagues developed a pyochelin reconstitution assay using recombinant 
PchD, PchE, PchF, PchG with substrates and cofactors, monitoring the formation of mature 
pyochelin by HPLC analysis.10 Patel et al reported that mutation of the second glycine of a core 
AdoMet binding motif (GxG) to an arginine (G1167R) in PchF resulted in undetectable amounts 
of pyochelin.10 The authors suggested that pyochelin formation was inhibited due to a lack of 
methyl transfer from AdoMet to the HPTTred intermediate (Figure 2-1 B,D).  We attempted to 
generate G667R-PchF-AMP, but overexpression yielded negligible amounts of protein.  We 
therefore proposed that substitution of the same glycine with a bulky hydrophobic residue would 
likewise inhibit AdoMet binding, and designed a glycine to isoleucine mutation, G667I-PchF-
AMP, which proved easier to purify in necessary amounts for kinetic analysis.   
Each of the PchF variants was co-expressed with PA2412, an MbtH-like protein (MLP) 
from the pyoverdin biosynthetic cluster of P. aeruginosa, which increases the amount of the 
PchF variants purified. This is consistent with other reports that have shown that MLPs greatly 
enhance NRPS solubility and are sometimes even necessary for expression.28, 29, 44, 45  Recently, 
MLPs were co-crystallized with NRPS modules showing complex formation with the 
adenylation domains.28, 45-48 While each PchF variant was co-expressed with PA2412 and the 
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proteins co-eluted by nickel chelating chromatography, the proteins were separated by gel 
filtration chromatography. Therefore, the final purified PchF variants did not contain PA2412.  
The PchF-AMP and G667I-PchF-AMP purification protocols included an additional anion 
exchange step to achieve >95% purity, estimated by polyacrylamide gel electrophoresis.  
 
Steady-state kinetics of adenylation activity. The adenylation domains of NRPS modules catalyze 
two activities.  First, an aminoacyl-AMP is produced.  Second, the amino acid is transferred to the 
thiol of a phosphopantethienyl-modified serine residue (the Ppant tether) of the carrier domain.49 
Once the amino acid is attached to the Ppant tether, the next enzymatic steps are carried out by 
downstream condensation, tailoring, or thioesterase domains. For an adenylation assay to enter the 
steady state, only the first reaction can be catalyzed: the amino acid cannot be transferred to the 
Ppant tether of the carrier domain, which would lead to a single turnover.  Furthermore, some 
adenylation domains do not release pyrophosphate when the second reaction is not catalyzed.50 
Therefore, a nucleophilic surrogate may be required.  The addition of hydroxylamine allows for 
nucleophilic attack of the aminoacyl-AMP, generating an aminoacyl-hydroxymate and AMP 
allowing for the release of the bound intermediate from the active site, promoting continuous 
turnover. Using this premise, Aldrich et al previously described a continuous assay to measure 
activity of adenylation domains by linking pyrophosphate production to an absorbance change  
(Figure 2-5).51  The coupled assay uses inorganic pyrophosphatase (IPP) to hydrolyze the 
pyrophosphate generated by the adenylation reaction to two inorganic phosphate ions.  
Subsequently, purine nucleoside phosphorylase (PNP) converts 7-methylthioguanosine (MesGR) 
to ribose 1-phosphate and the chromogenic 7-methythioguanine (MesG), with the change 
measured as an increase in absorbance at 360 nm.  This assay was optimized to measure  
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Figure 2-5: Adenylation assay (based on the assay designed by the Aldrich laboratory1, 2). The 
adenylation domain of PchF is specific for L-cysteine, forming an aminoacyl-AMP bond and 
releasing pyrophosphate (PPi). The native protein is post-translationally modified with coenzyme 
A, generating a 4’phosphopantetheinyl (Ppant) on a conserved serine in the peptidyl carrier 
protein (P) domain. The high energy aminoacyl-adenylate bond is used to link the cysteine 
substrate to the Ppant arm of the P-domain. In this assay, the recombinant PchF variants are not 
post-translationally modified with the Ppant stalling the enzyme after the formation of the 
aminoacyl-AMP intermediate, with the adenylation domain trapped in the “closed” 
conformation. Opening of the active site and release of pyrophosphate (PPi) can be promoted by 
addition of the nucleophile surrogate hydroxylamine, allowing the adenylation activity to enter 
the steady state.  Inorganic pyrophosphatase (IPP) converts one pyrophosphate (PPi) molecule to 
two inorganic phosphate (Pi) molecules. Purine nucleoside phosphorylase (PNP) catalyzes the 
phosphorylation of 7-methylthioguanosine (MesGR), generating ribose 1-phosphate and the 
chromogenic 7-methylthioguanine (MesG), which is monitored at 360 nm (bottom). Two 
molecules of MESG are generated for every one aminoacyl-AMP formation.  Structures of 
LgrA3 from gramicidin biosynthesis are used to illustrate the open (PDB: 5ES5) and closed 




adenylation of L-cysteine in the stuffed adenylation-methyltransferase didomain of PchF-FL, 
PchF-AMP, and G667I-PchF-AMP. Without hydroxylamine addition, detection of the 
downstream chromogenic MesG was within error of negative controls through 30 minutes, 
whereas the inclusion of hydroxylamine gave reliable steady state turnover (Figure 2-6), 
suggesting that the adenylation domain remains in a closed conformation and inorganic 
pyrophosphate is not released until after attachment of the amino acid to the Ppant tether 
(mimicked here by the hydroxylamine surrogate).  A representative assay with and without 
hydroxylamine can be found in Figure 2-6, along with Michaelis-Menten curves for the three PchF 
variants. Steady state kinetic parameters for adenylation of all three constructs can be found in 
Table 2-1.  Note that kcat values are within 1.2-fold for all three constructs.  The KM values are 
within 2-fold of each other, which accounts for the similar variance in kcat/KM. These values 
indicate that all three constructs have similar adenylation parameters, suggesting differences in 
catalytic efficiency for the methyltransferase domains are due to specific changes within the 
methyltransferase domains. It is interesting to note that kinetic parameters were found to be an 
entire magnitude different for PchF-FL than previously reported by Walsh et al (Table 2-1), 
highlighting discrepancies between the reverse assay measuring the incorporation of radioactive 
[32P]-pyrophosphate into ATP used by Walsh and the assay described herein. The disparities 
between these two assays were  formerly reported by Aldrich et al.51  
 
Substrate analog synthesis. Kinetic characterization of NRPS domains can be difficult because the 
biological substrate is attached to the PCP-domain through the Ppant tether.  Previously, substrate 
analogues, the peptidyl N-acetylcysteamine thioesters (peptidyl-SNACs), have been synthesized  
 53 
 
Figure 2-6: Hydroxylamine is a necessary addition for the adenylation assay. PchF catalyzes 
the adenylation of L-cysteine by ATP forming an aminoacyl-adenylate bond, releasing 
pyrophosphate. In the adenylation assay (Figure 2-5), pyrophosphate is converted to two 
inorganic phosphates by inorganic pyrophosphatase. 7-methylguanosine is then phosphorylated 
by purine nucleoside phosphorylase to generate 7-methylguanine, which absorbs at 360 nm. A) 
PchF variants do not turnover with L-cysteine and ATP (A), but do with the addition of 
hydroxylamine as a nucleophilic surrogate (B).  Michaelis-Menten steady-state kinetics (C) were 
performed comparing the L-cysteine adenylation activity of PchF-FL, PchF-AMP, and the 





Table 2-1: L-Cysteine adenylation assay – kinetic parameters  
 PchF-FLa PchF-FL PchF-AMP G667I-PchF-AMP 
kcat (min-1) 415 2.6 ± 0.2 3.2 ± 0.2 3.0 ± 0.3 
KM (L-Cys µM) 537 25 ± 2 41 ± 8 54 ± 6 
kcat/KM (M-1s-1) 13300 1800 ± 200 1300 ± 300 900 ± 100 
a Quadri, Keating, Patel, Walsh. Biochemistry 1999, 38, 14941-14954. Quadri et al used an 




and used to elucidate substrate specificity and kinetic parameters of NRPS domains.52 For 
example, Ehmann and colleagues revealed the enantioselectivity of the upstream substrate in the 
condensation domain of TycB from tyrocidine biosynthesis.52 Schneider et al used peptidyl-SNAC 
mimics to study the kinetics of the oxidase activity of EpoB from epothilone biosynthesis and 
BlmIII of bleomycin biosynthesis.15 Tseng et al also generated peptidyl-SNACs, peptidyl N-
acetylethanolamine esters (ONACs) and peptidyl N-acetylethylenediamine amides (NNACs) to 
probe thioesterase cyclization and hydrolysis capabilities of the thioesterase domain of Srf from 
surfactin biosynthesis.53 However, there are several examples where aminoacyl-SNACs or analogs 
have not been able to replace carrier-protein-bound thioesters or a substrate covalently bonded to 
CoA, and likely several more examples exist, though have not been published.54-58 As natural 
product biosynthesis advances through the NRPS assembly line, intermediates become more 
complex, often including non-proteogenic amino acids, special tailoring, and enantioselectivity, 
further complicating organic synthetic routes to generate intermediate analogs.   
During reconstitution assays, the growing peptide chain tethered by the 
phosphopantetheinyl (Ppant) thioester is susceptible to hydrolysis, releasing a carboxylate 
derivative of the intermediate of the biosynthetic pathway. HPT-Cys-Me, HPToxT-CO2− and 
HPTTred-CO2− (Figure 2-1D) had been detected during pyochelin reconstitution assays.6, 10 As a 
starting point for synthesis of potential substrate analogs to probe the methyltransferase kinetics 
of PchF, we generated these compounds, and derivatives altering the carboxyl to a terminal ester 
generating, HPT-Cys-Me, HPToxT-CO2Et and HPToxTred-CO2Et, to more closely mimic the 
natural thioester linkage of the Ppant tether.  
Synthesis of HPToxT-CO2− and HPToxT-CO2Et was previously reported.42  For HPToxTred-
CO2− and HPToxTred-CO2Et, 2-hydroxyphenyl boronic acid and 2-bromothiazole-4-carbaldehyde 
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were coupled by a Suzuki reaction to generate the 2-(2-hydroxyphenyl)thiazole-4-carbaldehyde 
product providing a 70% yield (Scheme 2-1). Condensation of the aldehyde with L-cysteine 
furnished the desired HPToxTred-CO2− substrate analog as a diastereomer in 95% yield. The 
terminal carboxylic acid was transformed to an ethyl ester by generation of an acyl chloride before 
nucleophilic addition of the solvent ethanol providing HPToxTred-CO2Et in 55% yield also as a 
diastereomer (Figure 2-3). HPT-Cys-Me was furnished by first synthesizing D-HPT-CO2− before 
performing an amino acid coupling with L-cystine using COMU as the coupling reagent. 
Generation of the free thiol HPT-Cys-Me, was performed in vitro by TCEP reduction and was 
confirmed by LC-HRMS.  
 
Steady-state kinetics of methyltransferase activity.  Using the synthesized substrate analogs, the 
steady-state capabilities of the stuffed methyltransferase domain of PchF-FL, PchF-AMP, and 
G667I-PchF-AMP were analyzed by a discontinuous assay performed in the presence of excess 
AdoMet. Neither HPT-Cys-Me, HPToxT-CO2Et, nor HPToxTred-CO2− demonstrated methyl 
transfer after 1-hour incubation.  Methylation of HPToxTred-CO2Et by both PchF-FL and PchF-
AMP was observed, generating HPToxTred-M-CO2Et, and the substrate and product were separated 
by HPLC (Figure 2-7). Product formation was confirmed by secondary ion mass spectrometry. 
G667I-PchF-AMP did not catalyze methyltransferase activity, even after extending the assay to 
10 hours. Kinetic parameters from the methyltransferase assay can be found in Table 2-2 and 
Michaelis-Menten plots can be seen in Figure 2-8. It is important to note that PchF-FL and PchF-
AMP provided comparable kinetic parameters using HPToxTred-CO2Et as a substrate analog, 




Figure 2-7: Methyltransferase Assay. PchF catalyzes methyl transfer from its natural co-
substrate AdoMet to the synthesized substrate analog, HPToxTred-CO2Et. Steady-state Michaelis-
Menten kinetics were performed by a discontinuous assay. Substrate analog (eluting at 20 min) 






Table 2-2: Methyltransferase assay varying substrate analog HPToxTred-CO2Et – kinetic parameters 
 PchF-FL PchF-AMP G667I-PchF-AMP 
kcat (min-1) 1.96 ± 0.04 2.9 ± 0.1 Not Detected  
KM  (AdoMet µM) 3.6 ± 0.2 7.5 ± 0.2 Not Detected  
kcat/KM  (M-1s-1) 9100 ± 500 6500 ± 300 Not Detected  
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Figure 2-8: Methyltransferase Assays Michaelis-Menten Curves.  Methyltransferase assay of 
PchF-FL, PchF-AMP, and G667I-PchF-AMP. Michaelis-Menten steady-state kinetic plots of (A) 




was 1.5-fold greater and the KM was 2.1-fold greater for PchF-AMP than that of PchF-FL. This 
resulted in PchF-AMP having a 1.4-fold lower catalytic efficiency compared to PchF-FL.  
 
Onium chalcogen effects on the methyltransferase kinetic parameters of PchF variants. 
Replacement of the sulfonium of AdoMet with selenonium (SeAdoMet) and telluronium 
(TeAdoMet) has been used to investigate the mechanism of cyclopropane fatty acid (CFA) 
synthase. Because the mechanism has been well-defined experimentally, steady-state kinetics of 
catechol O-methyltransferase (COMT) using AdoMet, SeAdoMet, and TeAdoMet were 
determined and kinetic parameters were used as a control.59 The primary (kcat) and secondary 
(kcat/KM) rate constants for methyltransferase activity of CFA synthase and COMT follow the 
trend SeAdoMet > AdoMet > TeAdoMet, parallel to the electrophilicities determined for the 
onium chalcogen.39, 59  Additional kinetic isotope effects (KIEs) using S-adenosyl-L-[methyl-
d3]methionine have been interpreted to support a tight SN2 transition state for CFA and COMT. 
The methyltransferase assay described above was performed with varying concentrations of 
AdoMet and co-substrate analogs, SeAdoMet and TeAdoMet, while keeping HPToxTred-CO2Et in 
excess. The effect of AdoMet, SeAdoMet, and TeAdoMet on PchF-FL, PchF-AMP, and G667I-
PchF-AMP is displayed in Table 2-3 and kinetic ratios are reported in Table 2-4. Michaelis-
Menten curves are in Figure 2-8. When AdoMet was used as the co-substrate for PchF-FL kcat 
and KM were 1.2 ± 0.1 min-1 and 3.3 ± 0.8 µM. SeAdoMet acted as a better co-substrate 
displaying a turnover number 1.9-fold greater and the KM was within error compared to AdoMet.. 
Substitution of AdoMet with TeAdoMet required the assay to be run 36-times longer (6 hours) 
with twice the enzyme concentration for both PchF-FL and PchF-AMP to detect product 
formation. Comparatively, TeAdoMet demonstrated a kcat that was 21-fold slower and a KM that  
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Table 2-3: Onium chalcogen effects for methyltransferase activity of PchF-FL and PchF-
AMP. 
Enzyme Substrate kcat (min-1) KM (µM) kcat/KM (M-1s-1) 
PchF-FL 
AdoMet 1.2 ± 0.1 3.3 ± 0.8 6000 ± 2000 
SeAdoMet 2.3 ± 0.6 3 ± 1 13000 ± 5000 
TeAdoMet 0.056± 0.003 160 ± 10 6.0 ± 0.5 
PchF-AMP 
AdoMet 2.48 ± 0.04 7.3 ± 0.8 5700 ± 600 
SeAdoMet 5.4 ± 0.8 5.4 ± 0.5 17000 ± 3000 





was 47-fold greater in comparison to AdoMet. When performing the same assay with PchF-
AMP, the kinetic values were comparable, yielding kcat/Km values within error to those for the 
full-length protein.  Overall, the primary and secondary rate constants for the different onium 
chalcogen co-substrate and analogs follow the trend for an sN2 mechanism. 
 
Discussion 
Peptides generated by nonribosomal peptide synthetases are not simply peptides but have 
been modified by tailoring domains to provide these natural products with their structural 
diversity and unique bioactive properties. Tailoring domains can be divided into three categories: 
independent, stand-alone, and stuffed. Independent tailoring domains are commonly incorporated 
into NRPS modules following the carrier domain, modifying the nascent chain in cis. Stand-
alone tailoring domains, like PchG of pyochelin biosynthesis, are separate enzymes that modify 
the natural product biosynthetic intermediates in trans.  Intriguingly, an increasing number of 
tailoring domains have been identified that are stuffed within the NRPS adenylation domain, 
replacing loops between signature adenylation domain sequences. 12, 13 Natural products built 
using stuffed tailoring domains have been isolated and used in the clinic as anticancer, 
antifungal, or antibiotic drugs.  However, investigation of stuffed tailoring domains has been 
limited, leaving the structural and biochemical characterization of these domains and their 
distinctive integration into the NRPS bioassembly as an emerging area of study.  
 A mechanistic and structural characterization of the stuffed methyltransferase domains 
involved in thiocoraline and kutzneride biosynthesis, microbial depsipeptides, has been 
previously reported.12, 19, 25-27 These stuffed methyltransferase domains perform O-methylation of 
a serine residue (kutzeride) and N- and S-methylation of cysteine residues (thiocoraline).  An 
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adenylation domain consists of two subdomains, an Acore subdomain, which includes the 
catalytic machinery, and the Asub subdomain that works with the carrier domain to orient the 
substrate attached to the Ppant tether into each active site of the NRPS module.46, 49, 60 The 
methyltransferase domain of the adenylation-methyltransferase didomain of the kutzneride 
assembly line for O-methylation of serine is in the second module of the protein KtzH and is 
stuffed into a loop of the Asub subdomain between the A8 and A9 adenylation core sequence 
motifs.27  The methyltransferase domains of the adenylation-methyltransferase didomains of the 
thiocoraline assembly line for N-methylation are found in the two modules of TioS and are 
likewise stuffed into loops of the Asub subdomain between the A8 and A9 adenylation core 
sequence motifs.  The didomain for S-methylation is in the standalone protein TioN, and the 
methyltransferase domain is stuffed into loops of the Acore subdomain between the A2 and A3 
adenylation sequence motifs.19, 25, 26  The premise of the previous mechanistic work on these 
didomains was that methylation could occur on the free amino acid, the aminoacyl-AMP 
intermediate, the amino acid after thiolation (attachment to the Ppant tether), or as part of the 
condensed chain before being passed to the next module.19, 25-27 Experiment has ruled out 
methylation of free serine or cysteine by these didomains.19, 25-27  The authors maintain that the 
substrate of the methyltransferase domain is either the aminoacyl-AMP intermediate, or the 
amino acid after thiolation but before condensation with the growing peptide chain.19, 25-27 
 The first structure of a stuffed adenylation domain from the second module of TioS, co-
crystallized with the MbtH-like protein (MLP), TioT, was recently reported to 2.90 Å.26  The 
authors describe the structure as a dumbbell with the N-terminal Acore and methyltransferase 
domains being the two balls of the dumbbell, with the discontinuous Asub domain connecting 
these two domains as the dumbbell bar.  By comparison to the structures for the initiation 
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module involved in biosynthesis of the antibiotic gramicidin (LgrA) and to the termination 
module of the enterobactin biosynthetic pathway (EntF), this new structure is in the “thiolation” 
conformation13, 46, 61.  In other words, the C-terminal Asub domain is in position for thiolation 
chemistry by the adenylation Acore subdomain (the conformation for attachment of the amino 
acid substrate to the Ppant tether), even though the carrier domain is not present in the TioS 
construct.  The structure is quite valuable, showing for the first time an Asub subdomain 
interrupted by a tailoring domain and yet maintaining the expected secondary and tertiary 
structure. 26  However, it does not answer mechanistic questions such as the order of events for 
peptide formation and tailoring; for example, whether methylation occurs before or after 
condensation to the nascent peptide. 
Adenylation domains are considered the ‘gate-keepers’ of the growing chain,62 selective 
for the amino acid that gets attached to the carrier domain, and in the case of adenylation-
methyltransferase stuffed didomains, successively methylated. If the amino acid attached to the 
Ppant tether is the substrate for the tailoring domain, then the methylated amino acid could 
subsequently condense with the upstream growing peptidyl chain.  Conversely, the substrate for 
the stuffed methyltransferase domain could be the condensed product of the module, a last step 
before interaction with the downstream module.  Thiocoraline and kutzneride are complex 
natural products, and probing the methyltransferase activities that occur late in the biosynthesis 
becomes increasingly difficult as intermediates become increasingly complex. Thus, studying the 
stuffed methyltransferase didomain of PchF, also interrupting the A8 and A9 core motifs in the 
Asub of the adenylation domain, is ideal: pyochelin is a much simpler natural product and 
intermediate analogs can be easily synthesized.   
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Previous studies of PchF and pyochelin biosynthesis do not support the model proposed 
for thiocoraline or kutzneride biosynthesis in which the stuffed methyltransferase didomains act 
upon the amino acid tethered to the carrier domain prior to condensation with the upstream 
peptidyl chain. From reconstitution assays Walsh and colleagues isolated and characterized HPT-
Cys-Me, HPToxT-CO2−, and HPTTred-CO2−, but not their methylated analogues, indicating 
condensation to the upstream nascent peptide occurs before methylation (Figure 2-1 C,D).6, 10, 11 
However, pyochelin biosynthesis is further complicated by the cyclization reaction that generates 
the thiazoline, which is hypothesized to be catalyzed by the condensation domain.  Methylation 
may occur after condensation and before cyclization, after cyclization and before reduction, or 
after cyclization and reduction directly prior to release of the mature peptide (Figure 2-2).6, 10, 11 
To decipher when on the pathway methylation occurs, intermediate analogs were synthesized 
mimicking isolates from the reconstitution assays (Figure 2-1D): HPT-Cys-Me is an ester analog 
mimicking the growing peptide chain after condensation and before cyclization; HPToxT-CO2Et 
is an ethyl ester mimicking the growing peptide chain after cyclization but before reduction; and 
HPToxTred-CO2Et mimics the growing chain after cyclization and reduction. Importantly, methyl 
transfer was only observed when HPToxTred-CO2Et was used as the substrate analog, indicating 
that condensation, cyclization, and reduction by PchG are necessary events prior to methylation 
by PchF. It should also be noted that methyl transfer was not observed for the carboxylic acid 
analogue, HPToxTred-CO2−, suggesting that the previously isolated acid is not a substrate. The 
ester, HPToxTred-CO2Et, which more closely resembles the natural thioester, serves as a substrate 
analogue for methyl transfer.  
Steady-state kinetic parameters were measured for PchF-FL, PchF-AMP, and G667I-
PchF-AMP, for both the adenylation methyltransferase activity.  The adenylation activity assay 
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showed that all three constructs, PchF-FL, PchF-AMP, and G667I-PchF-AMP, had similar 
adenylation parameters, indicating that the methyltransferase variant did not negatively impact 
the larger didomain (Table 2-1).  While the catalytic efficiency was an order of magnitude less 
than that previously reported, the assays are significantly different, as documented in the Results 
section, and similar differences are well documented.51, 63 A newly defined, discontinuous HPLC 
methyltransferase assay gave reliable kinetic parameters, with the G667I-PchF-AMP variant 
showing complete loss of methyltransferase activity.  
In 1976, Schowen and colleagues proposed that catechol O-methyltransferase (COMT) 
used a symmetrical and “tight” SN2 transition state, one in which the bonds being formed and 
broken were both short, based on kinetic isotope effects measured with deuterated and 13C-
labeled AdoMet.64 More recently (2016), Luo and colleagues have used similar experiments to 
probe the transition state of SET8, a lysine methyltransferase, and showed a “tight” yet early 
asymmetrical transition state,  with a C-N distance of ~2.4 Å and a C-S distance of ~2.0 Å.64, 65  
In addition to measuring KIEs and BIEs, the authors also measured steady state kinetic 
parameters with SeAdoMet and found the values to be in agreement with the slightly weaker Se-
C bond expected for the leaving group due to the intrinsic chemical properties of the chalcogen.39  
Indeed, onium chalcogen effects have been used to probe methyltransferase activity.  By 
monitoring the formation of 5’-methylthioadenosine (MTA),  5’-methylselenoadenosine 
(SeMTA), and 5’-methyltelluroadenosine (TeMTA), a model for relative electrophilicities was 
observed and followed the trend: SeAdoMet > AdoMet > TeAdoMet.39 Interestingly, substitution 
of AdoMet with its onium chalcogen analogs used in steady-state analysis with cyclopropane 
fatty acid synthase and COMT resulted in primary (kcat) and secondary (kcat/KM) rate constants 
following the same trend.59   In this study, AdoMet and its onium congeners, SeAdoMet and 
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TeAdoMet, were used as co-substrate and co-substrate analogs in the PchF methyltransferase 
assay. PchF-FL and PchF-AMP exhibited primary and secondary rate constants that followed the 
SeAdoMet > AdoMet > TeAdoMet trend.  By comparison of onium chalcogen steady state 
kinetics for methyltransferases of determined transition state (Table 2-4), these results allow us 
to hypothesize that PchF methyl transfer proceeds by an SN2 reaction mechanism for this 
secondary amine.    
 
Conclusion 
In summary we have characterized the stuffed methyltransferase didomain of PchF in 
pyochelin biosynthesis. Potential substrate analogs were synthesized based on previously 
recovered biosynthesis intermediates. The stuffed methyltransferase didomain of PchF catalyzes 
AdoMet dependent methyl transfer, the penultimate step in pyochelin biosynthesis, after 
condensation of the cysteine onto the upstream peptide, cyclization to form the thiazoline, and 
reduction to form the thiazolidine, but before release of the mature peptide. Onium chalcogen 
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Table 2-4: Kinetic parameter comparison between AdoMet, SeAdoMet, and TeAdoMet 
Enzyme Substrate Analog 
kcat  
AdoMet / (Se/Te)AdoMet 
kcat/KM  
AdoMet / (Se/Te)AdoMet 
CFA a 
Synthase  
SeAdoMet 1.8 2.8 
TeAdoMet 0.50 0.059 
COMT a 
SeAdoMet 1.1 1.2 
TeAdoMet 0.16 0.0089 
SET8 b SeAdoMet 1.9 1.9 
PchF-FL 
SeAdoMet 1.9 2.2 
TeAdoMet 0.047 0.0010 
PchF-AMP 
SeAdoMet 2.2 3.0 
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 Bacteria, fungi, and plants employ nonribosomal peptide synthetases (NRPSs) to generate 
a chemically and functionally diverse set of natural products. Aside from peptide bonds, other 
hallmarks of nonribosomal peptides (NRPs) include azoles/azolines/azolidines resulting from 
threonine (Thr), serine (Ser), or cysteine (Cys) cyclodehydration reactions, and inclusion of D-
amino acids in the mature NRP. Introduction of heterocyclic azole derivatives and/or D-amino 
acids to NRPs are often important or necessary to induce their biological activity.1-3 
Additionally, the chemical uniqueness given by the altered stereochemistry of peptide a-carbons 
and/or heterocyclic azole derivatives creates NRPs that are less susceptible to proteolytic 
cleavage.4, 5 These reasons likely contribute to the evolution of natural product biosynthesis to 
include heterocyclic azole derivatives which are found in effective secondary metabolites, such 
as siderophores, (i.e. pyochelin,6 yersiniabactin,7 vibriobactin,8 mycobactin9) and some of which 
have been isolated with antibacterial (i.e. myxothiazole,10, 11 bacitracin A,12 zelkovamycin13), 
antitumor (i.e. bleomycin,14 epothilone15), and immunosuppressant (i.e. argyrin16) properties. 
Similarly, NRPs isolated with D-amino acid stereochemistry include secondary metabolites such 
as siderophores (i.e. pyochelin,6 yersiniabactin,7 vibriobactin,8 mycobactin9), and have also been 
found to possess antibacterial (i.e. tyrocidine A17, bacitracin A12), antitumor (i.e. thiocoraline18), 
and immunosuppressant (i.e. cyclosporin A19) properties. Overall, many of these NRPs have 
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therapeutic implications for a variety of diseases. Understanding the mechanistic and structural 
aspects of NRPSs involved in heterocycle formation and inclusion of, or altered stereochemistry, 
continues to be a major importance in novel drug design and development. 
 The formation of heterocycles and inclusion of D-stereocenters are normally catalyzed by 
cyclization and epimerase domains. Interestingly, NRPS condensation domains, cyclization 
domains, and canonical epimerase domains share overall tertiary similarity. Condensation, 
cyclization, and epimerase domains are pseudodimers with each monomer structurally related to 
monomeric chloramphenicol acetyltransferase (CAT), although CATs exist as homotrimers and 
share low sequence identity with condensation, cyclization, and epimerase domains (Figure 3-
1).4, 20 Structural and mechanistic characterization of condensation, cyclization, and epimerase 
domains has provided a better understanding of their distinctive active site residues involved in 
catalysis. However, many questions regarding the molecular mechanisms remain.4, 20-22 This 
chapter aims to further understand cyclization and epimerase domains in NRPS biosynthesis by 
studying PchE of pyochelin biosynthesis, a siderophore from Pseudomonas aeruginosa. 
Pyochelin is a tricyclic NRP consisting of a hyrdroxyphenyl, D-thiazoline, and an N-
methylated L-thiazolidinic acid (Figure 3-2). The biosynthesis of pyochelin employs two 
cyclization domains, for the cyclization of Cys residues to generate the thiazoline and 
thiazolidine rings, and a non-canonical stuffed epimerase domain, hypothesized to convert the L-
thiazoline to the D-configuratrion.23-25 PchE is proposed to be responsible for the addition and 
modification of the D-thiazoline, consisting of 5 different domains: an N-terminal aryl carrier 
protein domain, a cyclization domain, an adenylation and stuffed epimerase didomain, and a C-




Figure 3-1: Condensation, cyclization, and epimerase domains share tertiary structure. 
NRPS condensation (green, PDB: 4ZXH, an  NRPS from unknown pathway in Acinetobacter 
baumanii)26, epimerase (cyan, 5ISW, from gramicidin S synthetase of gramicidin A biosynthesis 
from Brevibacillus brevis)22, and cyclization (orange, 5T3E, from bacillamide synthetase from 
bacillamide biosynthesis in Thermoactinomyces vulgaris)4 domains share a pseudo-dimeric 
tertiary fold similar to the tertiary structure of chloramphenicol acetyltransferase shown here as a 
monomer but naturally exists as a trimer (violet, PDB: 3CLA, from Escherichia coli).27 
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Previously, Walsh and colleagues performed in vitro experiments to elucidate the order 
and biochemical steps performed by PchE in pyochelin biosynthesis.24, 25 The authors showed the 
adenylation domain was specific to L-Cys, not D-Cys, and that L-Cys retained its stereochemistry 
once loaded upon the Ppant tether.24 Other experimental results aimed at understanding 
condensation, cyclization, and epimerization were inconclusive. However, the authors  
proposed the following model (Figure 3-3A, top). After L-Cys is primed to the Ppant tether 
(CysL-Ppant), a condensation reaction ensues with the upstream salicylate in the cyclization 
domain forming a hydroxyphenyl-L-Cys-S-Ppant (HP-CysL-Ppant). Next, HP-CysL-Ppant travels 
from the cyclization domain to the epimerase domain where the a-carbon of the Cys is 
abstracted and randomly re-protonated creating a new HP-CysD-Ppant intermediate or 
regenerating the HP-CysL-Ppant intermediate. The peptide then returns to the cyclization domain 
for cyclodehydration of the Cys creating a thiazoline (T) or HPTL/D-Ppant biosynthetic 
intermediate. Walsh and colleagues propose that the downstream cyclization domain of PchF, the 
next biosynthetic enzyme, is a gatekeeper, only continuing chain elongation with HPTD-Ppant 
and not HPTL-Ppant. Indeed, condensation domains have displayed stereospecificity towards 
their substrates stereochemistry and epimerase activity of the acyclic HP-CysL-Ppant to HP-
CysD-Ppant may be necessary to catalyze cyclodehydration to the HPTD-Ppant intermediate, 
although this does not support the formation of its racemate, HPTL-Ppant.17, 28 Also, to our 
knowledge, this would be the only cyclization domain not performing condensation and 
cyclization chemistries back-to-back, suggesting PchE may have a novel cyclization domain. 
Alternatively, we propose PchE sequentially condenses the salicylate to L-Cys-Ppant and 
immediately following, cyclizes the Cys to a thiazoline forming HPTL-Ppant (Figure 3-3A, 




Figure 3-2: Different 2-hydroxyphenylthiazoline-4-thiazolidine natural products from 
bacteria. Pyochelin, yersiniabactin, micacocidin, enantiopyochlin, watasemycin, and thiazostatin 
are all secondary metabolites each having at least a tri-cyclic hydroxyphenyl, thiazoline, and 
thiazolidine ring. Interestingly, the stereochemistry of the thiazoline, thiazolidine ring system is 
either R, R or S, S for each natural product.  
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stereochemistry to HPTD-Ppant before condensing with the downstream module. There are a few 
attributes supporting this hypothesis. This biosynthetic route would be more energetically 
favorable; only requiring two domain movements as opposed to three. Epimerization would also 
be more likely to occur on the thiazoline rather than the acyclic Cys as the a-carbon of a 
thiazoline would have a much lower pKa (Figure 3-3A). 
Intriguingly, PchE’s epimerase domain shares sequence homology with canonical 
methyltransferase domains but not canonical epimerase domains.24, 25 However, the GxG S-
adenosyl methionine (AdoMet) binding motif is RxG in PchE which would inhibit AdoMet 
binding to the stuffed tailoring domain. Yersiniabactin, a siderophore from Yersinia pestis, has a 
C-methyltransferase (M2 domain of Irp1) proposed to methylate the a-carbon of a thiazoline 
(Figure 3-3B).29 The proposed mechanism for methylation of the thiazoline includes an active 
site base that abstracts a proton forming an enol-intermediate and prompting nucleophilic attack 
of the electrophilic methyl of AdoMet. The nucleophilic attack towards the methyl group occurs 
on the opposing side of the enol altering the stereochemistry of the thiazoline carbon to its D-
isoform. PchE’s stuffed epimerase domain may act similarly.  An active site base abstracts a 
proton from the L-thiazoline forming an enol intermediate. When AdoMet is not present, the a-
carbon becomes re-protonated by an active site acid forming a HPTD-Ppant which condenses 
with the downstream peptide. Alternatively, if no active site acid exists, solvent re-protonation 
occurs until the correct stereochemistry is achieved.24, 30 
This chapter aims to further elucidate the cyclization and epimerase chemistry performed 
by PchE. Herein we purify recombinant PchE (PchE-FL) and a shortened variant only consisting 





Figure 3-3: Proposed biosynthetic pathways of PchE in pyochelin biosynthesis, Irp1 
methyltransferase proposed intermediate in yersiniabactin biosynthesis, and the PchE 
constructs used for experimentation. A) The proposed biosynthetic pathways of PchE in 
pyochelin biosynthesis. The currently accepted pathway in the literature is depicted on top. 
PchE’s cyclization domain condenses the L-Cys to the upstream salicylate forming HP-CysL-
Ppant. The a-carbon of the Cys is then abstracted by an active site base in the stuffed epimerase 
domain forming a carbanion. The carbanion is randomly re-protonated in succession before 
traveling back to the cyclization domain to be cyclized to form HPTL/D-Ppant. The condensation 
domain of PchF is proposed to be specific only condensing the downstream aminoacyl-Ppant 
with HPTD-Ppant. A second pathway is proposed on the bottom. Within the cyclization domain 
domain, the L-Cys is condensed to the upstream salicylate and cyclized to form HPTL-Ppant. The 
peptidyl chain then travels to the stuffed epimerase domain where a proton is abstracted forming 
an enol intermediate before random re-protonation occurs generating HPTD-Ppant. The bottom 
pathway requires only two domain movements compared to the top pathway requiring three 
movements between domains. B) The proposed enol intermediate of the cyclized thiazoline 
would be a shared intermediate with the proposed substrate of the independent tailoring domain 
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(M2) from Irp1 of yersiniabactin biosynthesis. The stuffed epimerase domain in PchE is 
sequentially similar to methyltransferase domains, although the AdoMet binding domain is 
mutated, suggesting AdoMet is unable to bind to PchE. We propose the mechanism for 
epimerase activity of the stuffed epimerase domain is similar to the mechanism of NRPS C-
methyltransferases sharing the enol intermediate.  C) PchE-FL, consisting of the full-NRPS 
module with two carrier protein domains, a cyclization domain, and an adenylation and stuffed 
epimerase didomain. In this work, we purified a full-length enzyme (PchE-FL) and a variant 
enzyme consisting of only the adenylation and stuffed epimerase didomian (PchE-AE).  
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substrate and product analogs and attempt assays to further define the order in which PchE 
performs its chemical steps during pyochelin biosynthesis. 
 
Materials and Methods 
pche-fl Overexpression Plasmid  
The overexpression construct for pche-fl was gifted to the lab from the laboratory of Christopher 
Walsh.1 The construct received was in pET28b, a kanamycin resistant plasmid (Novagen). 
 
pche-ae Overexpression Plasmid 
The pche-ae variant plasmid was generated by site directed mutagenesis using Herculase 
polymerase supplemented with 4-10% DMSO and the genomic DNA from Pseudomonas 
aeruginosa PAO1 which was purified using the DNeasy® Blood & Tissue Kit (Qiagen) as per 
the manufacturer’s instructions. The forward primer (5’-ATT AGA CAT ATG CCG TTG CCC 
TGG GCG CAG CAG-3’) including a NdeI site (underlined) and reverse primer (5’-ATA CTC 
GAG TCA AAG TGC GCG GGT CAT GCT C-3’) including an XhoI site (underlined) were 
used to amplify the gene of interest. The amplified sequence was ligated into the kanamycin 
resistant pET28b plasmid (Novagen) digested with the same restriction enzymes. The isolated 
plasmid sequence was sequenced and encodes the entire adenylation domain and proposed 
epimerase domain, residues 532 to 1339 of PchE-FL. 
 
pa2412 Overexpression Plasmid. The pa2412 overexpression plasmid was a gift from the 
laboratory of Andrew Gulick.31 PA2412 is an MbtH-like protein (MLP) that has been shown to 
increase P. aeruginosa NRPS protein expression including PchE and PchF (data not shown).32-35 
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The pa2412 gene is in a modified pET15b plasmid with ampicillin resistance and contains a 
5XHis affinity tag in addition to a TEV protease cleavage recognition site for thrombin 
proteolysis. 31 
 
PchE-FL protein overexpression and purification 
BL21 (DE3) pLysS E. coli cells containing the pa2412 and pche-fl expression plasmids were 
grown in LB broth containing 50 µg/mL kanamycin and 200 µg/mL ampicillin at 37°C with 
shaking (250 rpm). Protein expression was induced by the addition of isopropyl β-D-
thiogalactopyranoside (IPTG) to a final concentration of 200 µM after the OD600 reached 0.6. 
The temperature of the culture was lowered to 30˚C following induction. After 3 hours, the cells 
were harvested by centrifugation (4 230 x g, 10 min, 4˚C). The pellet was resuspended in 25 mM 
potassium phosphate pH 8.0, 50 mM sodium citrate, 500 mM NaCl, 5 mM imidazole, 1 mM n-
octyl-b-D-glucopyranoside, and 10% glycerol (buffer A). The resuspended pellet was flash 
frozen at -80˚C until further use. While thawing, 10 µL of 75 mg/mL lysozyme was added to the 
pellet. The cells were disrupted using a French pressure cell (35 000 psi), and cellular debris 
were removed by centrifugation (11 950 x g, 40 min, 4˚C). The supernatant was injected onto a 
nickel charged Sepharose fast-flow column (Amersham Biosciences) pre-equilibrated in buffer 
A. After 8 column volumes of buffer A, the protein eluted by linear gradient of buffer B (buffer 
A supplemented with 250 mM imidazole) from 0-100% over 10 column volumes. The fractions 
containing PchE-FL and pa2412 were pooled together and dialyzed using SnakeSkinâ Dialysis 
Tubing (10 kDa cutoff) at 4˚C against 25 mM potassium phosphate pH 8.0, 1 mM n-octyl-b-D-
glucopyranoside, 1 mM dithiothreitol, 1 mM ethylenediaminetetraacetic acid, and 10% glycerol 
(buffer C). The dialysate was exchanged twice after incubating one hour and once more before 
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incubating overnight. The dialyzed sample was concentrated using a stirred cell with YM30 
membrane filter and applied to a Source 30Q (GE Healthcare Life Sceinces) anion exchange 
column pre-equilibrated in buffer C. After injection, the column was washed with 4 column 
volumes of buffer C and followed with a 50% step gradient of buffer D (buffer C supplemented 
with 500mM NaCl and 1 mM n-octyl-b-D-glucopyranoside) for 4 column volumes followed by 
100% buffer D for 5 column volumes. The fractions containing PchE-FL were identified by 
SDS-PAGE, collected, and concentrated as above. The concentrated sample was subjected to a 
Superdex 200 size-exclusion column (Amersham Biosciences) equilibrated in 50 mM Tris pH 
8.0, 50 mM sodium citrate, 1 mM n-octyl-b-D-glucopyranoside, 1 mM dithiothreitol, and 10% 
glycerol (buffer E). PchE-FL fractions were collected and concentrated as above. The final 
concentration of PchE-FL was determined by the general Beer-Lambert law and the predicted 
A280 of ε = 190 675 M-1 cm -1 (ProtParam).36 A total of 3.8 mg of PchE-FL was obtained from 
the 3 L cell growth. The protein was flash cooled and stored at -80˚C until further used.  
 
PchE-AE protein overexpression and purification 
BL21 (DE3) E. coli containing the pche-ae and pa2412 expression plasmids were grown in LB 
broth containing 50 µg/mL kanamycin and 200 µg/mL ampicillin at 37 °C with shaking (250 
rpm). Protein expression was induced when the OD600 reached ~0.7 by the addition of isopropyl 
β-D-thiogalactopyranoside (IPTG) to a final concentration of 200 µM. The temperature was 
lowered to 15 °C following induction. The cells were harvested by centrifugation (4 230 x g, 10 
min, 4 °C) after ~20 hours.  The cell pellet was resuspended in 25 mM potassium phosphate 
buffer pH 7.5, 500 mM NaCl, 50 mM sodium citrate, 1 mM n-octyl-b-D-glucopyranoside, 5 mM 
imidazole, and 10% glycerol (buffer A).  Cells were disrupted by French press (35 000 psi), and 
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cellular debris was removed by centrifugation (23 430 x g, 60 min, 4 °C).  The supernatant was 
applied to a chelating Sepharose fast-flow column (Amersham Biosciences) charged with nickel 
chloride and pre-equilibrated in buffer A.  Four-column volumes of buffer A were followed by a 
4-column volume wash with 10% buffer B (buffer A supplemented with 500 mM imidazole). An  
8-column volume linear gradient to 100% buffer B was used to elute the PchE-AE and PA2412 
proteins together in 1 peak at ~125 mM imidazole. The pooled fractions were dialyzed using 
SnakeSkinâ Dialysis Tubing (10 kDa cutoff) at 4˚C against 50 mM potassium phosphate buffer 
pH 7.5, 1 mM DTT, 50 mM sodium citrate, 1 mM n-octyl-b-D-glucopyranoside, and 10% (v/v) 
glycerol (buffer C). The dialysate was exchanged for fresh buffer two times after stirring for an 
hour each, before being exchanging to dialyze overnight. The dialyzed protein was concentrated 
using a 30 kDa cutoff Amicon ultracentrifugal spin filter. The concentrated protein was applied 
to a Superdex 200 size-exclusion column (Amersham Biosciences) equilibrated with buffer C. 
PchE-AE eluted separately from PA2412 and the PchE-AE fractions were concentrated as above 
to 1.62 mg/mL as determined by the general Beer-Lambert law and the predicted A280 of ε = 106 
505 M-1 cm -1 (ProtParam).36 A total of 10.7 mg was obtained from the 3 L of cell growth. The 
protein was flash cooled and stored at -80 °C. For the adenylation assay, 1 mL of purified PchE-
AE was subjected to a PD-10 column to exchange the buffer to 50 mM Tris pH 8.0, 1 mM DTT, 
50 mM sodium citrate, and 10% (v/v) glycerol (buffer D) and was concentrated to 1.70 mg/mL, 
determined analogously, and was flash cooled and stored at 80˚C until further use.  
 
Preparation of Substrate Analogues (Scheme 3-1).  
General experimental procedures. Initial compounds used in synthesis were purchased from 
chemical suppliers are used without any further purification methods. Chromatic separations  
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Scheme 3-1:  Substrate analog synthesis of HPL-Cys, HP-CysL-Me, HPTL-CO2–, HPTL-
CO2Et, HPTL-CH2OH. Substrate analogs were generated to assess the epimerase capabilities of 
PchE. Product analogs were synthesized by replacing the starting reagent with its D-isomer. 
Reagents and conditions: i) DMF/CH2Cl2, RT; ii) pyridine/CH2Cl2, 0˚C; iii) dithiothreitol/3N 
HCl in MeOH; iv) 1M NH4OH, pH 9.0/EtOH; v) dithiothreitol, NH4OH, pH 9.0/EtOH, RT; vi) 
NaOH/MeOH, RT; vii) phosphate buffer, potassium carbonate, pH 8/MeOH, 50˚C; viii) 
SOCl2/EtOH, 40 °C; ix) Ca(BH4)2/EtOH. 
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were performed with a Teledyne Isco CombiFlash Rf. or by flash column chromatography using 
silica gel (4-63 mm) purchased from Sorbent Technologies. Chromatography was also performed 
with a Teledyne Isco CombiFlash Rf. 1H and 13C NMR were recorded using a 500 MHz Bruker 
AVIII spectrometer equipped with a cryogenically-cooled carbon observe probe using 
tetramethyl silane as an internal standard. Chemical shifts (δ) are reported in ppm and coupling 
constants (J) are reported in Hz. High-resolution mass spectrum (HRMS) was performed on a 
LCT Premier (Micromass Ltd., Manchester UK) time of flight mass spectrometer with an 
electrospray ion source in either positive or negative mode. Melting points were measured with a 
Thomas Capillary Melting Point Apparatus and are uncorrected. Chiral analysis to determine 
racemic ratio was carried out using either a Chiralcel-OD, Lux Amylose-1 or Lux Cellulose-1 
column from Phenomenex using a Waters Acquity UPLC/UHPLC. Peaks were monitored at 254 
nm and 320 nm. The conditions for each racemic pair are included below. 
 
ethyl (R)-2-(2-hydroxyphenyl)-4,5-dihydrothiazole-4-carboxylate (HPTL-CO2Et). 
Thionyl chloride (10 mmol) was added dropwise at -10˚C to EtOH (10 mL) before the addition 
of (R)-2-(2-hydroxyphenyl)-4,5-dihydrothiazole-4-carboxylic acid (HPTL-CO2–,37 2.25 mmol). 
The reaction was warmed to 40˚C and stirred overnight. The mixture was concentrated to a black 
sludge under reduced pressure and reconstituted in Na2CO3 (100 mL). After filtering through a 
pad of celite the solution was extracted with CH2Cl2 (3 x 50 mL). The organic phase was 
concentrated under reduced pressure and the residue was further purified by Combiflash (0:1 to 
1:3 MeOH in CH2Cl2). The major peak was collected and concentrated under high pressure 
overnight yielding an light orange oil (1.6 mmol, 71%). 1H NMR (400 MHz, DMSO-d6) δ 12.39 
(s, 1H), 7.46 (t, J = 7.6 Hz, 2H), 7.03 – 6.92 (m, 2H), 5.57 (dd, J = 9.7, 7.5 Hz, 1H), 4.20 (q, J = 
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7.1 Hz, 2H), 3.76 (dd, J = 11.4, 9.7 Hz, 1H), 3.64 (dd, J = 11.4, 7.5 Hz, 1H), 1.24 (t, J = 7.1 Hz, 
3H). 13C NMR (101 MHz, DMSO-d6) δ 173.21, 169.84, 158.32, 133.80, 130.56, 119.37, 116.87, 
115.53, 76.09, 61.36, 33.33, 13.96. HRMS: [M + H]+ 252.0716 (calcd) 252.0702 (found). Ethyl 
(S)-2-(2-hydroxyphenyl)-4,5-dihydrothiazole-4-carboxylate was generated by replacing the 
starting HPTL-CO2–,with HPTD-CO2–,. The final ethyl (S)-2-(2-hydroxyphenyl)-4,5-
dihydrothiazole-4-carboxylate (HPTD-CO2Et) product produced matching values for 1H NMR, 
13C NMR, and HRMS. 
 
(R)-2-(4-(hydroxymethyl)-4,5-dihydrothiazol-2-yl)phenol (HPTL-CH2OH).  
Calcium chloride (0.9 mmol) and sodium borohydride (0.9 mmol) were added to a solution of 
EtOH (5 mL) at -20˚C. A solution of ethyl (R)-2-(2-hydroxyphenyl)-4,5-dihydrothiazole-4-
carboxylate (0.9 mmol) in EtOH (5 mL) was added dropwise to the calcium borohydride solution 
at -20˚C with vigorous spinning. The reaction was left at -20˚C and stirred overnight. The 
mixture was concentrated under reduced pressure before being quenched with deionized H2O (50 
mL). The mixture was extracted with CH2Cl2 (3 x 50 mL) and the combined organic phase was 
dried with Na2SO4. The product was purified by Combiflash (0:1 to 1:3 EtOAc gradient in 
hexanes over 30 minutes) yielding a yellow solid (0.16 mmol, 18%). 1H NMR (500 MHz, 
DMSO-d6) δ 12.65 (s, 1H), 7.41 (td, J = 7.2, 1.6 Hz, 2H), 7.01 – 6.90 (m, 2H), 5.11 (d, J = 6.6 
Hz, 1H), 4.80 (ddt, J = 8.9, 7.5, 5.4 Hz, 1H), 3.68 – 3.58 (m, 2H), 3.50 (dd, J = 10.9, 8.9 Hz, 1H) 
3.31 (dd, J = 10.9, 7.5 Hz, 1H). 13C NMR (126 MHz, DMSO-d6) δ 171.06, 158.39, 133.21, 
130.32, 119.11, 116.69, 115.79, 77.82, 62.31, 32.56. HRMS: [M + H]+ 210.0610 (calcd) 
210.0599 (found). (S)-2-(4-(hydroxymethyl)-4,5-dihydrothiazol-2-yl)phenol (HPTD-CH2OH) 
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was generated by replacing the starting HPTL-CO2Et with HPTD-CO2Et. The final HPTD-CH2OH 
product provided matching values for 1H NMR, 13C NMR, and HRMS. 
 
Steady-state Adenylation Assay  
The steady-state adenylation assay is thoroughly described in the PchF chapter and 
similar conditions are briefly described here. Each reaction contained 1mM MgCl2, 200 µM 2-
amino-6-mercapto-7-methylpurine ribonucleoside (MESGR), 0.002 U purine nucleoside 
phosphorylase (PNP, Sigma), 0.001 U inorganic pyrophosphatase (IPP, Sigma), 2 mM ATP, 150 
mM hydroxylamine, 0.375 µM enzyme, and varying concentrations of L-Cys. Reactions were 
also attempted with D-Cys, but no activity was observed (Figure 3-4). Stock concentrations of L-
Cys, ATP, and hydroxylamine were prepared the day of the reaction. L-Cys stock concentrations 
were serially dilute in 25 mM Tris pH 8 and 5 mM dithiothreitol. A parent mixture containing all 
components of the assay except substrate were incubated for 15 minutes at room temperature 
while the substrate was aliquoted into a 96-well flat bottom plate (Corning Cat. #9017). A  
multichannel pipette was then used to inject the reaction mixture into individual wells to initiate 
the 100 µL reaction. The production of 2-amino-6-mercapto-7-methylpurine (MesG) was 
monitored by an increase in absorbance at 360 nm with a Cary 50 UV-VIS Spectrophotometer 
with a plate reader attachment. The path length of the plate reader (0.29 cm) and the extinction 
coefficient of MesG (11,000 cm-1M-1)38 were used in the general Beer-Lambert’s law to convert 
AU/min to µM/min. The rate was then halved due to the catalytic hydrolysis of pyrophosphate to 
two inorganic phosphates by inorganic pyrophosphatase (IPP) which are then successively used 
by purine nucleoside phosphorylase (PNP) to convert MESGR to MESG. Negative controls were 




Figure 3-4: Adenylation assay. The adenylation domain of PchE catalyzes the formation of an 
aminoacyl-AMP bond from L-Cys and ATP, releasing pyrophosphate. A full description of the 
assay can be found in Chapter 2, Figure 2-5. Briefly, the assay to measure the adenylation 
capability of PchE-FL and PchE-AE is a coupled assay. Pyrophosphate released from the 
aminoacyl-AMP bond formation is hydrolyzed to two inorganic phosphates by inorganic 
pyrophosphatase. Each inorganic phosphate is then used to catalyze the phosphorylation of 7-
methylthioguanosine (MesGR) by purine nucleoside phosphorylase, producing ribose 1-
phosphate and 7-methylthioguanine (MesG), which absorbs at 360 nm. Because the natural 
substrate is replaced in the adenylation domain by the nucleophilic attack of the Ppant tether, 
NH2OH is used as a nucleophilic surrogate to allow for steady-state turnover. A) An adenylation 
assay showing the difference in activity with 20 mM L-Cys (green) and 20 mM D-Cys (blue) 
using PchE-FL. D-Cys is within error of experimental negative controls and does not appear to 
be a substrate for PchE. B) PchE-AE turnover with various amounts of L-Cys and ATP. C) 
Michaelis-Menten steady state analysis of PchE-FL and PchE-AE with L-Cys. Two separate sets 
of triplicate trials were performed on different days for a total of six trials.  
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greatest rate generated by a negative control was subtracted from all of the calculated reaction 
rates. Two separate triplicate trials were performed on successive days for each enzyme. The 
initial calculated rates were fit to the Michaelis-Menten equation using the nonlinear regression 
function in KaleidaGraph (Synergy Software). Kinetic parameters were generated for each of the 
six individual trials for each enzyme. The reported kinetic parameters were calculated by finding 
the average and the standard deviation of each parameter was considered the error.  
 
Epimerase Assay by Circular Dichroism   
Circular dichroism (CD) spectra using ultraviolet (UV) absorbance of reactions with and 
without PchE-FL or PchE-AE were recorded on a Jasco J-815 CD spectrometer at 20.0˚C in 50 
mM Tris pH 8.0 and 5mM TCEP. For each spectrum, three measurements were taken for every 2 
nm and averaged from 240 nm to 360 nm. Spectra are presented in millidegrees of ellipticity.  A 
solution of 100 µM substrate in 50 mM Tris pH 8.0 and 5 mM tris(2-carboxyethyl)phosphine) 
(TCEP) was made from a DMSO stock for a final volume of 2 mL. A CD measurement was 
taken as before addition of enzyme and directly after the reaction was initiated with 2.0 µM 
PchE-FL or PchE-AE. Subsequent measurements were taken at 5, 10, 15, 30, 45, and 60 minutes. 
Reactions using HPTL-CO2Et were extended to 4 hours. The reactions were performed at 20.0˚C. 
An additional endpoint assay was performed after a reaction incubated at room temperature for 8 
hours.  
 
Epimerase Assay by Chiral Chromatography 
Separation of synthesized racemic pairs was screened using Lux Amylose-1 and Lux 
Cellulose-1 columns with 4.6 mm x 100 mm dimensions and 5 µm beads purchased from 
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Phenomenex (Torrance, CA). Each racemic pair was subjected to a series of isocratic trials to 
optimize separation conditions. This was performed by varying the eluent by 10% ranging from 
10-90%. Standards were diluted using EtOH at a concentration of 1 mg/mL and 3 µL was 
injected onto the column. The mobile phase was a variation of H2O/ACN/TFA running at 0.5 
mL/min or 1 mL/min. An Acquity UPLC from Waters (Millford, MA) was used to perform the 
chromatography. HP-CysL-Me (rt 7.49 mins) and HP-CysD-Me (rt 7.05 mins) were separated 
using the Lux Cellulose-1 column with a mobile phase of H2O/ACN/TFA (60:40:0.1). HPTL-
CO2– (rt 7.35 mins) and HPTD-CO2–  (rt 6.80 mins) was also separated using the Lux Cellulose-1 
column with a mobile phase of H2O/ACN/TFA (70:30:0.1). HP-CysL (rt 8.73 mins) and HP-CysD 
(rt 7.84 mins) were separated using the Lux Cellulose-1 column with a mobile phase of 
H2O/ACN/TFA (85:15:0.1). HPTL-CO2Et (rt 3.77 mins) and HPTD-CO2Et (rt 4.45 mins) were 
separated using the Lux Amylose-1 column with a mobile phase of H2O/ACN/TFA (40:60:0.1). 
HPTL-CH2OH (rt 2.87 mins) and HPTD-CH2OH (rt 1.89 mins) were separated using the Lux 
Amylose-1 column with a mobile phase of H2O/ACN/TFA (40:60:0.1). Each enzyme reaction 
was performed in 50 mM Tris pH 7.5 with 1 mM L-substrate analog, except HPTL-CO2Et (300 
µM), and 1 µM PchE-FL or 1 µM PchE-AE. At 0 hr., 1 hr., 2hr., and 4hr., 100 µL of the reaction 
was quenched with 5 µL of 1 mM H2SO4. Quenched reactions were centrifuged to rid the 
enzyme before introduction to the column (10 600 x g, 10 mins, 4 ˚C). 3 µL of the reaction was 







Incubation of HP-CysL-Me or HP-CysD-Me with PchE-AE or PchE-FL resulted in an 
increased absorbance from 310 – 350 nm with a peak max at 335 nm and an increased 
fluorescence at 413 nm by excitation at 310 nm. A 250 µM solution of HP-CysL-Me and HP-
CysD-Me was made in 50 mM Tris pH 8.0 buffer from a 100 mM DMSO stock and was 
sequentially diluted for reaction concentrations.  PchE-AE was added to a final concentration of 
1.88 µM and fluorescence was measured from 350 – 550 nm by excitation at 310 nm very 2 
minutes for 34 minutes. Fluorescent measurements were carried out on a Varian Cary Eclipse 
fluorescence spectrophotometer with an excitation and emission slit set at 5 nm. Full progress 




Purification of PchE-FL and PchE-AE  
Two variants of PchE were purified by heterologous expression in E. coli cells. The first 
was the full-length enzyme, PchE-FL, consisting of two peptidyl carrier domains, a cyclization 
domain, and a stuffed epimerase-adenylation didomain. The focus of this study was the stuffed 
tailoring epimerase domain. Therefore, a second construct, called PchE-AE, was made consisting 
of only the stuffed epimerase-adenylation didomain, removing the possibility of catalytic 
contribution coming from the carrier and cyclization domains while attempting to assesses 
specific catalytic activities provided by the tailoring domain (Figure 3-1C).  Each construct was 
co-expressed with the MbtH-like protein (MLP), PA2412, from the pyoverdin biosynthetic 
cluster from P. aeruginosa, to enhance NRPS solubility.31, 32, 41, 42 Discussed in the PchF chapter, 
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MLPs are often necessary for expression and are frequently observed to increase solubility or 
catalytic efficiency of adenylation activity. Similarly, the stability of recombinantly expressed 
PchF, PchE, and variant constructs of PchF and PchE is improved when co-expressed with 
PA2412. PchE-FL and PchE-AE were purified by a N-terminal His-tag. Size exclusion 
chromatography was used to separate PchE-FL and PchE-AE from PA2412. An additional 
purification step of anion exchange chromatography was used during purification of PchE-FL.  
 
Steady-state kinetics of adenylation activity.  
 Adenylation activity of PchE-AE and PchE-FL assessed proper folding of the variants. 
PchE is responsible for the incorporation of the Cys that becomes the first thiazoline of 
pyochelin. In the final pyochelin product, the a-carbon has a stereochemistry that must result 
either from the incorporation of D-Cys or the epimerization of an L-Cys. Walsh and colleagues 
previously reported that the adenylation domain of PchE was specific to L-Cys and did not 
catalyze the adenylation of D-Cys, suggesting another catalytic event was responsible for 
epimerization.23 Therefore, the adenylation domain of PchE is hypothesized to catalyze the 
formation of an aminoacyl-AMP bond from L-Cys and ATP with release of pyrophosphate. The 
next step in NRPS assembly would be for the Ppant tether of the peptidyl carrier domain to 
perform a nucleophilic attack binding the amino acid to the thiotemplate and releasing AMP 
from the active site. In the experiments described in this chapter, PchE-FL and PchE-AE were 
not post-translationally modified with a Ppant tether to allow for steady-state turnover of the 
adenylation reaction, as described in the previous chapter. Hydroxylamine was used as a 
nucleophilic surrogate in place of the Ppant tether to release the aminoacyl-AMP intermediate 
promoting adenylation activity in the steady-state. The pyrophosphate is converted to two 
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inorganic phosphates by inorganic pyrophosphatase which are subsequently used by purine 
nucleoside phosphorylase to generate a chromogenic nucleoside. In our assessment, PchE-FL 
and PchE-AE were able to catalyze turnover of L-Cys but not D-Cys as previously observed by 
Walsh (Figure 3-4A).23 Steady-state kinetic parameters of adenylation activity were determined 
with L-Cys for PchE-FL and PchE-AE and can be found in Figure 3-4 and Table 3-1. The kcat 
for PchE-FL was almost 2.5-fold less than for PchE-AE and, surprisingly, the Km was nearly 2 
magnitudes less for PchE-FL than PchE-AE. The variants of PchF from the previous chapter 
were within 2-fold of one another for kcat, Km, and kcat/Km. The variant PchF-AMP still contained 
the peptidyl carrier domain whereas PchE-AE only consists of the stuffed tailoring and 
adenylation didomain.  
  
Substrate and product analog synthesis. 
Analyzing mechanisms of catalytic steps during NRPS biosynthesis becomes 
increasingly difficult as the peptide becomes elongated. Intermediates within the biosynthesis are 
tethered to a Ppant chain further increasing the complexity of the natural substrate. Thus, 
intermediate analogs have been synthesized in which the terminal thioester linkage is altered to  
elucidate catalytic mechanisms of different domains in nonribosomal peptide and polyketide 
biosynthesis.15, 43-46 Our lab has observed and reported catalytic efficiency with substrate analogs 
designed for the pyochelin biosynthetic pathway. PchG, discussed in the following chapter, was 
found to catalyze the NADPH-dependent reduction of an intermediate analog replacing the 
thioester linkage with a terminal carboxylic acid, but was unable to catalyze reduction of 
compounds replacing the terminal acid with an ester or alcohol. Alternatively, PchF catalyzed S-  
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Table 3-1: L-Cysteine Adenylation Assay of PchE-FL and PchE-AE  
 PchE-FL* PchE-FL PchE-AE 
kcat (min-1) 38 3.7 ± 0.3 9 ± 2 
KM (L-Cys µM) 110 23 ± 3 1180 ± 70 
kcat/KM (M-1s-1) 6700 2700 ± 100 120 ± 30 
 
* - Quadri, Keating, Patel, Walsh. Biochemistry 1999, 38, 14941-14954. Walsh 
et al used an assay to measure adenylation activity by the incorporation of 
32pyrophosphate into ATP through the reverse reaction, a different assay than 
the coupled assay used herein.  
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adenosyl methionine (AdoMet)-dependent methyl transfer to an intermediate analog with a 
terminal ethyl ester, but not with a similar compound replacing the ester with a carboxylic acid. 
Proposed intermediate substrates for the stuffed epimerase domain of PchE were 
generated to determine when in biosynthesis epimerization occurs: 1) after condensation to the 
upstream salicylate but before cyclization of the Cys to a thiazoline, or 2) after cyclization to the 
thiazoline but before condensation to the downstream peptide. To elucidate the substrate of the 
stuffed epimerase domain, multiple substrate analogs of each proposed pathway were 
synthesized (Scheme 3-1). Both substrate (a-carbons with L-stereocenters) and product analogs 
(with D-stereocenters) were synthesized.  
Synthesis of analogs representing the acyclic hydroxyphenyl-Cys (HP-Cys) were 
performed in accordance to Bergeron et al.47 Synthesis was initiated by nucleophilic addition of 
L-cystine dimethylester (or D-cystine dimethylester) to acetylsalicoyl chloride providing the 
diamide in 35% yield, similar to the 31% yield previously reported.47 The diamide was 
subsequently used to generate both HP-Cys and HP-Cys-Me analogs. HP-Cys was generated by 
breaking the disulfide linkage of the diamide with dithiothreitol and a subsequent saponification 
step by NaOH to provide a 49% yield. The synthesis of HP-Cys-Me was continued from the 
diamide by selective deprotection of the hydroxyphenyl acetyl followed by reduction of the 
disulfide with dithiothreitol to provide a 54% yield.47   
Synthesis of HPT-CO2− was performed in alignment with a protocol provided by 
Bergeron et al.37 L-Cys (or D-Cys) was added to 2-hydroxybenzonitrile allowing for nucleophilic 
addition and cyclization of the Cys to a thiazoline retaining the stereochemistry at the a-carbon 
providing a comparable 74% yield. HPT-CO2− was altered to an ethyl ester by converting the 
carboxylic acid to an acyl chloride promoting nucleophilic addition of the ethanol solvent 
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providing HPT-CO2Et in 71% yield. The ethyl ester was further modified to generate HPT-
CH2OH by a calcium borohydride reduction to afford an alcohol, HPT-CH2OH, in 18% yield.  
A summary of each substrate and product analog used in this study can be found in 
Figure 3-5. Chiral purity was assessed for each synthetic substrate and product analog by chiral 
chromatography and enantiomeric ratios are summarized in Table 3-2. 
 
Cyclization assay.  
 The proposed catalytic pathway by PchE in pyochelin biosynthesis suggests L-Cys is 
activated in the adenylation domain and is then added to the Ppant tether of the peptidyl carrier 
domain. The Cys then condenses with the upstream salicylate in the cyclization domain before 
moving to the stuffed epimerase domain to alter the stereochemistry of the Cys a-carbon from 
(S) to (R). The altered peptide must then travel back to the condensation domain to be cyclized 
before condensation with the peptide from the downstream module. An experiment to test the 
proposed pathway is to identify if PchE is able to catalyze cyclization of the synthesized analogs:  
arrangement of the substrate is necessary for PchE catalyzed cyclization, L- and D- analogs could 
be used to substantiate the order of chemistry in the biochemical pathway. If cyclization takes 
place prior to epimerization, we would assume PchE would be more specific towards cyclizing 
L-analogs over the D-analogs. Conversely, if epimerization occurs on the  
acyclic intermediate before cyclization, PchE cyclization may be specific for the D-analogs and 
unable to catalyze cyclization of the L-analogs.  
 After synthesis, stock concentrations (100 mM) of the potential substrate analogs, HP-
CysL, HP-CysD, HP-CysL-Me, or HP-CysD-Me, were made in dimethylsulfoxide (DMSO) and 




Figure 3-5: Summary of substrate and product analogs generated for PchE epimerase 
assays. The natural substrate and product intermediates during peptide elongation are tethered to 
the Ppant tail covalently linked to the peptidyl carrier domain. Therefore, substrate and product 
analogs of the naturally thiolated intermediates were generated. A) The substrate and product 
analogs of proposed PchE epimerase intermediates before cyclization: HPL-Cys and HPD-Cys, 
and HPL-Cys-Me and HPD-Cys-Me. B) Substrate and product analogs synthesized mimicking the 
proposed epimerase intermediate after cyclization: HPTL-CO2– and HPTD-CO2–, HPTL-CO2Et 




Table 3-2: Synthesized substrate and product analog ratios determined by chiral  
                chromatography 
 Retention time L-substrate analog D-product analog 
 L D L (%) D (%) L (%) D (%) 
HP-Cys 8.73 7.84 99.1 0.9 0 ~100 
HP-Cys-Me 7.05 7.49 99.6 0.4 0 ~100 
HPT-CO2− 7.97 7.44 94.0 6.0 6.1 93.9 
HPT-CO2Et 3.77 4.45 87.1 12.9 91.1 8.9 





L-HP-Cys, D-HP-Cys, L-HP-Cys-Me, or D-HP-Cys-Me. Assuming correct stereochemical  
or PchE-AE resulted in a time-dependent increase in fluorescence at 413 nm (ex. 310 nm) while 
no change in fluorescence was observed with only substrate present (Figure 3-6 A, B).  
Cyclization of an acyclic Cys to a thiazoline would increase conjugation through the 
hydroxyphenyl ring changing the absorbance and fluorescence properties of the molecule. 
However, separation methods and identification of ions representative of cyclized products by 
mass spectrometry were irreproducible and often not detected. When fresh substrate stocks were 
made (still in DMSO), the addition of PchE-FL or PchE-AE did not result in a time-dependent 
increase in fluorescence (Figure 3-6C). Further investigation into the observed phenomenon 
suggests HP-CysL, HP-CysD, HP-CysL-Me, and HP-CysD-Me become dimeric by a disulfide 
bond while being stored in DMSO. The absorbance profile of freshly made stocks has a peak 
maximum at 325 nm where greater than 1-week-old DMSO stocks have an absorbance 
maximum at 300 nm. The addition of 50 µM dithiothreitol to the fresh stock does not alter the 
absorbance over a 1-hour period. However, the addition of 50 µM dithiothreitol to the greater  
than 1-week-old stocks causes a shift in absorbance towards the peak maximum of the 
monomeric substrate at 325 nm (Figure 3-6 D, E). The addition of 50 µM dithiothreitol to the 
greater than 1-week-old stocks also causes an increase in fluorescence at 413 nm (ex. 310 nm) 
overtime. The enzyme buffer provided a final concentration of 50 µM dithiothreitol to the 
fluorescent reactions suggesting that the observed spectral changes are the result of dithiothreitol 
oxidation or substrate reduction, but not substrate cyclization. Enzyme assays with fresh stock in 
the presence of 5 mM dithiothreitol or 5 mM tris(2-carboxyethyl)phosphine did not result in 





Figure 3-6: Absorbance and fluorescence changes observed with HP-Cys-Me are due to 
DTT reduction and not PchE catalyzed cyclization. PchE-FL and PchE-AE are stored in 
buffer with 1 mM DTT eventually determined to be the responsible reagent for changes in 
absorbance and fluorescence of HP-Cys and HP-Cys-Me from 1-week old DMSO stocks. A) A 
representative time course of HP-CysL-Me or HP-CysD-Me and PchE-AE or PchE-FL in 50 mM 
Tris pH 8.0 resulted in increased fluorescence overtime with an excitation wavelength of 310 nm 
and fluorescence peak maximum of 413 nm when diluted from 1-week old DMSO stock. B) The 
change in relative fluorescence units at 413 nm is plotted over a 240-minute time course of 225 
µM HP-CysL-Me diluted form old DMS0 stock in the presence of PchE-AE (blue) or absence of 
PchE-AE (red). C) A 20-minute fluorescence time course of freshly diluted HP-CysL-Me in Tris 
pH 8.0 and PchE-AE with excitation at 310 nm. D) A 1-hour time course reaction of freshly 
diluted HP-CysL-Me in Tris pH 8.0 and 50 µM DTT. The absorbance was taken every 2 minutes. 
E) A 1-hour time course reaction of HP-CysL-Me from a 1-week old DMSO stock in Tris pH 8.0 
and 50 µM DTT. The arrow is showing the direction of absorbance change overtime. A spectrum 
was captured every 2 minutes. F) A 20-minute fluorescence time course of HP-CysL-Me from a 




Circular dichroism epimerase assay. 
 Previously, Walsh et al reported in vitro reconstitution assays with PchD and PchE in the 
presence of 14C labelled L-Cys, ATP, and benzoate, replacing the natural salicylate substrate of 
PchD.24 Without the downstream PchF module, PchE derived intermediates accumulate on the 
thiotemplate of the second carrier domain of PchE. Walsh and colleagues added an external 
thioesterase or strong base to catalyze hydrolysis of the PchE derived intermediates and 
identified proposed intermediates based on HPLC alignment of synthetic standards. To assess the 
epimerase activity of PchE, we used the full length, PchE-FL, and a variant enzyme, PchE-AE, 
only consisting of the stuffed epimerase and adenylation didomain.  PchE-FL and PchE-AE 
incubated with substrate (HP-CysL, HP-CysL-Me, HPTL-CO2−, HPTL-CO2Et, or HPTL-CH2OH) 
and product analogs (HP-CysD, HP-CysD-Me, HPTD-CO2−, HPTD-CO2Et, or HPTD-CH2OH) for 
up to 8 hours and a circular dichroism spectrum was collected from 240 – 360 nm to observe if 
there was a change in stereochemistry of the analog. Experiments without enzyme present were 
used as negative controls. Because synthesized substrate and product analogs are racemic pairs 
of one another and were synthesized with the starting material in enantiomeric excess, the 
synthesized analogs with opposing stereochemistry display an equal but opposite circular 
dichroism spectral footprint that can therefore be traced if stereochemical changes were to occur 
(Figure 3-7). Eight-hour endpoint assays indicated that PchE-FL or PchE-AE were unable to 
catalyze the racemization of any of the substrate or product analogs that were synthesized 
(Figure 3-7). One-hour time course reactions of HP-CysL, HP-CysL-Me, HPTL-CO2−, HPTL-
CO2Et, and HPTL-CH2OH were also performed with PchE-FL and slight changes were observed 
for HPTL-CO2Et. Therefore, the time course was extended to 4 hours and spectra were overlaid  
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Figure 3-7: Circular dichroism reactions with substrate and product analogs to probe the 
epimerase activity of PchE. The synthesized racemic pairs of substrate and product analogs 
exhibit mirrored circular dichroism spectra. The degree of elliptical rotation is plotted over the 
wavelength range of 240 – 360 nm. The spectra are shown as endpoint data after an 8-hour 
incubation period at room temperature in 50 mM Tris pH 8.0 and 5 mM TCEP. Both L- and D- 
analogs were used as substrates for PchE-FL and PchE-AE. Control experiments were performed 
without the presence of enzyme. Spectra for each experiment are assigned by color: D-control 
(blue), L-control (green), PchE-FL with D-analog (black), PchE-FL with L-analog (red), PchE-
AE with D-analog (light blue), PchE-FL with L-analog (orange). Spectra are combined for each 





Figure 3-8: Circular dichroism time course with HPTL-CO2Et. Racemization of HPTL-CO2Et 
observed over 4 hours in 50 mM Tris pH 8.0 and 5 mM TCEP A) without enzyme and B) with 
PchE-FL. C) A linear regression of the change in ellipticity (mdeg) at 318 nm over the 4-hour 




(Figure 3-8). The negative control without enzyme also racemized over the 4-hour period.  The 
change in ellipticity at a local minimum (318 nm) was plotted for HPTL-CO2Et with and without 
enzyme present. The observed racemization is spontaneous at pH 8.0 and not enzymatically 
driven. 
 
Chiral chromatography epimerase assay.  
 Separation protocols for the substrate and product analogues were determined using 
chiral chromatography, allowing determination of the enantiomeric ratio of each analog 
synthesized (Figure 3-9). Additionally, the methodology to separate the racemic pair was further 
used as a more sensitive technique to determine if the stuffed epimerase domain of PchE 
expresses activity towards the substrate analogs. In agreement with the circular dichroism 
experiments, enzyme catalyzed racemization was not detected through a 4-hour reaction for any 
substrate analog. Control reactions with HPTL-CO2Et slightly racemized at pH 7.5, similar to 
what was observed during the circular dichroism experiment at pH 8.0.  
 
Discussion 
 Pyochelin is a small siderophore produced by P. aeruginosa whose chemical uniqueness 
is mostly attributed to its NRPS cyclization and tailoring domains. The cyclization domains, each 
in the second (PchE) and third (PchF) module of the NRPS system, first perform condensation of 
the upstream peptide to the module’s activated L-Cys-Ppant, which is tethered to its peptidyl 
carrier domain. Conventional understanding of NRPS cyclization domains suggest 
cyclodehydration of the Cys to a thiazoline would occur directly after condensation. However, 
Walsh and colleagues advocate for a different path in the second NRPS module, which is found  
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Figure 3-9: UPLC profile of racemic separation of substrate and product analogs. Substrate 
and product analogs were synthesized and separated via chiral chromatography using UPLC. 
Substrate analogs have L-stereochemistry and are depicted in green whereas product analogs 
have D-stereochemistry and are portrayed in blue. Respective analogs are next to the peak where 
they elute. The column and elution conditions used for chiral separation are listed in the figure. 
Each trace is representative of the absorbance at 320 nm from injecting a racemic mixture (0.5 
mg/mL of each substrate and product analog). Ratios of enantiomeric excess of each substrate 
and product analog can be found in Table 3-2. Enzyme assays with PchE-FL (1 µM) or PchE-
AE (1 µM) were performed separately with 1 mM HP-CysL, 1mM HP-CysL-Me, 1 mM HPTL-
CO2–, 1 mM HPTL-CH2OH, and 300 µM HPTL-CO2Et for 4 hours. Control experiments without 
enzyme were assayed simultaneously. No apparent racemization was observed with any substrate 
analog.   
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in PchE.24 They propose after condensation with the upstream salicylate, the newly generated 
HP-CysL-Ppant swings to the stuffed noncanonical epimerase domain where an active site base 
abstracts a proton form the a-carbon of the Cys, forming a carbanion, followed by random re-
protonation, creating HP-CysD-Ppant or regenerating the HP-CysL-Ppant intermediate.24 The 
peptide chain then travels back to the cyclization domain for cyclodehydration forming HPTL/D-
Ppant intermediates.24 Walsh et al hypothesize the following cyclization domain of PchF 
selectively condenses with HPTD-Ppant and not HPTL-Ppant.24 Indeed, canonical epimerase 
domains are often followed by selective downstream condensation domains, only condensing 
with the isomer exhibiting the correct stereochemistry.17  
 To our knowledge, this would be the only cyclization domain in NRPS chemistry not 
performing condensation and cyclodehydration chemistries back-to-back. The proposed pathway 
by Walsh et al also seems inefficient, traveling from the cyclization domain to the stuffed 
epimerase domain, and back to the cyclization domain. Additionally, Walsh et al also propose 
epimerization of the carbanion occurs through random re-protonation by the solvent and is a 
reversible process. If the incorrect stereochemistry is loaded and cannot condense with the 
downstream peptide, the tethered peptide can travel back to the stuffed epimerase domain to alter 
stereochemistry until HPTD-Ppant is generated.  
 Interestingly, the noncanonical epimerase domain of PchE shares sequence homology 
with methyltransferase domains.24, 25, 30 However, upon sequence alignment, the canonical 
AdoMet binding motif of PchE’s methyltransferase-like domain is mutated.24 Micacocidin, 
yersiniabactin, watasemycin, and thiazostatin (Figure 3-2) each have methyltransferase tailoring 
domains catalyzing methyltransfer to the a-carbon of a cyclized thiazoline, a substrate that is 
similar to what we propose the substrate is of the noncanonical epimerase domain of PchE. The 
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methylated a-carbon of micacocidin,48 yersiniabactin, 48 watasemycin49 and thiostatin49 are 
proposed to have D-stereochemistry although their adenylation domain activates L-Cys. The 
proposed mechanism of the C-methyltransferase suggests that cyclodehydration of L-Cys to L-
thiazoline occurs before methyl transfer.50 Next, an active site base is proposed to abstract the a-
carbon proton of the thiazoline forming an enol intermediate, and based on stereochemical 
assignment, nucleophilic attack of the enol to the electrophilic methyl of AdoMet occurs on the 
opposite side of the substrate, altering the stereochemistry of the carbon center to a D-
stereoisomer.  
We propose a more efficient route, with condensation and cyclodehydration occurring in 
succession to form the HPTL-Ppant. Next, the peptide travels to the noncanonical epimerase 
domain where it encounters an active site base that abstracts a proton forming an enol 
intermediate, which subsequently accepts a proton from solvent or an active site acid to alter the 
stereochemistry to HPTD-Ppant before condensing with the downstream amino acid in PchF’s 
cyclization domain. Overall, this model presents a substrate for the epimerase domain that has a 
lower pKa and less domain movements are required, providing an energetically more favorable 
path. 
 To identify and assess the chemistries catalyzed by the different domains of PchE we first 
generated recombinant variants: a full length PchE (PchE-FL) and a variant consisting of only  
the stuffed epimerase adenylation didomain (PchE-AE, Figure 3-1C). A continuous steady-state 
adenylation assay using hydroxylamine as a nucleophilic surrogate was used to determine the 
activity of the adenylation domain of both recombinant enzymes.51, 52 The adenylation domain of 
each variant was found to be active towards L-Cys but not D-Cys, consistent with previous 
studies.25 The catalytic efficiency was only 3-fold less for PchE-FL than that reported by Walsh 
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et al, although kcat and KM were nearly a magnitude different.25 This is likely attributed to the 
difference in assays where similar differences have previously been documented.51, 52 In this 
study, the shortened variant, PchE-AE, had a kcat that was nearly 2.5-fold greater than PchE-FL 
and a KM that was more than 50-fold greater, creating a kcat/KM that was a magnitude less than 
that of PchE-FL. A similar trend of increased kcat and KM was found in the previous chapter with 
a PchF variant missing its cyclization and thioesterase domains (PchF-AMP), although the 
difference was less drastic, having a kcat and KM within 2-fold of the full-length enzyme. This 
suggests the peptidyl carrier domain, as well as the other domains, may play an important role in 
adenylation efficiency. Importantly, the adenylation domain of PchE-FL and PchE-AE was 
active suggesting the other domain(s) in each variant are also likely properly folded and 
potentially active. 
Walsh et al previously attempted to characterize the biosynthetic steps of PchE by 
isolating intermediates using an external thioesterase and/or by strong base hydrolysis during 
reconstitution assays with PchD.24 While suggesting cyclodehydration occurs after 
epimerization, the results were inconclusive.24  Thus, the order and substrate of cyclodehydration 
and epimerization remain to be determined.24 To assess the possible substrate and order of 
catalytic steps of PchE’s cyclization and epimerase domain, we synthesized potential substrate 
and product analogs representative of each domain’s proposed chemistries (Figure 3-3 and 3-5). 
 
PchE cyclization domain 
Cyclization domains are commonly located upstream of a Thr, Ser, or Cys specific 
adenylation domain and perform two catalytic reactions.4, 7, 10, 12, 20, 21, 53, 54 The first reaction 
parallels the condensation domain performing a condensation reaction between the upstream 
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peptide and the downstream aminoacyl-S-Ppant. The second catalytic reaction is a two-step 
cyclodehydration. The hydroxyl (Thr, Ser) or thiol (Cys) performs a nucleophilic attack of the 
previously formed amide forming a hydroxylated azolidine. The amide oxygen is then released 
by a dehydration reaction forming the azoline heterocycle. The azoline loaded thiotemplate is 
now ready to move forward to the next step of the natural product bioassembly. It is understood 
that the cyclodehydration reaction is dependent on the condensation reaction taking place first.4, 
12, 53 Cyclization domains can be distinguished by a canonical DxxxxDxxS sequence, replacing 
the canonical HHxxxDG sequence found in condensation domains.12  Importantly, the second 
His of the condensation domain’s canonical sequence, proposed to be the active site base for 
condensation chemistry, is not conserved in the cyclization domain suggesting chemistry in the 
cyclization domain is likely different.4, 12, 21  
Recently, Schmeing et al and Drennan et al presented structures of cyclization domains 
in conjunction with mutational analyses.4, 21 Drennan et al published structures of EpoB from 
epothilone biosynthesis and Schmeing et al published structures of the second cyclization 
domain of bacillamide synthetase from bacillamide E biosynthesis.4, 21  Each structure is quite 
similar and the mutational analyses between the two cyclization domains are in agreement with 
one another. Previous mutation experiments have shown that mutating residues of the conserved 
DxxxxDxxS motif can lessen or abolish condensation and cyclization activity.53-55 Interestingly, 
both cyclization domain structures show the conserved motif as a loop with the Asp residues and 
Ser pointed away from the active site. The structures of the cyclization domains suggest that 
mutations to the conserved sequence is likely responsible to orient the substrate or provide 
structural stability to the domain, but not due to being part of the catalytic mechanism. 
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Schmeing et al presented mutational data distinguishing residues that are separately 
important for cyclization chemistry and not for condensation chemistry.4 They identified T1196 
and D1226 as essential residues for cyclodehydration but not condensation chemistry and 
proposed an acid/base catalytic mechanism by these two residues. This matched the analysis 
presented by Drennan and co-workers who provided evidence that the same spatial Asp (D449 of 
EpoB) is necessary for catalysis (although they did not distinguish which catalytic step was 
affected).21 Schmeing and colleagues also performed a bioinformatic investigation identifying 
seven core sequences of cyclization domains. Importantly, the bioinformatics also found that 
nearly 7% of predicted cyclization domains have an alanine mutation to the Thr seen to be 
essential for cyclodehydration chemistry, bringing their proposed mechanism into question. 
Schmeing et al suggest cyclization domains with Ala replacing Thr use a nearby Glu to assist in 
the acid/base chemistry instead but provided no evidence to support this claim.  
Intriguingly, PchE’s cyclization domain is part of the 7% of cyclization domains that 
have the Ala mutation to the conserved and proposed catalytic Thr, while the downstream 
cyclization domain of PchF alternatively possesses the conserved Thr. Experiments attempted 
herein to identify cyclodehydration of substrate analogs by PchE-FL or PchE-AE were 
unsuccessful. One possibility is that the substrate analogs were not similar enough to the actual 
substrate which is tethered to the P-domain by a Ppant linkage. Previously, aminoacyl-N-
acetylcysteamine (aminoacyl-SNACs) were synthesized and used as biosynthetic intermediates 
to characterize the substrate specificity of condensation domains.43 While condensation occurred 
with an aminoacyl-SNAC analog being used as either a downstream acceptor or upstream donor 
to a natural Ppant substrate, condensation was not observed when both donor and acceptor 
SNAC-analogs were used together, suggesting the necessity of a Ppant tether with either the 
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donor or acceptor substrate or a peptidyl carrier domain interaction with the condensation 
domain.43 Interestingly the condensation domain was specific to the correct stereochemistry of 
the aminoacyl-donor.43 Although we were hopeful that PchE’s cyclization domain could catalyze 
cyclodehydration of a carboxy (HP-CysL, HP-CysD) or ester (HP-CysL-CO2Me, HP-CysD- 
CO2Me) analog, no cyclized product was detected. Future experiments will be necessary to 
further elucidate the catalytic mechanism of the unique cyclization domain of PchE.  
 
PchE noncanonical epimerase domain 
Substrate and product analogs of the proposed cyclized or acyclic substrates were 
synthesized to examine the epimerase activity of PchE (Figure 3-5). In these experiments, 
analogs varied by a terminal hydroxy, carboxy, or ester group replacing the natural thioester 
linkage of the Ppant tether. Unfortunately, circular dichroism (Figure 3-7 and 3-8) and chiral 
separation (Figure 3-9) experiments suggested PchE was not able to alter the stereochemistry of 
any of the five substrate analogs. While we have observed catalysis of substrate analogs with a 
carboxy or ester terminus for other tailoring domains in pyochelin’s biosynthetic pathway (PchF 
and PchG)56, failure to observe catalysis with substrate analogs is not rare for NPRS enzymes.57-
61 Likely, other examples of failed substrate analogs have not been reported. The inability of 
PchE to turnover these particular analogs could, again, be due to the necessity of the Ppant tether 
interactions or domain-domain interactions between the peptidyl carrier domain and stuffed 
tailoring domain.  
Another possible explanation is that the stuffed epimerase domain is simply a non-
functional methyltransferase domain and does not have any catalytic activity. While the acyclic 
substrate analogs (HP-CysL, HP-CysL-CO2Me) and carboxyl- and hydroxy-cyclized analogs 
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(HPTL-CO2–, HPTL-CH2OH) were relatively stable isomers, the closest related analog to the 
natural substrate, HPTL-CO2Et, racemized overtime at pH 7.5 and pH 8.0 (Figure 3-8). The 
transformation from the acyclic Cys to the thiazoline increases the acidity of the a-carbon 
proton. Generating potential analogs that are more similar to the thioester linkage of the Ppant 
tether are also likely to racemize at the a-carbon of the 2,4-substituted thiazoline. In fact, a 
similar analog, phenylthiazolinyl-SNAC, has only a 2-hour half-life in D2O before becoming 
completely racemized.15 It seems possible that HPT-Ppant is naturally in a racemic state 
alternating between L- and D-isomers.  
While pyochelin isomers with alternating stereocenters have been synthesized (i.e. 
neopyochelin)62, no evidence of pyochelin-like natural products retaining opposing 4’R, 4”S or 
4’S, 4”R have been reported to our knowledge since watasemycin’s and thiazostatin’s 
stereochemistry has recently been reassigned (Figure 3-2).49 The 2-carbon of a 2,4 disubstituted 
thiazolidine ring rapidly alternates between stereocenters and is well documented.63 Pyochelin is 
isolated as a diastereomer due to the rapid racemization of the 2” carbon but in the presence of a 
divalent metal, the 2” carbon shifts and locks into an R stereocenter.63, 64 If, in fact, the stuffed 
domain of PchE is defunct in catalytic activity, there may be an undetermined enzymatic or 
chemical driving force responsible for promoting the 4’R, 4”R stereocenters of pyochelin which 
may also be the cause for the 4’R, 4”R or 4’S, 4”S stereochemistry of 2-
hydroxyphenylthiazoline-4-thiazolidine pyochelin-like natural products.  
Walsh and colleagues suggested the downstream PchF cyclization domain may 
discriminate between the L- and D-isoform.24 In a later study, Walsh et al generated a chimeric 
enzyme, replacing the stuffed domain of PchE with the oxidase domain of MtaD from 
myxothiazol biosynthesis.65 The chimeric enzyme was able to oxidize the thiazoline ring to a 
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thiazole and condense with the downstream L-Cys of PchF, suggesting condensation of PchF’s 
cyclization domain is not stereospecific. However, Walsh and colleagues reported no detection 
of cyclization of the second added Cys implying a stalled system after condensation.65 
Interestingly, we were able to catalyze PchF methyltransferase activity with a substrate analog 
containing a thiazole replacing the D-thiazoline, suggesting the stereochemistry of the thiazoline 
a-carbon was not necessary for PchF methyltransferase activity (Chapter 2). 
Recently, the stereochemistry of watasemycin and thiazostatin, two metabolic products 
from Streptomyces venezuelae, were reassigned.49  Watasemycin and thiazostatin have a very 
similar biosynthetic gene cluster to pyochelin and are part of the 2-hydroxyphenylthiazoline-4-
thiazolidine family of iron-chelating NRPs (Figure 3-2).49 Challis and colleagues determined the 
PchE homolog in watasemycin biosynthesis has a stuffed methyltransferase-like domain that is 
non-functional as a methyltransferase or epimerase, retaining the L-isoform configuration of the 
thiazoline a-carbon from the activated L-Cys. The following module, similar to PchF, also 
generates a second cyclized thiazoline from an activated L-Cys and is predicted to alter its 
stereochemistry during methyltransferase activity by the stuffed methyltransferase domain of 
Sven0517. The proposed mechanism is similar to the C-methylation in yersiniabactin 
biosynthesis: proton abstraction, enol intermediate formation, and nucleophilic attack on the 
opposite side to the electrophilic methyl of AdoMet. Based on isolated intermediates, Challis et 
al observed methylation of the a-carbon occurred before reduction or any other methylation 
during watasemycin biosynthesis.49 Overall the stereocenter of each azole-like heterocycle in 
watasemycin is an S-stereocenter. The first activated L-Cys retains its stereochemistry due to the 
defunct stuffed methyltransferase-like domain while the stereochemistry of the second activated 
L-Cys is altered to its D-isoform during methyltransferase activity. 
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Intriguingly, Pseudomonas fluorescens, a non-pathogenic pseudomonad, generates 
enantiopyochelin, the optical antipode of pyochelin (Figure 3-2).3 The noncanonical stuffed 
epimerase domain found in PchE from P. aeruginosa is missing from the PchE homolog of P. 
fluorescens, likely accounting for the retained L-isoform of the first thiazoline in 
enantiopyochelin. However, the origin of the altered stereochemistry of the second heterocycle 
by the PchF homolog to the D-isoform remains unknown. Youard et al identified a few 
possibilities for the change in stereochemistry.3, 66 The PchF homolog could activate D-Cys 
instead of L-Cys in its adenylation domain. Or it may be possible that the stuffed 
methyltransferase domain in the PchF homolog of P. fluorescens can catalyze methyl transfer to 
the thiazolidine N and epimerization of the neighboring a-carbon. In P. fluorescens, no sequence 
homology of PchG is present, although PchK, a predicted putative thiazolinyl reductase, appears 
to replace the pchg gene in the operon. Based on sequence homology, this is the only major 
difference between the two operons that encode pyochelin and enantiopyochelin. Upon a BLAST 
alignment, it is interesting to find PchK shares 28% sequence homology over 85 amino acids 
with the stuffed E-domain of PchE from pyochelin biosynthesis.67  
Future purification and characterization of the NRPS enzymes involved in 
enantiopyochelin biosynthesis is necessary to identify how the altered stereochemistry is 
generated in comparison to pyochelin. However, based on our work and the stereochemical 
assignments of other 2-hydroxyphenylthiazoline-4-thiazolidine natural products, we propose 
noncanonical stuffed epimerase domains are not catalytically active and are likely an 
evolutionary artifact. It may be necessary to perform experiments in the presence and absence of 
metal to determine if stereochemistry change is catalyzed by metal binding. Future studies are 
necessary to further examine this hypothesis.  
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Conclusion 
In this study we examined PchE, the second module of pyochelin biosynthesis, and began 
a detailed characterization of the adenylation, cyclization, and epimerase domains. The PchE 
module’s adenylation domain is specific towards activating L-Cys. Potential substrate and 
product analogs were synthesized to gain further insight into the cyclization and epimerization 
chemistry performed by PchE. These chemistries were not observed to be catalyzed by PchE 
during in vitro assays. While this may be due to the substrate analog being too dissimilar to the 
natural Ppant tethered substrate, recent stereochemical assignments of other 2-
hydroxyphenylthiazoline-4-thiazolidine natural products bring into question whether the stuffed 
noncanonical epimerase domain of PchE is a functional epimerase domain, or simply a non-
functional methyltransferase-like domain. Future experiments aimed to elucidate the differences 
between the biosynthesis of pyochelin and enantiopyochelin are necessary to better understand 
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Substrate analog and inhibitor synthesis of stand-alone thiazolinyl reductase and salicylate 
adenylation domains, respectively, in NRPS biosynthesis 
 
*Portions of this chapter were published in Meneely, K. M., Ronnebaum, T. A., Riley, A. P., Prisinzano, T. E., and 
Lamb, A. L. (2016) Holo Structure and Steady State Kinetics of the Thiazolinyl Imine Reductases for Siderophore 
Biosynthesis, Biochemistry 55, 5423-5433. 
 
Introduction 
 The human body has evolved over time to sequester and store essential elements from 
bacterial intruders making it difficult for bacteria to grow and survive.1, 2 However, bacterial 
pathogens have also evolved possessing creative mechanisms to scavenge essential elements 
needed for growth, virulence, and pathogenicity. One of these intricate systems is the production 
of secondary metabolites called siderophores, or iron scavenging molecules, that are generated 
by means of nonribosomal peptide synthetases (NRPSs) in times of iron deficiency.3-5 
Pseudomonas aeruginosa, a multidrug-resistant ESKAPE pathogen, Mycobacterium 
tuberculosis, the etiological agent of tuberculosis, and Yersinia pestis, the causative agent of 
plague, hold serious global threats to human health and are bacterial pathogens that produce and 
utilize salicylate-capped siderophores for iron acquisition in human hosts (Figure 4-1).6-8 Many 
reports have suggested that salicylate-capped siderophores from these systems are essential for 
bacterial growth and virulence in iron limiting environments, making the siderophore 








Figure 4-1: Salicylate capped siderophores. Pyochelin, yersiniabactin, and mycobactins are 
salicylate capped siderophores. The biosynthesis of these siderophores is initiated by a stand-
alone adenylation domain predicted to be structurally homologous based on sequence identity. 
Importantly, these stand-alone adenylation domains are share conserved active site residues. The 
numbers in the yersiniabactin and pyochelin compounds are indicative of carbons used in the 
text. In the mycobactin structure, R1 is sometimes methylated and R2 is lipophilic chains that 




NRPS assembly lines are not found in humans them attractive drug targets. The 
beginning ideal steps in drug design targeting enzymes is to understand 1) the detailed 
mechanism by which the enzyme performs its catalysis and 2) understand the three-dimensional 
space occupied by the enzyme in which you are trying to inhibit.17, 18 Thoughtful experiments 
detailing the structural and mechanistic details of an enzyme allows for rational drug design. 
NRPS biosynthesis has been finely detailed in the previous chapters and a great deal highlights 
the difficulty in deciphering the mechanistic details and structural identity of NRPSs during 
peptide assembly. Briefly, peptide bond formation and elongation occur by transfer between 
4’phosphantetheinyl (Ppant) thiotemplates covalently attached to carrier domains of NRPS 
modules. This creates a complex substrate making it difficult to perform kinetic experiments in 
attempt to decipher intermediate mechanisms. Additionally, the large and flexible modular 
structures of NRPSs make it difficult to structurally characterize by traditional methods. Because 
of these difficulties, smaller stand-alone domains, such as stand-alone adenylation and stand-
alone tailoring domains, from NRPS biosynthetic pathways become more manageable drug 
targets because of their comparatively smaller size allowing for easier structural determination.   
Pyochelin (from P. aeruginosa), yersiniabactin (from Y. pestis), and mycobactins (from 
M. tuberculosis), are all salicylate capped siderophores (Figure 4-1). The biosynthesis of each of 
these siderophores is initiated by structurally homologous stand-alone salicylate adenylation 
domains (PchD from pyochelin biosynthesis, YbtE from yersiniabactin biosynthesis, and MbtA 
from mycobactin biosynthesis). These enzymes catalyze the formation of salicyl-AMP with 
release of pyrophosphate from salicylic acid and ATP (Figure 4-2). The next step in natural 





Figure 4-2: PchD catalyzes the formation of salicyl-AMP. PchD is a stand-alone adenylation 
domain that catalyzes the adenylation of salicylic acid with ATP forming salicyl-AMP and 




domain, binding the amino acid and releasing AMP. Over a decade ago, Ferreras et al presented 
salicyl-AMS, a tight-binding and non-hydrolyzable substrate mimic that inhibits salicylate 
adenylation domains.19 Salicyl-AMS exhibits nanomolar IC50 and Ki values towards PchD, 
MbtA, and YbtE, displays growth inhibition of M. tuberculosis and Y. pestis culture in 
micromolar concentrations, and has shown decreased rates of growth of M. tuberculosis in 
murine models.19, 20 Over the years, several alterations to salicyl-AMS have been performed in 
hopes to increase efficacy, half-life, and bioavailability of the compound.21-28 However, rigorous 
modifications and experimentation have not resulted in more efficacious inhibitors. Recently a 
crystal structure of apo-MbtA was published, the first published salicylate adenylation domain.29 
Unfortunately, we were scooped as we have synthesized salicyl-AMS and novel salicyl-AMS 
derivatives which have provided holo-structures of PchD (not published), the first holo-structures 
of salicylate adenylation domains. This breakthrough provides a platform for rational drug 
design of new salicylate adenylation inhibitors. 
The biosynthesis of pyochelin (PchG) and yersiniabactin (YbtU of Y. Pestis, Irp3 of Y. 
enterocoletica) also employ a stand-alone tailoring domain acting in trans with the NRPS 
system. PchG and Irp3 are proposed to NADPH-dependent thiazolinyl reductases.30, 31 Walsh et 
al provided evidence through reconstitution assays that PchG reduces the second L-thiazoline 
ring attached to the Ppant tether of PchF during pyochelin biosynthesis (Figure 4-3).31 Our work, 
presented in Chapter 2, agrees with Walsh’s hypothesis that reduction of the substrate is 
necessary for N-methyltransfer, subsequent hydrolysis, and release of mature pyochelin.31, 32 
While there has been evidence supporting the intermediate substrate and order of PchG’s role in 




Figure 4-3: Proposed roles of PchG in pyochelin biosynthesis and Irp3 in yersiniabactin 
biosynthesis. PchG and Irp3 are NADPH dependent thiazolinyl reductases and structural 
homologs based on sequence identity. A) Proposed role of PchG in pyochelin biosynthesis. PchG 
and Irp3 share 26% structural identity and may have the same substrate. B and C are possible 
substrate candidates for Irp3 reduction. B) If PchG and Irp3 share the same substrate, the 
growing peptide chain would be tethered to P2 of Irp2. C) Irp3 may also be the last step of 
yersiniabactin biosynthesis before release of the mature peptide.   
 131 
Mutations to the YbtU gene inhibits siderophore production, downregulates 
yersiniabactin biosynthetic genes, and inhibits growth of yersiniabactin in iron-deficient media.33 
During reconstitution assays, Walsh et al observed a mass representative of an oxidized mature 
yersiniabactin in the absence of YbtU suggesting two possibilities: 1) reduction by YbtU is the 
last step of yersiniabactin biosynthesis, or 2) reduction occurs elsewhere in the assembly line but 
is not required for subsequent steps.31 Irp3 share a 26% sequence identity with PchG.34 PchG and 
Irp3 may share a similar substrate. However, the order in which Irp3 performs reduction could 
change which carrier domain the growing peptide is attached. If the substrate is shared with 
PchG, the growing peptide is linked to Irp2 (high-molecular weight protein 2 of Y. pestis), but if 
reduction occurs later in the biosynthesis, the peptide would be tethered to Irp1 (high-molecular 
weight protein 1 of Y. pestis) (Figure 4-3). Previously, our lab has reported apo- and NADP+-
bound structures of Irp3 in an open confirmation.35 Irp3 is a homodimer and structurally 
homologous to sugar oxidoreductases and biliverdin reductase.35 While these structures provide a 
significant step towards better understanding the role of Irp3 in yersiniabactin biosynthesis, the 
order of interaction in the biosynthetic pathway and thus, the substrate remain elusive.   
This chapter will focus on the structural biology and mechanistic enzymology of the 
stand-alone salicylate adenylation domain, PchD, from the biosynthesis of pyochelin from P. 
aeruginosa and stand-alone thiazolinyl reductase domains involved in the biosynthesis of 
pyochelin from P. aeruginosa, PchG, and yersiniabactin from Y. pestis, Irp3. My contribution to 
this project was the synthesis of substrate analogs and potential inhibitors. Drs, Kathleen M. 
Meenely and Catherine Shelton used these compounds to perform steady-state kinetic assays and 
co-crystallization experiments. Substrate analog synthesis aided in determination of the first 
closed-holo-structure of a thiazolinyl reductase, Irp3, at a high resolution of 1.28 Å, and provided 
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steady-state kinetic parameters of NADPH-dependent PchG. Synthesis of potential salicylate 
adenylation inhibitors were co-crystallized with PchD and an adenylation assay was performed 
providing steady-state kinetic parameters of salicylate for PchD.  
 
Materials and Methods 
Preparation of Substrate Analogue and Inhibitors.  
General experimental procedures. All chemical reagents were purchased from commercial 
suppliers and used without further purification. Flash column chromatography was performed on 
silica gel (4-63 mm) from Sorbent Technologies. Separation was also performed with a Teledyne 
Isco CombiFlash Rf. Microwaved reactions took place in a Biotage Microwave reactor. 1H and 
13C NMR were recorded using a 500 MHz Bruker AVIII spectrometer equipped with a 
cryogenically-cooled carbon observe probe using tetramethyl silane as an internal standard. 
Chemical shifts (δ) are reported in ppm and coupling constants (J) are reported in Hz. High-
resolution mass spectrum (HRMS) was performed on a LCT Premier (Micromass Ltd., 
Manchester UK) time of flight mass spectrometer with an electrospray ion source in either 
positive or negative mode. Melting points were measured with a Thomas Capillary Melting Point 
Apparatus and are uncorrected. Chiral analysis was carried out on an Agilent 1200 RRLC with 
photo diode array on a Chiralpak ID column. 
 







Scheme 4-1:  Synthetic route to potential warhead inhibitors of salicylate adenylation 
enzymes. A) Reagents and conditions: i) TBSCl, imidazole/DMF, RT, 20 hr.; ii) TFA-H2O-THF 
(1:1:4), 0˚C, 5 hr.; iii) (Bu3Sn)2O, PhH, reflux 2 hr.; iv) H2NSO2Cl, dioxane, 5˚C, 0.5 hr.; v) 
salicylic acid, CDI, 60˚C, 2hr./DBU, CH3CN, 60˚C, 0.5 hr. vi) TBAF, THF, rt. 2hr. B) Salicyl-
AMS, 3-cyano-salicyl-AMS, and 4-cyano-salicyl-AMS were generated by the synthetic scheme 
illustrated above. C) Salicyl-AMS can be divided into four motifs as defined by Aldrich et al.: an 




4-cyano-2-hydroxybenzoic acid (0.24 mmol, ArkPharma) and 1,1-carbonyldiimidazole (0.575 
mM) were added to anhydrous acetonitrile (5 mL) under argon and stirred at 60˚C for 2 hours.  
1,8-diazabicyclo[5.4.0]undec-7-ene (0.24 mmol) and ((2R,3R,4R,5R)-5-(6-amino-9H-purin-9-
yl)-3,4-bis((tert-butyldimethylsilyl)oxy)tetrahydrofuran-2-yl)methyl sulfamate 37 (0.16 mmol) in 
1 mL of anhydrous acetonitrile were then added to the reaction dropwise and the reaction stirred 
at 60˚C for an additional 30 minutes. The reaction was subsequently quenched and extracted 
with EtOAc (4 x 20 mL). The organic layer was washed with 1M HCl (1 x 20 mL), NaHCO3 (1 
x 20 mL), and brine (1 x 20 mL). After being dried with MgSO4, the organic phase was 
concentrated under reduced pressure and the TBS-protected product was purified by Combiflash 
(0-30% MeOH gradient in CH2Cl2 over 40 minutes). Fractions containing the TBS-protected 
product were collected and concentrated in vacuo and left on high vacuum overnight to afford a 
red-orange solid (25 mg). The protected product was dissolved in anhydrous THF (1.6 mL) and 
1M TBAF in THF (100 µL) was added dropwise and the reaction stirred at room temperature for 
30 minutes. The product was purified by Combiflash (0-35% MeOH gradient in CH2Cl2) to yield 
a red-orange solid (13 mg, 16%). The product was only 59% pure based on the UV-VIS trace 




A mixture of 3-cyano-2-hydroxybenzoic acid (0.72 mmol) and 1,1-carbonyldiimidazole (0.86 
mM) were in anhydrous acetonitrile (9 mL) was stirred at 60˚C for 2 hours under an argon 
atmosphere. After cooling to room temperature, 1,8-diazabicyclo[5.4.0]undec-7-ene (0.36 mmol) 
and ((2R,3R,4R,5R)-5-(6-amino-9H-purin-9-yl)-3,4-bis((tert-
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butyldimethylsilyl)oxy)tetrahydrofuran-2-yl)methyl sulfamate 37 (0.24 mmol) in anhydrous 
acetonitrile (1 mL) was added in a dropwise manner. The resulting mixture was heated to 60˚C 
and stirred for an additional 30 minutes. The reaction was subsequently quenched and extracted 
with EtOAc (4 x 30 mL). The organic layer was washed with 1M HCl (1 x 30 mL), NaHCO3 (1 
x 30 mL), and brine (1 x 30 mL). After being dried (MgSO4), the organic phase was concentrated 
under reduced pressure to afford a crude oil that was purified by flash column chromatography 
(0-20% MeOH step gradient in CH2Cl2). Fractions containing the TBS-protected product were 
collected and concentrated in vacuo and left on high vacuum overnight to afford a yellow-orange 
solid (41 mg). The protected product was dissolved in anhydrous THF (1.6 mL) and 1M TBAF 
in THF (100 µL) was added dropwise and the reaction stirred at room temperature for 30 
minutes. The product was purified by Combiflash (0-50% MeOH gradient in CH2Cl2 over 25 
minutes) to yield a yellow-orange solid (24.9 mg, 21%). The product was only 40% pure based 
on the UV-VIS trace from LC-HRMS. HRMS: [M + H]+ 492.0859 (calcd), 492.0940 (found). 
 
Steady-state Adenylation Assay  
The coupled steady-state adenylation assay is thoroughly described in the previous two chapters. 
The adenylation assay was performed with PchD and salicylic acid. PchD was used at 750 nM 
enzyme concentration and salicylic acid ranged from 0 – 20 µM. All other reaction components 







Scheme 4-2: Substrate analog synthesis for PchG and Irp3.  
Reagents and conditions: a) Pd(PPh3)4, K2CO3/DME, H2O, 150 °C, 49%; b) MeOH, K2HPO4(aq) 




Preparation of PchG and Irp3 substrate analogs (Scheme 4-2). 
2-(2-Hydroxyphenyl)thiazole-4-carbonitrile  
A microwave vial was charged with 2-bromo-4-cyano thiazole (1.06 mmol), 2-hydroxyphenyl 
boronic acid (1.38 mmol), and Pd(PPh3)4 (0.0529 mmol). The vial was sealed and flushed with 
argon for 5 minutes. Dimethoxyethane (8 mL) and a 2 M potassium carbonate solution (1.06 mL, 
2.12 mmol) were added through the septum, and the reaction was stirred at room temperature for 
an additional 5 minutes, then heated to 150˚C for 45 minutes using a microwave reactor. The 
reaction was cooled to room temperature and diluted with EtOAc/H2O (2:1, 30 mL). The 
aqueous layer was extracted with EtOAc (2 x 30 mL). The organic layers were combined, 
washed with brine and dried over Na2SO4. The solvent was removed in vacuo and the resulting 
residue was purified by flash column chromatography (1:5 EtOAc/Pentane) to yield a pale 
yellow solid (104 mg, 49%). Mp: 169-172˚C. 1H NMR (500 MHz, DMSO-d6) δ 11.42 (s, 1H), 
8.84 (s, 1H), 8.17 (dd, J = 7.9, 1.7 Hz, 1H), 7.39 (ddd, J = 8.6, 7.2, 1.7 Hz, 1H), 7.07 (dd, J = 8.3,  
1.2 Hz, 1H), 7.00 (td, J = 7.8, 1.1 Hz, 1H). 13C NMR (126 MHz, DMSO-d6) δ 164.13, 155.12, 
133.20, 132.06, 127.36, 124.01, 119.60, 118.24, 116.30, 114.91. 
 
2'-(2-Hydroxyphenyl)-4,5-dihydro-[2,4'-bithiazole]-4-carboxic acid (HPToxT-CO2−) 
 L-Cysteine (0.546 mmol) and 2-(2-hydroxyphenyl)thiazole-4-carbonitrile (0.273 mmol) were 
combined in a round bottom flask. Methanol (5 mL) and 0.1 M potassium phosphate buffer pH 
6.5 (5 mL) were added and the reaction was heated to 60˚C and stirred for 14 hours. The reaction 
was cooled to room temperature, diluted with H2O (20 mL) and acidified with citric acid to ~pH 
2. The mixture was filtered through a pad of celite and extracted with CH2Cl2 (3 x 20 mL). The 
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organic layers were combined and dried over Na2SO4. The solvent was removed in vacuo to 
afford a light beige solid (58 mg, 70%). The purified product was in agreement with literature 
values for melting point, 1H NMR and 13C NMR.36 Enantiopurity was determined by chiral 
HPLC using a mobile phase of (A) water containing 0.05% formic acid (B) acetonitrile, gradient 
2% to 80% B over 12 minutes, and isocratic at 80% B from 12 to 15 minutes (R:S, 98:2). 
 
Ethyl 2'-(2-hydroxyphenyl)-4,5-dihydro-[2,4'-bithiazole]-4-carboxylate (HPToxT-CO2Et) 
Thionyl chloride (0.414 mmol) was added to ethanol (8.56 mmol) with vigorous stirring in a -
10˚C ice water bath. The mixture was warmed to room temperature. HPToxT-CO2− (0.153 mmol) 
was added and the reaction was the heated to 40˚C for 4 hours. The mixture was cooled to room 
temperature and the solvent was removed in vacuo. The residue was reconstituted in saturated 
Na2CO3 (10 mL) and extracted with CH2Cl2 (4 x 10 mL). The organic layers were combined and 
the solvent was removed in vacuo to afford a yellow oil (24.8 mg, 49%). 1H NMR (500 MHz, 
DMSO-d6) δ 11.24 (s, 1H), 8.34 (s, 1H), 8.14 (dd, J = 8.0, 1.7 Hz, 1H), 7.35 (ddd, J = 8.5, 7.2, 
1.8 Hz, 1H), 7.05 (dd, J = 8.2, 1.1 Hz, 1H), 6.99 (ddd, J = 8.2, 7.2, 1.2 Hz, 1H), 5.38 (dd, J = 9.7, 
8.4 Hz, 1H), 4.20 (qd, J = 7.1, 2.4 Hz, 2H), 3.64 (ABX, JAX 8.4 Hz, JBX 9.8, JAB 11.4, 2H), 1.25 
(t, J = 7.1 Hz, 3H). 13C NMR (126 MHz, DMSO-d6) δ 170.96, 164.92, 163.34, 155.50, 147.07, 
131.95, 127.81, 122.74, 120.08, 119.25, 116.92, 78.60, 61.61, 34.71, 14.52. HRMS: [M + H]+ 
335.0449 (calcd), 335.0516 (found).  
 
2-(4-(Hydroxymethyl)-4,5-dihydro-[2,4'-bithiazol]-2'-yl)phenol (HPToxT-CH2OH) 
NaBH4 (0.236 mmol) was added to a mixture of HPToxT-CO2Et (0.236mmol), CaCl2•2H2O 
(0.109 mmol) and EtOH (1.5 mL) at -20˚C. The reaction was stirred at that temperature 
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overnight. The solution was raised to room temperature and saturated NH4Cl (1 mL) was added. 
The reaction was then concentrated under reduced pressure leaving a residue. Deionized H2O (8 
mL) was added and the mixture was extracted with CH2Cl2 (3 x 15 mL). The combined organic 
layer was dried over Na2SO4 and the solvent was removed in vacuo to afford a crude oil. The oil 
was purified using the CombiFlash (4:1-5:1 EtOAc/CH2Cl2 gradient) to afford an off-white solid 
(22 mg, 31%). Mp: 159-160˚C. 1H NMR (500 MHz, DMSO-d6) δ 11.23 (s, 1H), 8.23 (s, 1H), 
8.13 (dd, J = 8.0, 1.7 Hz, 1H), 7.34 (ddd, J = 8.6, 7.2, 1.7 Hz, 1H), 7.04 (dd, J = 8.3, 1.1 Hz, 1H), 
7.02 – 6.96 (m, 1H), 4.99 (t, J = 5.7 Hz, 1H), 4.72 (dtd, J = 8.8, 7.2, 4.4 Hz, 1H), 3.69 (ddd, J = 
10.9, 5.5, 4.4 Hz, 1H), 3.55 (ddd, J = 10.9, 6.9, 5.9 Hz, 1H), 3.45 (dd, J = 11.0, 9.0 Hz, 1H), 3.31 
(dd, J = 10.9, 7.4 Hz, 1H).  13C NMR (126 MHz, DMSO-d6) δ 163.25, 162.04, 155.48, 147.74, 
131.88, 127.82, 121.85, 120.08, 119.26, 116.93, 79.99, 62.77, 34.41. HRMS: [M + H]+ 293.0340 
(calcd), 293.0419 (found). 
 
Results and Discussion 
Salicyl-AMS 
NRPS adenylation domains assist in catalyzing two distinct reactions. First, an amino 
acid, including nonproteinogenic acids and hydroxy acids, is activated at the expense of ATP 
forming an aminoacyl-AMP bond and releasing pyrophosphate. Second, the free thiol of a Ppant 
tether, covalently attached to a carrier domain, performs a nucleophilic attack at the acyl carbon 
of the aminoacyl-AMP intermediate, releasing AMP, and binding the amino acid priming the 
NRPS module. The first part of the reaction forming the aminoacyl-AMP intermediate, is 
similarly catalyzed by tRNA synthetases. Although tRNA synthetases and adenylation domains 
are not structurally or sequentially related, both can be inhibited by non-hydrolyzable analogs of 
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their shared aminoacyl-AMP intermediate, such as derivatives of 5’-O-[N-(aminoacyl)-
sulfamoyl]adenosine (AMS).61-64 In 2003, Marahiel and colleagues published the first use of 
aminoacyl-AMS inhibitors to inhibit NRPS adenylation domains of gramicidin S-synthetase A 
(GrsA) and surfactin  synthetase C (SrfA-C) in vitro.63 At first glance, aminoacyl-AMS 
inhibitors did not appear as viable candidates for treatment of pathogenic bacteria and fungi 
through inhibition of NRPS-derived virulence factors due to their ability to also inhibit tRNA 
synthetases. However, many NRPS-derived natural products include building blocks of 
nonproteinogenic amino acids and hydroxy acids of which are ideal candidates for aminoacyl-
AMS inhibitor targets. Adenylation domains do not have human homologs and aminoacyl-AMS 
inhibitors of adenylation domains specific to nonproteinogenic amino acids or hydroxy acids will 
not be specific to tRNA synthetases.  
In 2005, Ferreras et al introduced the first biochemically confirmed inhibitor of 
siderophore biosynthesis, salicyl-AMS (Scheme 4-1), targeting salicylate adenylation domains 
of siderophore biosynthesis pathways, specifically MbtA from mycobactin biosynthesis of 
Mycobacterium tuberculosis (the causative agent of tuberculosis) YbtE from yersiniabactin 
biosynthesis of Yersinia pestis (the causative agent of the black plague) and PchD from the 
opportunistic pathogen, P. aeruginosa.19 Salicyl-AMS provided nanomolar IC50 and Ki values 
for MbtA, YbtE, and PchD and was effective in inhibiting M. tuberculosis and Y. pestis culture 
growth at low micromolar levels, 2.2 ± 0.3 µM and 51.2 ± 4.7 µM respectively.19 Since then, 
Aldrich and coworkers have established an extensive SAR profile of salicyl-AMS, altering the 
linker,21, 23, 24 glycosyl,22, 25 aryl,26 and base27, 28 regions of the molecule (Scheme 4-1C).65, 66 
Indeed, various and often combined modifications have only slightly improved growth inhibition 
in comparison to the original salicyl-AMS.22, 26 
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Quadri, Tan, and Bishai recently provided the first in vivo proof-of-concept for using 
salicyl-AMS as an antibacterial showing its effectiveness in slowing M. tuberculosis growth of a 
murine lung model in 2013.20 However, authors suggest further modifications to salicyl-AMS are 
ideal to lower toxicity and/or increase half-life, efficacy, and bioavailability of the compound 
before moving to primate models.  Up until this point, modifications to salicyl-AMS have been 
driven by using crystal structures of DhbE, a dihydroxybenzoic acid adenylation domain, as a 
model for salicylate adenylation active sites. Although sharing 40-50% sequence identity, DhbE, 
has varying residues in the aminoacyl-AMP binding pocket in comparison to PchD, MbtA, and 
YbtE which likely contributes to the ability of the domain to differentiate between different 
hydroxy acids.19, 67 Recently, our lab successively solved the structure of PchD, the salicylate 
adenylation domain from P. aeruginosa, with salicyl-AMS bound in the active site (Figure 4-4, 
unpublished) – the first holo-structure of salicylate adenylation domains. Using this structure, our 
goal is to rationally design novel salicyl-AMS warhead inhibitors increasing its efficacy by 
covalently binding to the enzyme. 
 
Inhibitor design and synthesis of novel salicyl-AMS inhibitors  
 
Initial analysis of the active site of PchD presented a Cys residue near the aryl moiety of 
salicyl-AMP. The Cys residue is found to be in similar position to a Ser residue of DhbE.  We 
hypothesized that adding an electrophile off the salicyl ring and in the vicinity of the Cys could 
induce a reversible or irreversible binding event from the Cys to the inhibitor. Therefore, we 
followed a similar synthesis protocol by Ferreras et al to generate new inhibitors (Scheme 4-1).19 
Starting with adenosine, each hydroxyl first undertook a silyation protection, before selective 
deprotection of the 5’-O-TBS group giving a 2’3’-bis-O-TBS-adenosine. Aminochloro-l6-
silanedione was separately synthesized to perform sulfamoylation on the unprotected 5’-O-  
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Figure 4-4: PchD co-crystallized with salicyl-AMS, 4-cyano-salicyl-AMS, and 3-cyano-
salicyl-AMS. Unpublished crystal structures of PchD co-crystallized with salicyl-AMS (2.11 Å, 
wheat with green mesh), 4-cyano-salicylAMS (1.69 Å, light blue with purple mesh), and 3-
cyano-salicylAMS (2.03 Å, cyan with blue mesh) (left). The box inserts (middle) display a 2Fo-
Fc omit map (mesh) contoured at 2s with the inhibitor modelled into the electron density. The 
linear structure of the inhibitor is on the right side of the panel. Protein structure figures were 
generated using Pymol.68 
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position of the silylated adenosine providing a silylated sulfamate. A hydroxy acid (3- or 4-
cyano-2-hydroxybenzoic acid) was charged with 1,1’-carbonyldiimidazole and coupled with the 
sulfamoyl amine of the silylated sulfamate. Deprotection of the silylated sugar hydroxyls 
wascarried out by TBAF to yield the desired cyano-salicyl-AMS. Unfortunately, careful steps to 
ensure purity of each intermediate step during the synthesis was not performed (i.e. 1H NMR and 
13C NMR) leaving the final purity of 3-cyano-salicyl-AMS and 4-cyano-salicyl-AMS to 40% and 
59%, respectively, as determined by LC-HRMS UV-VIS. Aldrich and colleagues have generated 
more robust protocols for synthesis of salicyl-AMS derivatives, including protection of the base 
amine and salicyl hydroxyl with a final global deprotection step. Future synthesis including 
protecting these groups is desired to maximize yield, reduce side products, and increase purity. 
 
PchD crystal structures with bound salicyl-AMS inhibitors and steady-state adenylation 
parameters. 
 The crude inhibitors were co-crystallized with PchD to a resolution between 1.69 Å – 
2.11 Å (Figure 4-4). The 2Fo-Fc maps contoured to 2s in Figure 4-4 clearly show the presence 
of each inhibitor in the active site of PchD. The targeted Cys of PchD, not depicted in the figure, 
did not appear to be covalently linked to the inhibitor. Both the 3- and 4-cyano-salicyl-AMS 
inhibitors aiming to generate a thioimidate with the Cys were approximately 2 – 3 Å away from 
the rotamer. New salicyl-AMS derivatives extending the length of the electrophile are currently 
being synthesized. Additional modifications altering the identity of the electrophile, including 
various Michael acceptors, are also a future goal of the lab. Knowing the crystallization 
condition to produce inhibitors bound to PchD is a major benefit to rationally design more 
effective inhibitors for salicylate adenylation domains.  
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 I performed steady-state kinetics of the stand-alone adenylation domain of PchD (Figure 
4-5).  The kinetic parameters can be found in Table 4-1. This assay was performed in a plate-
reader format and provides a proof-of-concept for generating in vitro IC50 values. 3-cyano-
salicyl-AMS and 4-cyano-salicyl-AMS were not used in this assay due to their crude nature.  
 
Substrate analog synthesis for PchG and Irp3. 
Mechanistic analysis of downstream tailoring domains in NRPS biosynthesis is difficult 
due to the complexity of the growing peptide covalently linked to the Ppant tether of the carrier 
domain, as previously discussed.39-43 Thus, we synthesized proposed intermediate analogs to use 
in mechanistic and structural studies of PchG, from pyochelin biosynthesis, and Irp3 of 
yersiniabactin biosynthesis. PchG and Irp3 are NADPH-dependent thiazolinyl imine reductases 
acting on the growing peptide in trans as stand-alone tailoring domains.30, 31, 44 While the two  
natural products are distinctive of one another, the upstream peptidyl motif of the proposed 
substrate for PchG and Irp3 is shared consisting of a three-ring system, a 2-hydroxyphenyl, a D- 
thiazoline, and a 4-L-thiazoline (HPTT-S-Enz). Reduction occurs on the 4-L-thiazoline. During 
reconstitution assays, the Ppant tether is susceptible to hydrolysis releasing a carboxylate 
intermediate. Walsh et al reported isolation of HPToxT-CO2− from pyochelin full-reconstitution 
assays in the absence of AdoMet, PchG, or NADPH.31 Additionally, we provide evidence in 
Chapter 2 suggesting the reduction of the L-thiazoline to thiazolidine is necessary for N-
methylation identifying the likely order of catalysis in pyochelin biosynthesis. Conversely, the 
order of Irp3 catalyzed reduction of the L-thiazoline in yersiniabactin biosynthesis is much less 
defined. During yersiniabactin full-reconstitution assays, experiments lacking YbtU (Irp3 
homolog from Y. pestis, sharing 98% identity) produced a product with a mass indicative of a  
 145 
 
Figure 4-5: Michaelis-Menten plot of PchD and salicylic acid from steady-state adenylation 
assay. The coupled adenylation assay is described in detail in previous chapters. Steady-state 
parameters were generated for PchD and salicylic acid establishing a viable assay to perform 




Table 4-1: Salicylic Acid Adenylation Assay of PchD 
 PchD* PchD 
kcat (min-1) 74 0.30 ± 0.02 
Km (Salicylic acid µM) 2.8 1.7 ± 0.2 
kcat/ Km (M-1s-1) 45000 3000 ± 400 
 
* - Quadri et al. Biochemistry 1999, 38, 14941-14954. A different 
assay used to measure adenylation activity. Activity quantitated by 
measuring the reverse incorporation of 32pyrophosphate into ATP by 
the reverse reaction. As discussed in chapter 2, Aldrich and coworkers 
have found considerable differences between the 32pyrophosphate 
assay and the assay found herein.69, 70  
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non-reduced thiazoline.30 Indeed, HPToxT-CO2− was also isolated during reconstitution assays, 
but this occurred with and without YbtU; suggesting reduction may occur at any point in the 
biosynthesis after cyclization of the L-cysteine to L-thiazoline as YbtU acts in trans during 
peptide assembly.30 However, isolation of the non-reduced product in the absence of YbtU 
suggests reduction of the thiazoline is not a precursor to the rest of yersiniabactin bioassembly, 
unlike PchG in pyochelin biosynthesis. Since HPToxT-CO2− was isolated from each pathway it 
remains a possibility that they share a common substrate. Therefore, we decided to use HPToxT-
CO2− as a starting template to generate substrate analogs. 
We provide a simpler synthetic method to HPToxT-CO2− (Scheme 4-2) than the route 
previously reported by Mislin et al.45 The synthesis requires two steps. First, 2-(2-
hydroxyphenyl)thiazole-4-carbonitrile was produced by a Suzuki coupling reaction between 2-
hyrdoxyphenyl boronic acid and 2-bromo-4-cyano thiazole providing a 49% yield. Second, L-
cysteine was added to the nitrile prompting nucleophilic addition and cyclization to a thiazoline 
affording a 70% yield of the product. HPToxT-CO2− retained a 98:2 (R:S) ratio as determined by 
chiral chromatography. Additional analogs were also generated varying at the carboxyl terminus. 
The terminal carboxyl was first altered to an ethyl ester more closely resembling the thioester 
linkage to the Ppant tether. The carboxyl of HPToxT-CO2− was transformed to an acyl chloride 
promoting nucleophilic addition of the solvent ethanol providing HPToxT-CO2Et in 49% yield. 
The ester was successively reduced by a calcium borohydride catalyzed reduction giving a 31% 
yield of HPToxT-CH2OH. Each of the substrate analogs, HPToxT-CO2−, HPToxT-CO2Et, and 
HPToxT-CH2OH were used in crystallization and kinetic experiments by other researchers in the 
lab. The following Irp3 and PchG sections highlight our findings. This work was published in 
Meneely et al.46 
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Crystallization and structural analysis of Irp3 with substrate analog HPToxT-CO2−. 
 Previously, our lab reported two structures of Irp3: an apo- (1.85 Å, PDB: 4GMF) and 
NADP+-bond form (2.31 Å, PDB: 4GMG).35 The overall structure of Irp3 is similar to sugar 
oxidoreductases and biliverdin reductase but shares no structural similarity with other imine 
reductases. Irp3 is a homodimer in solution and in its crystal forms. Each monomer consists of 
two domains: a N-terminal Rossman fold domain responsible for NADP(H)-binding and a C-
terminal a/b domain responsible for dimerization (Figure 4-6 A, B).35 A new crystallization 
condition in a lower symmetry lattice garnered a NADP+-bound Irp3 structure at a higher 
resolution (1.45 Å) with a root-mean-square deviation (r.m.s.d.) of 0.54 – 0.75 Å for 336-347 Ca 
residues depending on the monomer being compared.46 The apo- and NADPH-bound structures 
were missing a loop connecting the M-N strands in the C-terminal dimerization domain (residues 
250-277) whereas the NADPH-bound and holo-structures in the new crystal lattice provided a 
fully ordered loop forming a cap over the active site of the opposing monomer (Figure 4-6 C).46  
 A holo-Irp3 structure with the substrate analog, HPToxT-CO2−, and NADP+ was also 
determined in the new crystal lattice at a high resolution of 1.28 Å.46 The structure was very 
similar to the new NADP+-bound structure having a r.m.s.d. of 0.15-0.49 Å for 353 Ca residues 
depending on the monomer. The NADP+ was fully occupied in the active site although the 
HPToxT-CO2− was only 70-85% occupied depending on the monomer. HPToxT-CO2− bound in a 
seemingly hydrophobic pock with no apparent binding interactions (i.e., hydrogen bonding, pi 
stacking) with Irp3. The carboxyl of HPToxT-CO2− is within hydrogen bonding distance of the 
nicotinamide amine and tyrosine 128. It is important to note the actual substrate contains an 




Figure 4-6: Crystal structure of Irp3. A) The tertiary structure of Irp3 represents two domains. 
A N-terminal NADP(H) binding domain (brown) and a C-terminal dimerization domain (blue). 
B) The quaternary structure of Irp3 is a dimer: monomer A (blue), monomer B (purple). C) The 
new crystal structure of Irp3 (blue and white) was co-crystallized with NADP(H) (green sticks) 
and substrate analog, HPToxT-CO2H (cyan sticks), elucidating the M-N loop closing over top of 
the active site (inset – blue loop). This figure was taken directly from Meneely et al. 




A tunnel past the carboxylate of HPToxT-CO2− extends to the surface of the protein and is the 
likely cavity of the natural substrate. Further space is also found in the substrate binding cavity 
past the hydroxyphenyl of HPToxT-CO2−. However, it is unlikely that natural substrate would 
protrude further into that void as it would move the substrate beyond the nicotinamide ring of 
NADPH, making hydride transfer unlikely. The wideness of the cavity and few interactions with 
the protein likely allow the analog lacking the stereochemistry of the natural D-thiazoline (analog 
was altered to an oxidized thiazole) to bind in the active site. The natural substrate would provide 
a slightly angled spatial arrangement opposed to the planar orientation of the analog in the active 
site. 
 Donation of a hydride from the nicotinamide ring of NADP+ and a proton from a general 
acid residue is the proposed catalytic mechanism of the structurally homologous sugar 
oxidoreductases. 47-50 The general acid is hypothesized to be the lysine of the consensus sequence 
EKP (EHP in thiazolinyl reductases) or the final residue of the GGX3DX3(Y/H) consensus 
sequence.47-50 The GGX3DX3(Y/H) consensus sequence is not conserved in thiazolinyl 
reductases although tyrosine 128 is in the same three dimensional space as the Y/H in sugar 
oxidoreductases. The likely general acid candidate in Irp3 is tyrosine 128 which is 4.4 Å from 
the nitrogen of the substrate analog, HPToxT-CO2−, whereas the EHP histidine is 9.0 Å. 
Therefore, we propose a mechanism similar to dihyrofolate reductase where tyrosine 128 is the 
general acid donating a proton to the nitrogen as hydride transfer occurs on the electropositive 
carbon.32 
In the NADP+-bound structures, the nicotinamide ring is pi-stacking with phenylalanine 
17 of Irp3.  The nicotinamide and Phe17 are shifted in the holo-Irp3 to align the nicotinamide 
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with the second thiazoline ring of HPToxT-CO2−. Yersiniabactin and pyochelin are isolated from 
culture as diastereomers altering stereochemistry at the C-10 carbon (Figure 4-1).51-53 Although, 
when binding to iron or other transition metals, the labile carbon becomes locked in the (R) 
confirmation for both pyochelin and yersiniabactin.52, 54-60 Excellent electron density at this high 
resolution provides a greater amount of density around the sulfur atoms compared to the carbon 
and nitrogen atoms distinguishing the orientation of the analog (Figure 4-7). Interestingly, the 
substrate analog is positioned in a confirmation that would promote reduction to the 
stereochemistry of the non-metal binding diastereomer of yersiniabactin.  The current position of 
the hydride transfer and proton donation from the proposed general acid would promote (S) 
stereochemistry at the C-10 carbon. It may be possible that the substrate analog is bound in a 
catalytically incompetent manor. If this were the case, the entire molecule or the just the terminal 
thiazoline ring would need to be rotated 180˚ to regain catalytic competence. This would better 
position the carboxyl towards the proposed Ppant tunnel but would also move the nitrogen 
further way from the proposed general acid residues. Further investigation is necessary to 
ascertain the catalytically competent position of the substrate. It should also be noted that 
attempts were made to co-crystallize or soak in HPToxT-CO2Et or HPToxT-CH2OH with NADP+ 
but density for these analogs was not observed in the active site. 
 
Steady-state kinetics with HPToxT-CO2−. 
 Each of the substrate analogs (HPToxT-CO2−, HPToxT-CO2Et and HPToxT-CH2OH) were 
used to measure reductase activity of PchG and Irp3. Common experiments of NADPH-
dependent enzymes measure the decrease of absorbance at 340 nm as NADPH is oxidized to 





Figure 4-7: HPToxT-CO2H bound in the active site of Irp3. A stereoview of a simulated 
annealing map contoured to 1.5s (gray cages) showing the substrate analog, HPToxT-CO2H 
(cyan sticks), in the active site of Irp3. This figure was taken directly from Meneely et al. 




simple experimental setup. Therefore, an HPLC method was created to separate the analogs from 
NADPH and NADP+ monitoring the decrease in absorbance of the NADPH at 340 nm. 
Detection of NADPH oxidation did not occur with Irp3 and any of the substrate analogs. Steady-
state kinetics of PchG with HPToxT-CO2− was observed albeit at non-physiological rates. The 
kinetic parameters were determined: Km of 80 ± 20 µM, a kcat of 0.020 ± 0.001 min-1, and a 
kcat/Km of 4 ± 1 M-1s-1.46 It is important to remember the natural substrate for PchG and Irp3 is 
attached to a Ppant tether covalently linked to the carrier domain of another NRPS. Several 
explanations can be given as to why the substrate analogs were poorly or not at all compatible 
with each enzyme but two should be highlighted. First, the terminus of the analogs may not have 
mimicked the thioester linkage closely enough for PchG or Irp3. On the other hand, Irp3 
reduction may occur later in the biosynthesis and require the additional hydroxylated malonyl 
and methylated thiazoline of the mature yersiniabactin. Second, the domain interactions with the 
Ppant carrier domain may be necessary for catalysis or product release. Development of a series 
of analogs more closely mimicking the natural substrate of each enzyme may be necessary to 
further elucidate the mechanism.  
 
Conclusion 
In summary we have presented structural and kinetic studies of stand-alone adenylation 
domains and stand-alone tailoring thiazolinyl reductases of siderophore biosynthesis. First, by 
generating substrate analogs, we provide the first closed-holo-structure of a thiazolinyl reductase, 
Irp3, from yersiniabactin biosynthesis in addition to an NADP+-bound structure each determined 
at high resolution. The substrate analog bound in the active site provides support that tyrosine 
128 is the general acid for catalysis. Additional steady-state kinetics with the substrate analog 
provided kinetic parameters for NADPH-dependent reduction by PchG, albeit at physiologically 
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irrelevant rates. Second, co-crystallization of salicyl-AMS with PchD, a salicylate adenylation 
domain from pyochelin biosynthesis, allowed rational design for more effective inhibitors. Two 
additional inhibitors were presented here and co-crystallized in the active site of PchD. 
Adenylation steady-state parameters of PchD were also presented as a proof-of-concept for 
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Iron acquisition by siderophores 
 Pseudomonas aeruginosa is a Gram-negative bacterium that can exist in a variety of 
environments and is regularly found in soil, water, plants, animals, and humans. This commensal 
bacterium is considered an opportunistic pathogen, often infecting humans with 
immunodeficiency. P. aeruginosa is one of the leading nosocomial, or hospital-acquired, 
pathogens. According to the Center for Disease Control (CDC), in the United States, nearly 8% 
of all nosocomial infections are caused by P. aeruginosa and nearly 13% of these infections are 
multidrug resistant.1 Thus, the world health organization has named P. aeruginosa as a critical 
priority for expanded research.2  
The ability of P. aeruginosa to acquire metals needed for primary metabolic processes is 
not only necessary for its survival but is also a critical step in its pathogenesis. One of these 
essential elements is ferric iron. Eukaryotes sequester iron, leaving freely available ferric iron in 
limited concentrations ranging from 10-18 – 10-24 M.3, 4 While bacteria need micromolar 
concentrations to grow, pathogenic bacteria have developed many intricate systems to scavenge 
iron from its surrounding environment.3-7 One of the main strategies used by pathogenic bacteria 
to scavenge ferric iron is by the production of siderophores, or low-molecular weight molecules 
possessing a high affinity for ferric iron.4 P. aeruginosa utilizes two siderophores, pyoverdine 
and pyochelin, which have been shown to be virulence factors in different models of infection.8-
10 The enzymes responsible for the production of siderophores rarely have human homologues 
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making them ideal antimicrobial targets.11  This dissertation focuses on better understanding the 
nonribosomal peptide synthetase (NRPS) system responsible for the biosynthesis of pyochelin.  
 
Pyochelin biosynthesis and stuffed domains 
Pyochelin biosynthesis employs two accessory enzymes (PchA and PchB), one stand-
alone adenylation enzyme (PchD), one stand-alone tailoring enzyme (PchG), and two modular 
NPRS enzymes (PchE and PchF), each consisting of 5 different catalytic domains.12-15 While 
pyochelin is considered a small siderophore (324 Da),16-18 its biosynthesis includes many facets 
which are ubiquitous in NRPS bioassembly, yet remain poorly understood. One of the aspects is 
the inclusion of structurally unique tailoring domains which are stuffed within the adenylation 
domain in NRPS modules.19, 20 We consider these to be “stuffed” tailoring domains.20 PchE has a 
proposed stuffed non-canonical epimerase domain and PchF has a stuffed methyltransferase 
domain. A large portion of this work aimed to better understand each stuffed tailoring domain’s 
catalytic mechanism in addition to the order in which these domains perform their chemistry 
during pyochelin biosynthesis.  
Although mechanistic and structural studies of stuffed tailoring domains is in its infancy, 
the majority of the published work has been targeted towards stuffed methyltransferase domains, 
specifically in the biosynthesis of depsipeptides, thiocoraline and kutzneride.21-24 In these studies, 
Garneau-Tsodikova et al provide evidence and strongly advocate for a global mechanism of 
methyl transfer by stuffed methyltransferase domains. They suggest that methyl transfer occurs 
to either the aminoacyl-AMP intermediate or the amino acid tethered to the Ppant of the carrier 
domain, but before condensation with the upstream peptide.21-24 This would suggest stuffed 
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domains are not specific to the growing peptide but could generally be inserted into any 
adenylation domain to tailor the amino acid before condensing with the nascent peptide.  
 
Methyl transfer and epimerization in pyochelin biosynthesis 
The order of bioassembly, and in particular at which step the methyl transfer occurs 
during pyochelin biosynthesis, was previously not clearly defined. However, isolates of 
biosynthetic intermediates during reconstitution assays suggested methyl transfer transpires 
sometime after condensation with the upstream peptide, contradictory to the hypothesis 
presented by Garneau-Tsodikova et al. To elucidate the order of methyl transfer in pyochelin 
biosynthesis we purified recombinant variants of PchF, synthesized a series of substrate analogs 
representing different biosynthetic intermediates, and developed kinetic assays for adenylation 
and methyltransferase activities. Overall, our data provides evidence that methyl transfer is the 
penultimate step of pyochelin biosynthesis. After condensation of L-Cys with the upstream 
peptide, the L-Cys is cyclized to a thiazoline, which is subsequently reduced by NADPH-
dependent PchG, and then N-methylated by PchF’s stuffed methyltransferase domain, before 
being released through hydrolysis as mature pyochelin. This work provides a foundation that 
stuffed tailoring domains may be specific towards the nascent peptide and not simply to the 
aminoacyl-AMP or aminoacyl-Ppant intermediates. Onium chalcogen effects were also used to 
support that the methyltransferase reaction proceeds through an SN2 mechanism.   
Intriguingly, the stuffed domain of PchE shares sequence homology with 
methyltransferase domains but is considered to be a non-canonical epimerase domain. Currently, 
the accepted mechanism in the literature suggests the following order of events.25 PchE first 
condenses the upstream salicylate with the downstream CysL-Ppant in its cyclization domain 
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forming HP-CysL-Ppant. The peptide then travels to the stuffed epimerase domain where an 
active site base abstracts a proton from the Cys a-carbon forming a carbanion. Random re-
protonation from the solvent occurs altering the stereochemistry to HP-CysD-Ppant or 
regenerating HP-CysL-Ppant.  The nascent peptide then travels back to the cyclization domain 
for cyclodehydration of the acyclic Cys to a thiazoline forming a mixture of HPTL/D-Ppant. The 
downstream cyclization domain of PchF is proposed to selectively condense its CysL-Ppant with 
only the D-isomer before moving forward with peptide assembly.  
Herein, we proposed a more conventional and energy efficient pathway. Like other 
known cyclization domains, we hypothesize that condensation and cyclodehydration occur in 
chronological order forming HPTL-Ppant. The growing peptide then moves to the stuffed 
epimerase domain where the chemistry is similar to other C-thiazolinyl methyltransferases. An 
active site acid abstracts a proton from the thiazoline a-carbon forming an enol intermediate. 
When AdoMet is not present in the active site for methyl transfer, the enol becomes re-
protonated by an active site acid or by solvent to generate HPTD-Ppant, which moves forward in 
the biosynthetic pathway. This pathway entails only two domain movements (cyclization-
epimerase) to perform three chemistries (condensation-cyclization-epimerase), whereas the 
pathway proposed by Walsh et al suggests three domain movements (cyclization-epimerase-
cyclization) to perform the same three chemistries.25  
 If stuffed epimerase domains are simply defunct methyltransferase domains due to their 
inability to bind AdoMet, one could imagine the possibility of engineering the methyltransferase 
domain into an epimerase domain. Experiments discussed in this dissertation lay a groundwork 
to continue studies examining the evolution and relation between stuffed methyltransferase and 
epimerase domains. To examine these hypotheses, potential substrate and product analogs were 
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synthesized representing the acyclic (HP-CysL-Ppant and HP-CysD-Ppant) and cyclized (HPTL-
Ppant and HPTD-Ppant) proposed biosynthetic intermediates. Unexpectedly, especially 
considering the success of similar analogues in the methyltransferase assays, in vitro assays with 
PchE variants directed towards examining cyclodehydration and epimerization chemistry by the 
epimerase domains did not yield detectable product. This may be due to the analogs not being 
similar enough to the natural Ppant substrate but may also indicate the stuffed epimerase domain 
is non-functional. Other similar stuffed methyltransferase-like domains in other 2-
hydroxyphenylthiazoline-thiazolidine natural products biosynthetic pathways are non-functional 
as methyltransferases or epimerases.26  
 
Substrate analogues in the study of NRPS assembly lines 
NRPSs are fascinating enzymes generating many diverse natural products. Their 
impressive chemical logic works in an assembly line-like method, tailoring the nascent peptide 
and passing it to the next module by means of each post-translationally modified carrier domain 
through its Ppant tether. While the thiotemplate allows for this methodology, it makes it difficult 
to study each NRPS module or domain with its native substrate. In this work, we synthesized 
substrate analogs altering the natural thioester of the Ppant tether to a hydroxyl, carboxyl, and/or 
ester derivative. While PchF was able to use an ethyl ester mimic, it would not accept the 
carboxyl as a substrate analog for methyl transfer. Alternatively, PchG was able to reduce a 
carboxyl analog, but not an ester or hydroxyl analog.27 If the stuffed epimerase domain of PchE 
is functional, it was unable to perform epimerase activity with carboxyl, hydroxyl, or ester 
analogs. Indeed, analogs more similar to the Ppant tether have been generated to study substrate 
specificity or kinetics of NRPS enzymes such as peptidyl N-acetylcysteiamine (SNACs), 
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peptidyl N-acetylethanolamine esters (ONACs), and N-acetylethylenediamine amides 
(NNACs).28-30 However, several examples exist where peptidyl-SNACs or analogs do not work 
as substrate mimics and most likely, several more examples have gone unpublished.31-34 Thus, a 
more robust systematic approach to studying the chemistry of different NRPS domains is still in 
need.  
Burkart et al previously reported a synthetic method to generate pantetheine derivatives 
and successfully performed a one-pot chemo-enzymatic synthesis attaching the pantetheine 
derivatives to VibB, a carrier protein in vibriobactin biosynthesis.35 Coenzyme A (CoA) is 
biosynthesized from vitamin B5, or pantothenate, by 5 different enzymes, CoAA-E.35 Previously, 
Burkart and colleagues discovered CoAA was still able to phosphorylate the 4’-hyroxyl group of 
pantetheine derivatives in vivo and in vitro.35-37 Using this methodology, analogs mimicking 
nearly the entire Ppant tether can be generated (Figure 5-1A). While synthesis of these 
derivatives would be more similar to the actual substrate, Burkart et al also show the ability to 
post-translationally modify the carrier domain, VibB. Using the synthesized derivatives and CoA 
biosynthetic enzymes (CoAA, CoAD-E), Burkart and colleagues, generated CoA derivatives 
with terminal fluorescent probes.35 Once the CoA derivative is generated, Sfp, a commonly used 
phosphopantetheinyl transferase (PPTase), was used to post translationally modify the carrier 
domain of VibB. This methodology can be used to generate intermediate analogs of NRPS 
biosynthetic pathways, in turn, directing and unifying a module to view a specific chemical step 





Future work related to the PchE and PchF modules 
An important question to answer is whether the lack of activity detected by the stuffed 
epimerase domain is the result of an evolutionary defunct domain or due to not generating 
substrate analogues that are effective mimics of the physiologically important substrate.  An 
amino acid coupling reaction can be used with the carboxyl derivatives synthesized and 
presented in this dissertation to generate more comparable analogs for intermediates in pyochelin 
biosynthesis, differing only by an amide linkage instead of the thioester linkage of a Ppant tether 
(Figure 5-1 A,B). For example, substrate and product analogs of PchE (HP-CysL, HP-CysD, 
HPTL-CO2–, and HPTD-CO2–) can be coupled with the amine-containing, p-methoxyphenyl 
protected pantothenic acid. After deprotection, newly generated substrate (HP-CysL-N-pant and 
HPTL-N-pant) and product (HP-CysD-N-pant and HPTD-N-pant) analogs can be used in the 
circular dichroism and chiral chromatography assays described in chapter 3. If epimerase activity 
still cannot be detected, each N-Ppant analog can be further modified by CoAA, CoAD, and 
CoAE to generate a CoA-derivative that can be transferred to PchE’s P2-domain by Sfp, a 
commonly used Ppant transferase (Figure 5-1B). To ensure epimerase activity is being 
monitored in PchE’s stuffed domain, and that Sfp does not transfer the CoA-derivative to PchE’s 
P1-domian, a new PchE variant consisting of the stuffed tailoring-adenylation didomain and the 
P2-domain should be used (PchE-AEP). After PchE-AEP is modified, it can be purified by size-
exclusion chromatography, removing the other enzymes. The modified PchE-AEP’s can be 
incubated with PchF-FL and CysL-N-pant to transfer the substrate analog to the CysL-N-pant 
through PchF’s C-domain, which can be isolated, analyzed, and compared to synthesized 
standards to determine if epimerase activity occurred on the acyclic or cyclic analog (Figure 5-
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1C). This last proposed experiment may have its pitfalls as post-translational modification and 
detection after a single turnover experiment may be too hopeful and provide difficulties.  
Similar modifications can be used in crystallography experiments. Specifically, PchF can 
be modified with HPToxTred-N-Ppant to unify the recombinant enzyme into promoting 
methyltransferase chemistry. Crystallography screens, including experiments along with other 
modular substrates (L-Cys, ATP) and products (AdoHCys) can be used. Successful structure 
determination would be the first holo-structure of an NRPS module with a stuffed tailoring 
domain in the conformation for tailoring chemistry. The structure would be important, because it 
would provide evidence for how the Asub-domain and peptidyl carrier domain migrate in 
accordance to the Ppant tether to promote the tailoring chemistry. Another interesting 
crystallography experiment could be co-crystallization of PchG and PchF after modifying PchF’s 
peptidyl carrier domain with HPToxTox-N-Ppant and incubating with NADP+. Structural 
elucidation of a holo-stand-alone tailoring domain in complex with its in trans NRPS partner 
would also be the first of its kind. If crystallization experiments prove to be too difficult, these 
large multimodular enzymes would be suitable for cryoEM experiments.  
 
Stand-alone domains of pyochelin biosynthesis 
In addition to PchE and PchF experimentation, structural and kinetic studies aimed 
towards the stand-alone adenylation domain, PchD, and stand-alone tailoring thiazolinyl 
reductases, PchG and Irp3, were presented in this dissertation. Substrate analogs were 
synthesized and used for kinetic assays with PchG and allowed determination of the first closed-
holo-structure of Irp3 with NADP+. Steady-state kinetics of the adenylation domain of PchD 
were performed with salicylate. Synthesis of potential warhead inhibitors were co-crystallized 
 169 
with PchD providing means for rational design of more effective inhibitors of salicylate 
adenylation domains. This project is currently ongoing in our lab.  
 
The benefit of studying pyochelin biosynthesis 
Many natural products biosynthesized by NRPS assembly lines are larger and more 
complex than pyochelin. Intermediate analogs of pyochelin biosynthesis are relatively easy to 
synthesize, allowing biochemical and structural analyses of downstream domains more feasible. 
Therefore, pyochelin bioassembly was exploited as an ideal model to study the complexities 
involved in NRPS biosynthesis. Overall, the experiments and results in this dissertation provide a 
groundwork for better understanding structural and biosynthetic aspects in pyochelin 
biosynthesis, and thus, NRPS enzymes as a whole. Continued studies aim to further elucidate 





Figure 5-1: Pantetheine and CoA derivatives and uses during in vitro pyochelin NRPS 
experiments.35-37 A) Synthetic scheme of PchE pantetheine substrate analog, HPTL-N-pant. B) 
Biosynthetic scheme of HPTL-CoA derivative and post-translational modification PchE-AEP 
providing a potential intermediate analog of pyochelin biosynthesis. CoAA phosphorylates the 4’ 
hydroxyl of the pantetheine analog. CoAD, a phosphopantetheine adenylyltransferase, and 
CoAE, a dephosphocoenzyme A kinase, can be used to create the CoA derivative. Sfp, a 
commonly used phosphopantetheinyl transferase, can catalyze transfer of the Ppant derivative by 
post-translationally modifying a serine in PchE-AEP’s peptidyl carrier domain. C) If epimerase 
activity is not catalyzed using pantetheine substrate analogs, PchE-AEP modified with HPTL-N-
Ppant or other substrate analogs can be incubated and added to PchF-FL and CysL-N-pant to 
promote condensation and possibly cyclization. The PchF product can be isolated and analyzed 
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